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Keratoderma – pathological hyperkeratosis of palms and soles - is a cause of 
disability in many clinical situations, including the rare and heterogeneous group of 
inherited palmoplantar keratodermas (PPKs). The aim of this study was to work 
towards better understanding of molecular mechanisms active in the pathogenesis of 
PPK by the creation of a cell and tissue culture resource and its initial application to 
laboratory studies. My study was based on a diverse group of autosomal dominant 
disorders, previously ascertained in families from Scotland, in whom the precise 
genetic aetiology was known. I established a tissue and cell culture resource of 
inherited keratodermas of known single-gene aetiology from patients with proven 
keratin 1, 9, 17, loricrin and mitochondrial mutations. An additional pedigree with 
striate keratoderma with an unknown mutation was recruited, and the causative 
mutation identified as a novel heterozygous A-to-T transversion in exon 5 
(c.430A>T) of the desmoglein 1 gene, converting an arginine residue to a premature 
termination codon (p.Arg144stop). The keratinocyte culture resource was established 
from patients with keratin 1, 9, 17 and loricrin mutations, as well as controls. Due to 
the pain associated with direct infiltration of plantar skin, biopsies were obtained 
using peripheral nerve block for plantar biopsy. The effectiveness of this approach, 
which may be useful for future administration of treatment, was made the subject of 
an open clinical trial. Histological and immunocytochemical studies were carried out 
on affected plantar skin obtained from PPK patients and compared to control tissue, 
in an attempt to identify common and distinct pathways resulting in hyperkeratosis.  
Histological changes, e.g. hypergranulosis, extent of hyperkeratosis, acanthosis or 
acantholysis, were not uniform across different subtypes of inherited PPK and varied 
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even between individuals within subtypes. Prominent eosin staining of spinous cells 
was a common feature in inherited PPK due to underlying K1 and K17 mutations. 
Electron microscopy showed abnormal keratin filaments in PPK with underlying 
keratin mutations only but was not a uniform finding within subtypes, and other 
electron microscopic features also varied between individuals. Immunocytochemical 
study did not demonstrate significant differences in expression of a selection of 
markers of differentiation (keratins 1, 9, 14 and 17), and cornified envelope protein 
filaggrin. Abnormal involucrin expression was observed, with premature expression 
in basal and lower spinous layers in all PPK subtypes raising the possibility of a 
common underlying mechanism in the development of hyperkeratosis. Prominent 
loricrin staining was noted in areas of acantholysis in K1 and K9 subtypes, but was 
uniform across other subtypes. Markers of proliferation and apoptosis demonstrated 
no overt change in epidermal turnover, although it is possible that only small changes 
in proliferative index are required to produce plantar hyperkeratosis. Overall, using 
morphological criteria, plantar hyperkeratosis was not readily distinguishable 
between inherited PPK of different underlying genetic causes. This raises the 
possibility that many of the reported structural features of inherited PPK are 
secondary phenomena as opposed to critical steps in the pathogenesis of 
hyperkeratosis. Initial attempts at RNA extraction using laser and manual 
microdissection have to date been unsuccessful in generating RNA of the quality and 
concentration to run a pilot microarray experiment, using standard RNA extraction 
kits. Plans for future projects include the further development of a possible 
microarray experiment in the Pachyonychia Congenita type 2 pedigree with the 
McLean laboratory in Dundee. The tissue resource has been made available for 
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collaborative study via the GENESKIN project, as well as through the McLean and 
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Aims and approach to study 
The underlying aim of the work described in this thesis is to increase 
understanding of molecular mechanisms active in the pathogenesis of 
palmoplantar keratoderma, in the hope that greater understanding will provide 
opportunities for better care. Towards this aim, the thesis describes both the creation 
of a cell and tissue culture resource, and the initial application of this resource to 
laboratory studies. 
 
Inherited keratodermas (reviewed in Chapter 1) represent a well-defined model 
system in which a systematic approach to identification to common (or distinct) 
pathways causing palmoplantar hyperkeratosis should be possible.   
 
Clinical features including response to previous treatment in the study population 
were characterised (Chapter 2.1). The collection of the resource is described in 
Chapter 2.2.  I studied only families in whom the underlying molecular aetiology had 
already been established, and one family in whom I was able to identify it (Chapter 
2.3). 
 
Palmoplantar skin was obtained for study (Chapter 2.2), necessitating the 
development of an effective approach to regional anaesthesia (Appendix A).  In 
addition, biopsies of non-palmoplantar skin were obtained, from which keratinocytes 




In the initial application of the resource thus obtained, morphological studies using 
light and electron microscopy (Chapter 3.1), and immunocytochemical studies using 
markers of epidermal differentiation and turnover (Chapter 3.2), are described. 





Chapter 1  Literature Review - The Inherited Palmoplantar 
Keratodermas 
1.1 Introduction 
Thickening of palmoplantar skin is a physiological response to repeated 
mechanical stress. Its inappropriate activation in a variety of pathological situations 
causes pain, orthopaedic problems, maceration and infection, with consequent 
disability.  
Palmoplantar hyperkeratosis may be seen in generalised disorders of 
keratinisation such as ichthyosis vulgaris, epidermolysis bullosa, ectodermal 
dysplasias, dysmorphic syndromes or metabolic disorders, and in inflammatory 
disease, including psoriasis, eczema and lichen planus (Judge et al., 2004).  
The inherited palmoplantar keratodermas (PPKs) are a heterogeneous group 
of conditions, characterized by marked thickening of the epidermis of the palms and 
soles, caused by a variety of underlying genetic defects (Lucker et al., 1994; Itin & 
Lautenschlager, 1995; Stevens et al., 1996; Ratnavel & Griffiths, 1997; Judge et al., 
2004; Itin & Fistarol, 2005). Although rare, these are often severe disorders, causing 
physical, social and occupational disability. There are three main clinical patterns: 
diffuse, focal with hyperkeratosis at points of friction, and punctate (Istin & Fistarol, 
2005). Many keratoderma syndromes are restricted to these sites although other 
ectodermal or systemic abnormalities may be associated.  
 The genetic defects identified in many inherited forms of PPK provide 
important clues to the mechanisms which lead to pathological hyperkeratosis. 
Keratoderma has been associated with defects in keratin intermediate filaments, 
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desmosomes, gap junction communication, and the process of cornification. The 
variety of defective genes causing keratoderma does not preclude final common 
pathways in the thickening of epidermis and stratum corneum. These pathways may 
represent the activation of physiological responses to mechanical stress or wounding. 
Alternatively, without excluding these mechanisms, they may invoke aspects of the 
epidermal inflammatory response. In either case, it is possible that not only 
genetically distinct, inherited forms of PPK share pathological mechanisms, but that 
these mechanisms will also be activated in other commoner conditions in which 
keratoderma is an important clinical feature. Thus, an improved understanding of the 
pathways of pathological hyperkeratosis in inherited PPK may lead to better 
management of a wide spectrum of common conditions in which palmoplantar 
hyperkeratosis is a cause of significant morbidity.  
In order to place in context pathogenic mutations in components of the 
epidermis, the physiology of normal epidermal formation and differentiation, and 
relevant structural elements, are discussed prior to considering what is already 
known about the major inherited PPKs. Most of the studies quoted have been 
conducted in hair-bearing skin, and their extrapolation to palmoplantar epidermis is a 
pragmatic assumption. 
1.2 Overview of Epidermal Differentiation 
Human epidermis is a stratified epithelium in which the continual processes of 
proliferation and terminal differentiation are highly regulated. A constant balance 
between these processes is vital in ensuring the normal structure of the epidermis 
(Figure 1). Keratinization or cornification are terms used to describe the process of a 






Figure 1.  Schematic representation of the palmoplantar epidermis. (Denecker et al., 2008). 
Formed from stem cells, basal keratinocytes proliferate into the suprabasal layers before developing 
into the squames of the stratum corneum, which flake off (desquamate). Desmosomes link 
keratinocytes by forming cell-cell junctions. Changes occur in gene regulation, such as in the keratins, 












This is the final step of differentiation for epidermal keratinocytes and involves 
dramatic cell condensation before death (Candi et al., 2005). Epidermal homeostasis 
is driven by stem cells which replace keratinocytes lost through normal 
differentiation and tissue turnover or through cell death following injury. Stem cells 
are defined by their ability to self-renew and to give rise to different cell lineages 
(Blanpain & Fuchs, 2009). Stem cell progeny are known as transit amplifying cells, 
which differentiate after several rounds of cell division (Clayton et al., 2007). 
Keratinocytes migrate into suprabasal layers, a key first step in the programme of 
terminal differentiation (Blanpain & Fuchs, 2009), with a switch from a cytoskeleton 
formed by keratins K5 and K14 to K1 and K10 (Fuchs & Green, 1980). Significant 
amounts of other keratins are expressed at other sites, such as K9 in palms and soles 
and K2e in thickened sites (see sections 1.4 and 1.5). Keratinocytes enlarge and start 
to express components of the cornified envelope, such as involucrin, loricrin and 
filaggrin or their precursors (Fuchs & Byrne, 1994).  
The stratum corneum (SC) is a thin (12-15μm) tough, outermost layer of the 
epidermis composed of overlapping flattened, corneocytes and lipid-rich, 
intercellular lamellae. It fulfils the major epidermal function of protection of the host 
from the external environment (Watt, 1989; Fuchs & Byrne, 1994). The SC 
permeability barrier limits the transcutaneous movement of water and electrolytes 
(Elias & Choi, 2005). 
The cornified envelope (CE) structure is built from one or many of the 
following components (Steinert & Marekov, 1997; 1999): annexin I, cystatin α, 
elafin, filaggrin involucrin, loricrin, type II keratin intermediate filament proteins, 
pancornulins, small proline-rich proteins (or cornifins), trichohyalin, and various 
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junctional proteins, including desmoplakin, envoplakin and periplakin. These 
proteins cross-link together by disulfide bonds and Nε-(γglutamyl) lysine isopeptide 
bonds formed by the action of transglutaminases, thereby becoming insoluble 
(Nemes & Steinert, 1999; Steinert & Marekov, 1999). CE assembly is a precisely 
regulated and orderly process triggered by a rise of intracellular Ca2+
Morphologic changes of the keratinocytes at the transition from granular 
layer to the SC have led to suggestions that terminal differentiation is a specialized 
form of apoptosis (Maruoka et al., 1997; Ishida-Yamamoto et al., 1999). However, 
differences exist between apoptosis and terminal differentiation, and the two 
processes have been shown to be subject to different and distinct stimuli (Gandarillas 
et al., 1999) (see chapter 3.2). 
 concentration 
coincident with a signal to initiate terminal differentiation (Kalinin et al., 2002). 
Corneocytes are embedded in the lipid-laden matrix which is composed of ceramides 
(Holleran et al., 1991), cholesterol (Menon et al., 1992a) and free fatty acids (Mao-
Qiang et al., 1993), together forming the lamellar membranes which limit water and 
electrolyte loss (Harris et al., 1997; Candi et al., 2005). 
The final event in terminal differentiation of the epidermis is desquamation. 
Breakdown of lipids in the intercellular spaces and loss of residual intercellular 
desmosomal connections occurs due to the action of proteolytic enzymes. This 
results in cell shedding from the SC (Elias, 2005). The SC contains three families of 
proteases: the epidermal-specific serine proteases, SC tryptic enzyme kallikrein-5, 
SC chemotryptic enzyme kallikrein-7, which are able to degrade corneodesmosome 
proteins; the cysteine proteases, SC thiol protease; and aspartate protease, cathepsin 
D (Brattsand & Egelrud, 1999; Hansson et al., 1994; Bernard et al., 2003; Horikoshi 
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et al., 1998). Kallikrein-7 and kallikrein-5 are highly expressed in the stratum 
granulosum and present in intercellular spaces of the SC (Sondell et al., 1995). 
Serine protease activity increases in the SC following barrier disruption (Denda et 
al., 1997), and serine protease/serine protease inhibitor balance has been shown to be 
important for normal permeability barrier homeostasis (Hachem et al., 2006). The 
cysteine protease, SC thiol protease, is a product of late epidermal differentiation, 
which has been shown to be inhibited by cystatin M/E, a cysteine protease inhibitor 
expressed in the stratum granulosum (Zeeuwen et al., 2001). Mouse models 
containing a null mutation for the cystatin M/E gene have been shown to have 
ichthyosiform skin changes and barrier disruption (Zeeuwen et al., 2002). Human 
cathepsin V has also been shown to be a target for cystatin M/E, and both these 
molecules are thought to have an important role in epidermal differentiation and 
desquamation (Zeeuwen et al., 2007). 
When the permeability of the SC is disrupted, by mechanical injury or topical 
treatment removing extracellular lipids, the barrier function is repaired by a 
homeostatic response initiated by the epidermis (Taljebini et al., 1996). Although 
this process is not fully understood, extracellular calcium and potassium levels 
surrounding stratum granulosum cells play a role (Menon et al., 1992b). 
1.3 Keratin intermediate filaments 
The main stress-bearing structure within the cytoplasm of epithelial cells is the 
keratin intermediate filament (KIF) cytoskeleton (Fuchs & Cleveland, 1998; 
Coulombe & Omary, 2002; Omary et al., 2004; Magin et al., 2007; Moll et al., 
2008). They make up the largest subgroup of intermediate filaments and represent 
the most abundant proteins in epithelial cells (Coulombe & Omary, 2002). These 
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proteins are encoded by a large multigene family whose at least 65 individual 
members can be partitioned into two major sequence types. The pairwise regulation 
of type I (K9-K23; Ha1-Ha8) and type II (K1-K8, Hb1-Hb6) keratin genes reflects 
the composition of keratin polymers, which are built from heterodimers (Coulombe 
& Omary, 2002). Since the first keratins were sequenced and identified as type I and 
II intermediate filaments proteins, the increasing numbers of keratins has provided an 
ongoing challenge for their clear identification and logical classification across 
species. A new nomenclature system has been structured to divide the 54 human 
keratins and their genes into three categories: (1) epithelial keratins/genes, (2) hair 
keratins/genes, and (3) keratin pseudogenes and a fourth category of nonhuman 
epithelial and hair keratins of other mammalian species (Schweizer et al., 2006). 
All intermediate filament proteins have a prototypical structure consisting of 
a coiled-coil, α-helix rod domain (two polypeptide α-helixes wound around each 
other) that is interrupted by linkers and flanked by N-terminal head and C-terminal 
tail domains (Figure 2). This domain exists in four segments (1A, 1B, 2A and 2B) 
interrupted by three non-helical linkers (L1, L12, L2) and is flanked by globular head 
and tail domains, the functions of which are unclear. (Omary et al., 2004; Lane & 
McLean, 2004; Parry et al., 2007). The helix boundary peptides, at the start and end 
of the rod domain, are thought to be critical in mediating end-to-end overlap 
interaction during filament assembly (Steinert et al., 1993). Type II keratins have two 
additional subdomains, H1 and H2 located between the rod and tail domains; the H1 
subdomain is essential for polymerization (Geisler & Weber, 1982; Lane & McLean, 
2004; Parry et al., 2007).  
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The keratin cytoskeleton forms a network of filaments acting as protein 
scaffolds with structural and regulatory functions (Magin et al., 2007). The assembly 
of this network involves several steps: firstly, the formation of obligate heterodimers 
by parallel alignment of a type I and type II keratins. Dimers align to form tetramers 
that then polymerize laterally and longitudinally to form 2-3nm protofilaments, 
although the precise mechanism is still uncertain (Steinert et al., 1993). Two 
protofilaments then align to form a 4.5nm protofibril, and these inter-twine to form a 
complete 10nm keratin filament consisting of 32 monomer chains before assembling 
into structurally resilient cytoskeletal networks (Fuchs & Cleveland, 1998; Herrmann  
et al., 2000; Herrmann & Foisner, 2003). These networks have been shown to be 
highly dynamic structures (Windoffer et al., 2004). 
Keratin genes are clustered in two chromosomal regions in the human 
genome: type I keratins map to 17q12-q21 (except K18) and type II keratins are 
located in a gene cluster on chromosome 12q11q-14 (Moll et al., 2008). 
1.4 Functions of keratins 
The keratin cytoskeleton not only acts as an important structural stabilizer of 
epithelial cells. It also allows rapid and localized restructuring, while being involved 
in all aspects of cell behaviour including migration, differentiation and proliferation 
(Magin et al., 2007). The significance of their mechanical function is emphasised by 
both knock-out mouse models (Magin et al., 2004; Gu & Coulombe, 2007) and a 
number of human hereditary keratin diseases (Omary et al., 2004). Keratins are not 
simply static intracellular structures but are highly dynamic, even in stationary 
interphase cells (Yoon et al., 2001; Windoffer et al., 1999; 2004). Keratin 
intermediate filaments demonstrate high viscoelasticity and flexibility, yet  
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Figure 2. Schematic diagram of basic intermediate filament structure. Type I and Type II keratin 
intermediate filaments are shown, with the coiled –coil α-helical segments of the central rod domain 
(1A, 1B, 2A and 2B) shaded in pink and turquoise, and non-helical segments (L1, L12 and L2) in 
blue. At the beginning and end of the rod domain are the highly conserved helix boundary motifs, the 
helix initiation peptide (HIP)(amino terminus) and helix termination peptide (HTP)(carboxy terminus) 
in the 1a domain and the end of helix 2B respectively. H1 and H2 subdomains are present in type II 
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retain the ability to harden in response to stress, yield rapidly without breaking and 
recover quickly when deforming stress is removed (Janmey et al., 1991; Ma et al., 
1999).  
 The contribution of keratins to the mechanical stability of tissues is apparent 
when considering the number of blistering diseases caused by single point mutations 
of keratin (Omary et al., 2004; Lane & McLean, 2004; Gu & Coulombe, 2007). 
Mechanical trauma exacerbates blistering in diseases such as epidermolysis bullosa 
simplex (EBS) demonstrating the loss of mechanical resilience (Magin et al., 2007). 
Keratins are anchored by desmosomes and their mechanical functions must be 
considered in conjunction (section 1.6 and chapter 2.3). Keratin knockout mouse 
models have further confirmed their essential mechanical role, such as deletion of K5 
leading to pronounced cytolysis and neonatal death (Peters et al., 2001), and K14 
null mice demonstrating a less severe phenotype, probably due to compensation by 
K15, its related type I keratin (Lloyd et al., 1995). 
 New functional roles of keratins have been defined and are emerging (Moll et 
al., 2008), including protection from apoptosis (K17, Tong & Coulombe, 2006) and 
the regulation of protein synthesis and cell size during wound healing by intracellular 
signalling pathways (K8, Caulin et al., 2000; Ku et al., 2003a; K17, Kim et al., 2006) 
(see chapter 3.2 and section 4). In addition, K8, K18 and K19 protect the placental 
and trophoblast barrier function (Hesse et al., 2000; Jaquemar et al., 2003) and K8 
and K18 protect the liver from stress and injury (Zatloukal et al., 2000; Ku et al., 
2003b). Beyond their biological functions, keratin expression patterns are distinct 
during different stages of epithelial differentiation and have thus evolved to be 
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important epithelial differentiation and tumour markers in cell biology, embryology 
and surgical pathology (Moll et al., 2008). 
1.5 Keratin expression in epidermis and epidermal appendages 
Like other intermediate filaments, keratins are characterized by tissue-specific 
expression patterns which make them useful tools for diagnostic pathology (Lane & 
McLean, 2004). Selective expression in certain cell types and during differentiation 
is an important aspect of the genes encoding intermediate filaments and is relevant to 
the association of mutations in these genes with a broad range of tissue-specific 
diseases (Omary et al., 2004) (Table 1). An overview ‘map’ of the major keratin 
expression patterns in the skin epithelia is shown in Figure 3. Keratin expression can 
define the differentiation status of keratinocytes (Patel et al., 2006) e.g. K5 and K14 
in basal cells, K1 and K10 in differentiating suprabasal cells and K6, K16 and K17 in 
“hyperproliferating” cells (Coulombe, 1997; Freedberg et al., 2001) (see chapter 
3.2). Changes in keratin expression occur in response to epidermal injury, with 
downregulation of differentiation-specific keratins K1 and K10, and expression of 
inducible keratins K6, K16 and K17 (Paladini et al., 1996; Tomic-Canic et al., 1998) 


















Table 1. Expression patterns of keratins and known keratin disorders (adapted from Smith et al., 
2005; Corden & McLean, 1996; Magin et al., 2007). 
Keratin (pair) Main expression pattern Disorder 
K1, K10 Suprabasal cells of stratified, cornified 
epithelia 
Bullous congenital ichthyosiform 
erythroderma (BCIE), Diffuse non-
epidermolytic PPK 
K2e Late suprabasal cells of stratified, 
cornified epithelia 
Ichthyosis bullosa of Siemens (IBS) 
K2p  Hard palate specific keratin - 
K3, K12 Cornea specific keratins Meesmann epithelial corneal 
dystrophy (MECD) 
K4, K13  Mucosa, stratified non-cornified envelope White sponge naevus (WSN) 
K5, K14 Basal keratinoctyes of epidermis and 
stratified epithelia 
Epidermolysis bullosa simplex (EBS), 




K6a, K16 Palmoplantar epidermis (widespread), 
nail bed, oral mucosa, wound healing, 
epidermal appendages 
PC-1, Focal non-epidermolytic PPK,  
K6b, K17 Nail bed, palmoplantar epidermis 
(restricted), epidermal appendages, 
sebaceous gland, hair shaft, other 
epithelia, wound healing 
PC-2, Steatocystoma multiplex,  
K7 Myoepithelial cells, simple epithelia - 
K8, K18 Simple epithelia, hepatocytes Cryptogenic cirrhosis, inflammatory 
bowel disease 
K9 Palmoplantar epidermis Epidermolytic PPK 
K15 Basal keratinocytes - 
K19 Simple epithelia, epidermal appendages - 





Cortical trichocytes of the hair shaft Monilethrix 
K6hf Companion layer of hair follicle Pseudofolliculitis barbae 
K6irs Inner root sheath of hair follicle - 
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Figure 3. Summary of major consensus patterns of keratin expression in epidermis and 













Desmosomes are the most common type of intercellular junction which mediate 
stress-bearing intermediate filament anchorage at sites of cell-cell contact (Yin & 
Green, 2004). They are highly organised, disc-like structures, 0.1-0.5μm in diameter, 
that mechanically couple adjacent keratinocytes (Figure 4). A transcellular network 
is created throughout a tissue that is thought to resist forces of mechanical stress and 
this in turn attaches to the basal aspect of the cell by molecularly distinct junctional 
structures called hemidesmosomes (Green & Jones, 1996; Dusek et al., 2007).  
 Desmosomes are formed by mirror image, tri-partite electron-dense plaques, 
each opposing the plasma membranes of neighbouring cells, and which exhibit 
tissue-specific differences in both structure and composition (Green & Simpson, 
2007). Desmosomes consist of proteins from a number of distinct gene families, 
including cadherins, armadillo proteins and plakins (Yin & Green, 2004) (Figure 4). 
The cytoplasmic plaque comprises desmoplakin and plakoglobin, with desmoplakin 
being critical in linking keratin intermediate filaments to desmosomes forming a 
three-dimensional lattice throughout the cell (Green & Jones, 1996). The armadillo 
proteins include plakoglobin, plakophilins (PKP1-3) and p0071 (Hatzfeld, 1999; Yin  
& Green, 2004). Plakin family members include desmoplakins I and II, plectin, and 
the cell envelope proteins envoplakin and periplakin (Leung et al., 2002). The 
plakins share a similar structure consisting of a central α-helical coiled-coil rod 
domain flanked by globular N- and C-terminal domains. These domains mediate 
interaction with other proteins, the C-terminal region of desmoplakin binding to a 




Figure 4. Structural organisation of desmosomes and hemidesmosomes (Uitto et al., 2007), with 
attachment complexes at the cell-cell and cell-matrix interface, respectively. They are both connected 
to the keratin intermediate filament cytoskeleton, visualised by immunofluorescence on the upper 

























N-terminal portion of desmoplakin with the desmosomal cadherins (Kouklis et al., 
1995). The desmosomal cadherins, desmogleins (DSGs) and desmocollins (DSCs), 
are a family of glycoproteins which interact with the N-terminus of desmoplakin 
(Yin & Green, 2004). The cadherin genes are tightly clustered on chromosome 18 
and consist of four DSGs and three DSCs (Kljuic et al., 2003a; Whittock & Bower, 
2003a; Getsios et al., 2004).  
 Desmosomes not only form robust extracellular bonds essential in 
maintaining tissue integrity, but also play a role in the processes of differentiation 
and morphogenesis (Green & Simpson, 2007). This has been shown by mis-
expression or targeted deletion of desmosomal cadherins (Allen et al., 1996; Chidgey 
et al., 2001; Elias et al., 2001; Merritt et al., 2002; Cheng & Koch, 2004; Hardman et 
al., 2005) (see also chapter 2.3 & section 4).  
1.7 Connexins and gap junctions 
The direct communication between cells is considered an indispensable mechanism 
in the maintenance of cellular homeostasis (Meşe et al., 2006), which is mediated via 
intercellular channels that cluster in specialized regions of the plasma membrane to 
form gap junctions (Robertson, 1963; Revel & Karnovsky, 1967; Meşe et al., 2006). 
Gap junctional intercellular communication is actively involved in virtually all 
aspects of the cellular life cycle (Vinken et al., 2006), and is essential for many 
physiological events, including cell synchronization, differentiation, cell growth and 
metabolic coordination of avascular organs including epidermis and lens (White & 
Paul, 1999; Vinken et al., 2006). Gap junction channels are formed of related 
proteins called connexins (Goodenough, 1974) encoded by a family of genes 
categorized as α, β and γ according to their gene structure, overall homology and 
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specific sequence motifs (Meşe et al., 2006). Gap junctions typically gather in groups 
of 10 to 10,000, so-called plaques, at the membrane surface (Vinken et al., 2006) 
(Figure 5). Members of the connexin (Cx) family of proteins contain four membrane-
spanning domains, two extracellular loops, one cytoplasmic loop, one cytosolic N-
terminal tail, and one C-terminal region. The extracellular loops play roles in cell-
cell recognition and docking processes, with three cysteine residues in each loop 
solely forming intraconnexin disulfide bonds (Meşe et al., 2006). Variation between 
the connexin family members is mainly due to structural differences within the 
cytosolic areas (Vinken et al., 2006). Phosphorylation is thought to be important for 
the regulation of assembly and modulation of the physiological properties of the 
channels (Lampe & Lau, 2004; King & Lampe, 2005). In the plasma membrane, two 
opposing hemichannels or connexons are assembled as hexamers of protein subunits 
that dock in the intercellular space to form functional channels (Vinken et al., 2006). 
Homomeric, heteromeric and heterotypic channels differ in their content and spatial 
arrangement of connexin subunits (Meşe et al., 2006). 
 Two nomenclature systems are used to designate different connexin species, 
one distinguishing connexins by molecular weight, as predicted by cDNA 
sequencing (e.g.Cx32). The other divides connexins according to sequence similarity  
and cytoplasmic length domain, into subclasses α, β or γ, using the prefix “GJ” for 
gap junction and the order of their discovery (e.g. Cx32 is GJB1) (Vinken et al., 
2006). 
 There are at least 21 connexin isoforms in the human genome, with nearly all 
human cells expressing at least one type of these genes at some point, such as Cx26 
in cochlea, liver, skin and placenta, compared to Cx46 and Cx50 in the eye alone  
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Figure 5.  Schematic representation of connexins and gap junction channels (Meşe et al., 2006). 
(a) The connexin structure consists of two extracellular loops, four membrane-spanning domains, one 
cytoplasmic loop, one N-terminal tail, and one C-terminal tail. (b) Hexameric connexons 
(hemichannels) are composed of six connexins, which align in the extracellular space for form gap 
junctions. Homomeric, heteromeric and heterotypic channels differ in their content and spatial 



















(Meşe et al., 2006). Connexins show overlapping expression patterns, with co-
expression of multiple genes possibly providing compensatory mechanisms for the 
loss of one isoform (Kretz et al., 2003). These patterns vary in response to various 
receptor activated signalling pathways, toxic agents, cellular proliferation and 
transformation (Richard, 2000).  
 An elaborate gap junction network exists within the skin, with Cxs expressed 
by keratinocytes in specific and often overlapping patterns within differentiating 
layers of the epidermis (Salomon et al., 1994; Di et al., 2001). Cx43 is the most 
broadly expressed in interfollicular epidermis, throughout the stratum spinosum and 
granulosum, as well as focally in stratum basale. It is found in sebaceous glands, and 
the lower portion, the cortex, inner and outer root sheet cells of hair follicles 
(Salomon et al., 1988; Salomon et al., 1994; Tada & Hashimoto, 1997; Lucke et al., 
1999). In contrast, Cx26 is usually patchily distributed in basal keratinocytes, most 
prominently in palms and soles, but is highly expressed in hair follicles and eccrine 
sweat glands (Lucke et al., 1999; Salomon et al., 1994). 
 The association of human genetic disease with specific connexin mutations is 
establishing a key role for gap junctions in a diverse range of physiological 
processes. The first disease-associated connexin was Cx32, in the X-linked form of 
Charcot-Marie-Tooth disease, a progressive neuropathy resulting from myelin 
disruption and axonal degeneration of peripheral nerves (Richard, 2000). A myriad 
of connexin mutations have been found to cause deafness and skin disease (Kelsell et 
al., 2001), and in particular genodermatoses characterized by PPK (Maestrini et al., 




1.8 Connexins and proliferation, differentiation and growth control 
Gap junctional communication plays a central role in keratinocyte growth and 
differentiation with the epidermis being highly coupled by intercellular channels 
(Meşe et al., 2006). To date, nine connexin genes are known to be expressed during 
the keratinocyte differentiation process including Cx26, Cx30, Cx30.3, Cx31 and 
Cx43 (Kelsell et al., 2000; Di et al., 2001). Normal skin can regenerate after 
wounding or damaging, which involves proliferation, migration and differentiation of 
keratinocytes (Martin, 1997; Jacinto et al., 2001). The dynamically regulated switch 
of the pattern of connexin expression in the skin correlates with changes in the 
program of proliferation and differentiation of keratinocytes (Richard, 2000). The 
expression of connexins in rat skin is altered in response to the repair process, with 
strong up-regulation of Cx26 in differentiated cells proximal to the wound edge 
compared to a simultaneous decline in Cx31 and Cx43 (Goliger & Paul, 1995). Cx26 
expression was induced initially in a patchy pattern in the basal cell layer, then later 
extensively in basal and suprabasal cell layers, preceding an increase in cell 
proliferation in human skin following tape stripping (Lucke et al., 1999). In 
connexin-deficient mice, the down-regulation of Cx43 appeared to be a prerequisite 
for the coordinated proliferation and mobilization of keratinocytes during wound 
healing (Kretz et al., 2003).  
Cx26 upregulation has been reported under hyperproliferative skin conditions 
such as psoriasis, despite normal levels of Cx43 expression (Labarthe et al., 1998; 
Rivas et al., 1997; Djalilian et al., 2006). Cx37 and Cx31.1 are also induced in 
psoriasis and erythrokeratoderma variabilis (EKV)(Masgrau-Peya et al., 1997), and 
Cx26 expression has been noted in viral warts, overlapping with Cx43 (Lucke et al., 
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1999). A similar increase and coexpression of Cx26 and Cx43 has been noted during 
treatment of human epidermis with topical retinoic acid (Masgrau-Peya et al., 1997). 
Although the expression of Cx26 seems characteristic of chronic epidermal 
hyperplasia, Cx26 positive cells have been shown not to proliferate, suggesting that 
Cx26 is associated with differentiation rather than proliferation (Lucke et al., 1999). 
However, the relationship between Cx26 upregulation and keratinocyte proliferation 
and the signalling cascades involved in this process is not fully understood (Meşe et 
al., 2006). 
In contrast, the disruption of gap junction intercellular communication may 
be associated with abnormal cell growth and carcinogenesis (Richard, 2000). Cx26 
and Cx43 are almost completely abolished in basal cell carcinoma and squamous cell 
carcinoma (Kamibayashi et al., 1995; Sawey et al., 1996). The loss of differentiation 
in tumour progression, invasion and metastasis is associated with a quantitative and 
qualitative reduction in expression of Cx43, Cx26 and Cx31.1 (Kamibayashi et al., 
1995; Budunova et al., 1995, 1996). Thus there is increasing evidence for the critical 
role of Cx-mediated signalling in the control of epidermal morphogenesis, 
differentiation and growth (Richard, 2000). Connexins are also emerging as 
therapeutic targets to improve wound healing (Qui et al., 2003; Coutinho et al., 2005; 
Mori et al., 2006). 
1.9 Palmoplantar Skin 
Multiple studies have suggested that palm and sole skin is structurally different from 
skin in other sites (Fuchs & Green, 1980; Matoltsy et al., 1983; Egelrud & Stigbrand, 
1989). It has a number of unique features: it contains the highest density of eccrine 
sweat glands, it is devoid of pilosebaceous follicles and its surface is characterized 
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by alternating ridges and grooves forming a highly individual pattern, the 
dermatoglyphics (Swensson & Eady, 1996). 
 Study of the structure and physiology of palmoplantar epidermis has been 
relatively neglected compared with that of hair-bearing skin. Keratinocytes in ridged 
skin have an unusually large amount of keratin filaments in their cytoplasm 
compared to thin skin, with densely aggregated keratin filament bundles (Swensson 
& Eady, 1996), possibly due to the expression of palmoplantar-specific keratin 
(Knapp et al., 1986; Moll et al., 1987; Langbein et al., 1993). Palm and sole 
epidermis demonstrates a complex pattern of keratin expression, with at least six 
different keratins being expressed suprabasally, among these, keratin 9 appears to be 
expressed almost exclusively in suprabasal keratinocytes of palms and soles (Knapp 
et al., 1986). It is not clear whether the apparent abundance of keratin filament 
network in ridged epidermis is functionally significant, serving a protective function 
in a tissue that is vulnerable to exceptional forces (Swensson & Eady, 1996). Specific 
patterns of other keratins have also been documented in ridged skin, suggestive of 
regional adaptations of this epidermis to a high cell turnover rate (see chapter 3.2). 
These differences between ridged and thin skin highlight the potential pitfalls of 
misinterpreting site-related morphological features as pathological. 
 The expression pattern of connexins in palmoplantar epidermis is also distinct 
as discussed above (section 1.8). 
1.10 Wound healing 
Epidermal wound healing provides permanent closure of a wound and a restoration 
of important functions of the skin, such as its barrier function (Brandner et al., 2004). 
The process is complex, involving the proliferation and migration of keratinocytes in 
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the regenerated epidermis (Odland & Ross, 1968). For migration to occur, cells must 
become motile and modulate their adhesions with each other, and the process of 
“kick-starting” is of great interest (Martin, 1997). Keratinocytes at the wound edge 
withdraw from terminal differentiation in response to epidermal injury and undergo 
changes in morphology and gene expression (Grinnell, 1992). This process of 
“keratinocyte activation” involves cell hypertrophy, retraction of keratin filaments 
from the cell periphery, alterations of desmosomes and widening of intercellular 
spaces (Odland & Ross, 1968). Two theories of wound re-epithelialization have been 
proposed. “Leap-frogging” involves proliferating keratinocytes distant from the 
wound edge entering the suprabasal compartment, with suprabasal keratinocytes 
downregulating desmosome expression, migrating over adherent basal keratinocytes 
and reverting to a basal phenotype at the wound bed (Krawczyk, 1971). “Tractor-
tread” suggests basal keratinocytes migrating over the wound bed, pulling the 
remaining epidermis, while desmosomal junctions are maintained (Woodley, 1996). 
Basal keratinocytes migrate as in epidermal cell culture with suprabasal cells having 
an ancillary role (Clark et al., 1996).  
 Epidermal injury represents a dramatic change with keratinocytes required to 
become more flexible to facilitate epidermal migration across a wound bed and 
rapidly close the wound, when normally they would differentiate to form rigid 
structures (Patel et al., 2006). Transplantation of culture keratinocytes into wounds 
induces and accelerates wound healing (Leigh et al., 1991; Moll et al., 1995; 1998). 
It is thought that this is due to cytokines produced by transplanted keratinocytes 
which activate epidermal and/or adnexal keratinocytes (Leigh et al., 1991).  
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 Growth factors including EGF, TGFα, heparin-binding EGF, and 
keratinocyte growth factor are involved in stimulating epithelial cell motility and 
proliferation in wounded epidermis (Marikovsky et al., 1993). The keratin 
cytoskeleton also appears to play a role (Guo et al., 1995; Paladini et al., 1996). 
Epidermal injury is associated with changes in both keratin expression (Paladini et 
al., 1996; Tomic-Canic et al., 1998) (see 1.5 & chapter 3.2) and connexin 
distribution (Hodgins, 2004) (see 1.8). Cx43 is greatly reduced in keratinoctyes 
migrating into the margins of healing wounds, with a subsequent induction of Cx26 
and Cx30 near the wound margins (Brandner et al., 2004). In mouse models, a 
reduction of Cx43 has been shown to accelerate incisional wound closure (Kretz et 
al., 2003; Qiu et al., 2003). In contrast, in hyperproliferative skin, an upregulation of 
Cx26 occurs. This suggests that a change in gap junction properties might be a 
requirement for effective wound closure (Hodgins, 2004). 
1.11 Classification of Inherited PPK 
Clinical classification of the inherited PPKs has been difficult, based upon 
eponymous case reports of individual families, with lack of uniform nomenclature 
(Ratnavel & Griffiths, 1997). On historical grounds, PPKs are based on clinical 
descriptions and morphology of lesions, mode of inheritance, age of onset, presence 
of lesions in areas other than palms and soles and associated diseases or 
malformations (Itin, 1992). The molecular basis has been identified in the majority of 
PPK syndromes, however marked clinical overlap often exists (Itin & Fistarol, 
2005). Consequently, no single classification system unites satisfactorily clinical 
presentation, pathology and molecular pathogenesis (Greither, 1977; Salamon, 1986; 
Zemstov & Veitschegger, 1993; Lucker et al., 1994; Itin & Lautenschlager, 1995; 
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Stevens et al., 1996; Ratnavel & Griffiths, 1997). The inherited PPKs discussed in 
this thesis are outlined (Table 2). 
1.12 Genotype/Phenotype Correlation 
The association of a specific mutation in a given gene with a corresponding 
phenotype has great relevance in understanding mechanisms of disease and in 
facilitating truly informed genetic counselling. As more data are reported, the 
association of mutations in one gene with a distinct phenotype has become more 
complex. In the genodermatoses, clinical and genetic heterogeneity occurs. Clinical 
heterogeneity occurs when clinically distinct phenotypes are produced by different 
mutations in the same gene e.g. the range of phenotypes caused by mutations in the 
gene encoding desmoplakin 1 (see section 1.15 and chapter 2.3). Genetic 
heterogeneity refers to a situation where identical clinical phenotypes are attributed 
to mutations in several genes e.g. striate PPK caused by mutations in the genes 
encoding desmoglein 1, desmoplakin and keratin 1 (see section 1.5 and chapter 2.3) 





Table 2. Principal hereditary palmoplantar keratodermas (adapted from Judge et al, in press) 
Type Eponym(s) Inheritance 
(presumed) 







      
Diffuse group       




Thost-Unna AD Some 12q11-q13 2-5 or later N Likely to be heterogeneous 
Loricrin keratoderma Camisa; variant 
Vohwinkel 




Greither; Sybert AD Some 1p; Keratin 
1 
3-8 Y  Likely to be heterogenous 
Keratoderma with 
scleroatrophy 
Huriez AD 4q23  Y Squamous carcinomas 
Mal de Meleda  AR SLURP-1 0-3 Y Dermatophyte infection common 
Autosomal recessive 
transgredient keratoderma* 
Gamborg-Neilsen AR - 8-10 Y Likely to be heterogeneous 
Palmoplantar and periorificial 
keratoderma 






Wachters AD -   Includes painful hereditary callosities 
Focal keratoderma with oral 
leukokeratosis 
 AD Keratin 16 3-5 N Oral leukokeratosis 




AD Keratins 6a, 16 3-5 N Oral lesions, follicular keratoses 
Pachyonychia congenita type 
2 







 N  
Hidrotic ectodermal dysplasia Clouston AD Connexin 30  Y Nail and hair dystrophy 
Keratodermas with 
extracutaneous features 
      
Keratoderma with 
oesophageal carcinoma 
Howel-Evans AD 17q23  N Focal PPK with oral lesions 
Striate keratoderma, woolly 
hair and arrythmogenic 
cardiomyopathy 
Naxos disease AR Plakoglobin  N  
Striate keratoderma, woolly 
hair and dilated 
cardiomyopathy 
 
 AR Desmoplakin  N  
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Cicatrizing keratoderma with 
 hearing loss 
Vohwinkel AD Connexin 26 5-10 Y Papular lesions becoming confluent, 
starfish keratoses. Mild hearing 
impairment 
Keratoderma with prelingual 
deafness 
 AD Connexin 26 0-5 Y Mild diffuse PPK but profound 
deafness 
Mitochondrial hearing loss 
with keratoderma 
 Matrilineal A7445G  N Variable mild focal PPK 
Keratoderma with 
neuropathy* 




Papillon-Léfèvre AR Cathepsin C  N Severe periodontal and other pyogenic 
infections 
Keratoderma with eyelid cysts Schöpf-Schulz-
Passarge 
AR -  N Diffuse keratoderma, hypotrichosis, 
nail fragility, loss of deciduous teeth, 
adnexal tumours 
Oculocutaneous tyrosinaemia Richner-Hanhart AR Tyrosine 
aminotransferase 
 N Corneal ulcers, painful keratoses, 
progressive mental impairment 
Punctate group       
Punctate keratoderma* Brauer-Buschker-
Fischer 
AD 8q24; 15q22 10-40 N Possible association with malignancy 
in some families 
Punctate keratoderma of 
palmar creases 
 AD - 10-40 N Palmar creases, sometimes marginal 
lesions 




Papuloverrucous keratoderma Touraine; Jakac-
Wolf 
AR - 2-6 N Follicular keratoses; dysplastic teeth 




1.13 Keratins and Skin Disorders 
Mutations in keratin genes underlie a variety of epidermal and non-epidermal cell-
fragility disorders (Corden & McLean, 1996) and are the genetic basis of a number 
of the PPKs. The cell-type and tissue-specific expression profile of the mutated 
keratin dictates the cell type and body site that is affected in the disorder. The 
majority of these mutations are clustered, indicating that these ‘hotspot’ regions of 
the protein are important for normal keratin function (Kelsell & Stevens, 1999). 
 Most keratin diseases are inherited in an autosomal dominant fashion. Keratin 
filaments whose structural integrity is compromised by the presence of a mutated 
component are weaker, causing the filament network of a keratinocyte to collapse 
when the cell undergoes physical trauma. Mutations in K5 or K14 cause 
epidermolysis bullosa simplex (EBS), (Figure 3) in which the basal cells are fragile 
and may fracture if the epidermis is subjected to even quite mild physical trauma. All 
forms of EBS can show associated palmoplantar keratoderma, with the epidermis 
and stratum corneum becoming greatly thickened. K1 and K10 are the major 
secondary differentiation-specific keratins of interfollicular epidermis and are 
expressed by suprabasal epidermis and any other stratified squamous epithelia that 
becomes orthokeratinized (Lane & McLean, 2004). Mutations in K1 and K10 are 
associated with bullous congenital ichthyosiform erythroderma (BCIE), or EH 
(epidermolytic hyperkeratosis) in which suprabasal cells become fragmented easily. 
The keratin mutations in K1 and K10 which lead to these disorders are found 
predominantly in the helix boundary motifs of either keratin, in the H1 region of K1 
and occasionally the L12 linker region (Lane & McLean, 2004). It is notable that in 
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BCIE, hyperkeratosis is a much more marked element of the phenotype than 
blistering. 
In attempting to understand genotype-phenotype correlation in the inherited 
PPKs, the Human Intermediate Filament Database (HIFD) provides a useful resource 
(http://www.interfil.org). With the increasing number of pathogenic defects being 
reported in intermediate filament genes, the HIFD catalogues mutations and 
polymorphisms in parallel with data on protein structure, gene, and chromosomal 
location (Szeverenyi et al., 2008). 
1.14 Inherited PPK and keratins 
K9 is a type I keratin expressed in suprabasal cells in the epidermis of palm and sole 
(Moll et al., 1987), where it may contribute a specific reinforcing effect to withstand 
the greater stress at these sites (Swensson et al., 1998). K9 was thus a strong 
candidate gene for palmoplantar specific keratoderma (Lane & McLean, 2004) and 
linkage of EPPK to the type I keratin cluster was demonstrated. With the cloning of 
the K9 cDNA and corresponding gene KRT9, missense mutations have been 
associated with EPPK, the autosomal dominant skin fragility disease diffuse 
epidermolytic PPK (Vörner’s syndrome) (Vörner, 1901) and are continuing to be 
reported (www.interfil.org) (Reis et al., 1994; Navsaria et al., 1995; Covello et al., 
1998a; Coleman et al., 1999; Lee et al., 2003). 
This disorder is characterized by a confluent keratoderma which is 
indistinguishable clinically from the diffuse non-epidermolytic PPK (NEPPK) 
described by Thost and Unna (Thost, 1880; Unna, 1883), but with histological 
features of epidermolytic hyperkeratosis. Infants may develop diffuse keratoderma. 
A confluent keratoderma sparing dorsal surfaces is present in adults, with a sharp 
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demarcation and erythematous edge. A history of blisters or fissuring of the palms 
may hint at reduced strength, although blistering is not a major feature. Hair, teeth 
and nails are not affected (Judge et al., 2004). The degree of cytolysis present may 
result in proliferation signals to the epidermis in an aberrant wound response (Lane 
& McLean, 2004). A total of 65 mutations have been reported in K9 in association 
with EPPK (http://www.interfil.org) of which the majority occur in the region 
encoding the first half of helix 1A of K9, a mutation “hotspot” in other keratins. In 
general, these mutations are substitutions, but there has been one report of a 3-bp 
insertion designated 1362ins3 in exon 6 (Coleman et al., 1999).  
Although mutations in K1 and K10 are associated with BCIE, there are also 
reports of mutations in K1 causing PPK (Kimonis et al., 1994; Hatsell et al., 2001; 
Terron-Kwiatkowski et al., 2004; 2006) both associated with/without epidermolysis, 
challenging the existence of NEPPK as a distinct entity. The phenotype in these 
families has been distinct from BCIE as they lack the generalized hyperkeratosis 
distributed over the entire body, and it was restricted to palmoplantar surfaces 
(Hatsell et al., 2001). A mutation in the V1 subdomain of K1 resulted in a distinct 
phenotype being associated with diffuse NEPPK and limited hyperkeratosis of the 
areola, umbilicus, and knuckle pads of the dorsal aspects of the finger joints. This 
mutation changes residue lysine-72 to isoleucine, found in a highly conserved 22 
residue sequence involved in cross-linking of the cornified cell envelope by 
transglutaminases present in all type II keratins except K7 and K8  (Kimonis et al., 
1994).  
Pachyonychia congenita (PC) is a group of inherited disorders of the 
epidermis and its appendages which can be divided into two main clinical subtypes, 
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PC-1 (OMIM 167200) and PC-2 (OMIM 167210) (Munro, 2001). PC-1 (Jadassohn-
Lewandowsky subtype) is characterised by hypertrophic dystrophy of the distal nail 
(pachyonychia) associated with focal PPK, follicular keratoses, oral leukokeratosis, 
angular chelosis and hoarseness. PC-2 (Jackson-Lawler subtype) is similarly 
distinguished by pachyonychia, follicular keratoses and focal PPK, but is also 
associated with natal teeth, multiple pilosebaceous cysts, protruberant eyebrows, and 
(in children) unruly hair (Gorlin et al., 1976; Jadassohn & Lewandowsky, 1906; 
Jackson & Lawler, 1951).  
There were a number of reasons why PC was thought to be a keratin-related 
disease (Munro et al., 1994). Blistering in some cases of PC was worse in warm 
weather and improved with age,  resembling EBS, which was known to be due to 
mutations in genes for the keratins of the basal layer of the epidermis, K5 and K14 
(Coulombe et al., 1991; Bonifas et al., 1991; Lane et al., 1992). Marked increases of 
tonofilaments in the peripheral cytoplasm of keratinocytes from the basal layer 
upwards had been found in PC-1 (Thormann & Kobayasi, 1977; Thomas et al., 
1984).  
Stress response keratins K6, K16 and K17 are rapidly induced on injury or 
inflammation, and are also constitutive components of the epithelium in several 
epidermal appendages such as hair follicle and nail (Fig.3)(Lane & McLean, 2004). 
Four keratins are associated with PC: mutations in K6a or K16 cause PC-1 (Bowden 
et al., 1995; Mclean et al., 1995; Shamsher et al., 1995; Lin et al., 1999; Smith et al., 
1999a; 2000; Terrinoni et al., 2001; Zhou et al., 2007) and mutations in K6b or K17 
lead to PC-2 (McLean et al., 1995; Smith et al., 1998). There is so far only one 
reported exception to this rule, in a case where there was considerable clinical 
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overlap between PC-1 and PC-2 (Ward et al., 2003). The two phenotypes are closely 
correlated with the cell and tissue types in which these keratins are constitutively 
expressed: whilst K16 is a major secondary keratin in orogenital epithelia and in 
palmoplantar epidermis, K17 is only a minor component of these tissues in the fully 
developed epidermis, whereas it is significantly expressed in the deep hair follicle 
where the hair shaft is being formed. In steatocystoma multiplex, the cysts are 
formed in association with the hair follicle, and are known to be caused by mutations 
in the same K6b and/or K17 genes as PC-2 (Lane & McLean, 2004). 
In general, the mutations are either heterozygous missense mutations or 
small-in-frame deletion/insertion mutations. To date, the majority of those reported 
fall within the highly conserved helix boundary domains at either end of the α-helical 
rod domain. These regions are thought to be vital for end-to-end overlap interactions 
during the elongation phase of filament assembly (Liao et al., 2007). The N171 
codon of K6a is emerging as a mutation hotspot in PC-1, and in PC-2, the majority of 
mutations are in the helix initiation motif of K17 with mutations at two codons, N92 
and R94 accounting for more than 50% of cases (Smith et al., 2005).  
However, as more pedigrees of PC are studied, rarer genetic variants have 
emerged. One candidate variant is late onset PC or ‘PC tarda’ (Munro, 2001). PC 
usually begins in infancy, but onset as late as the 4th or 5th decade has been reported 
(Paller et al., 1991). These have been associated with less disruptive mutations. 
Connors et al. (2001) report a novel mutation in the mid-region of the 2B helical 
domain of keratin 16 compared to previously reported mutations which have affected 
one of the highly conserved peptide sequences at either end of the helical rod domain 
common to all keratin molecules. As with many other genetic disorders, 
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identification of the underlying keratin gene defects in PC has raised further 
questions. It is not fully understood why phenotype and age of onset may vary with 
the same mutation, and why mutations that are theoretically highly disruptive to 
filament assembly may in some subjects cause little disease (Munro, 2001).  
1.15 Inherited PPK and desmosomes 
As mutations in keratins result in epidermal fragility, similarly mutations in the 
structural desmosomal proteins have been found to underlie other disease phenotypes 
(Kelsell & Stevens, 1999). Desmosomal proteins are the target antigens in several 
autoimmune blistering disorders: pemphigus vulgaris (desmoglein 3), pemphigus 
foliaceous (desmoglein 1), IgA pemphigus (desmocollins), and paraneoplastic 
pemphigus (desmoplakins, envoplakin, periplakin, plakoglobin, and desmogleins 1 
and 3) (Amagai et al., 1998; Anhalt et al., 1999; Ishii et al., 2001).  
Desmosomal mutations have been found to underlie striate PPK, a rare 
group of autosomal dominant genodermatoses characterized by PPK with both focal 
and streaking, linear hyperkeratosis of the palm of the hand and extending along each 
finger. Armstrong et al. (1999) demonstrated a heterozygous C to T transition in 
exon 4 of the desmoplakin gene, causing a premature termination codon in the 
amino-terminal region of the peptide and resulting in haploinsufficiency. Rickman et 
al. (1999) demonstrated that a mutation in the desmoglein 1 gene caused aberrant 
splicing of exon 3, which would be expected to compromise strand dimer formation 
and the function of the first calcium-binding site of desmoglein 1. Therefore 
mutations in both the cadherin and plakin components of epidermal desmosomes 
have been implicated as causes of autosomal dominant non-syndromic striate PPK. 
Further genetic heterogeneity of striate keratoderma has been demonstrated by the 
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identification of a frameshift mutation in the V2 domain of human keratin 1 in a 
four-generation family of British descent (Whittock et al., 2002a) (see chapter 2.3). 
Thus, the disorder displays locus heterogeneity in that it has been associated with 
mutations in the desmoplakin gene (Armstrong et al., 1999; Whittock et al., 1999; 
Norgett et al., 2006), the desmoglein 1 gene (Rickman et al., 1999; Kljuic et al., 
2003b), and the keratin 1 gene (Whittock et al., 2002a).  It is believed that the 
striking hyperkeratotic lesions in patients with striate keratoderma result from 
impaired function of the desmosomes at sites where these cell-cell junctions are most 
critical, namely the palms and soles (Whittock et al., 1999). Mutations in other 
desmosomal proteins have been found to be associated with syndromic PPK (see 
chapter 2.3). PPK, woolly hair and dilated left ventricular cardiomyopathy (syn. 
Carvajal syndrome, OMIM 605676) is characterized by striate keratoderma, woolly 
hair and dilated left ventricular cardiomyopathy developing in teenage years due to 
mutation in desmoplakin (Carvajal-Huerta, 1998; Norgett et al., 2000). Naxos 
disease (OMIM601214) is an autosomal recessive disorder characterized by 
arrythmogenic right ventricular cardiomyopathy causing heart failure and sudden 
death, congenital woolly hair, and development of progressive, nonepidermolytic 
diffuse PPK, first reported in seven pedigrees from the Greek island of Naxos, due to 
mutation in plakoglobin (Protonotarios et al., 1986; 2001; McKoy et al., 2000). 
“Skin fragility-woolly hair syndrome” (OMIM 607655) is another recessive 
desmoplakin phenotype, consisting of keratoderma, woolly hair and nail dystrophy, 
but without cardiac abnormalities, due to mutation in desmoplakin (Whittock et al., 
2002b). Ectodermal dysplasia/skin fragility syndrome (OMIM604536) is an 
autosomal recessive disease resulting in trauma-induced skin erosions, dystrophic 
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nails, sparse hair, and painful PPK, due to mutation in plakophilin 1 (McGrath et al., 
1997).  
1.16 Inherited PPK due to altered terminal differentiation: loricrin 
Loricrin, a small basic protein synthesized in the upper granular layer, becomes a 
major constituent of the CE (Ishida-Yamamoto et al., 2000b). It is widely distributed 
in the epidermis in the granular layer and above. It is expressed at the final stage 
during the process of epithelial differentiation and occurs later than involucrin and 
profilaggrin expression. It is a unique structural protein, which is glycine-, serine- 
and cysteine-rich, highly insoluble, and 26kDa, consisting of 315 amino acid 
residues (Ishida-Yamamoto et al., 1998a). Its multiple glycine loop motifs and 
glutamine/lysine residues are thought to be necessary for cross-linking CE formation 
(Korge et al., 1997). Calcium and retinoids are both crucial regulators of loricrin 
expression, and the transcriptional control of loricrin and profilaggrin expression in 
the epidermis is closely coordinated (Kalinin et al., 2002). The intensity of loricrin 
expression varies in different body sites: it is abundant in foreskin and perianal skin, 
but less so in leg skin (Ishida-Yamamoto et al., 1998a).  
The physiological and pathological significance of loricrin was initially 
highlighted by discoveries of mutations in the loricirin gene in the variant form of 
Vohwinkel’s syndrome (VS) associated with ichthyosis but not deafness (Maestrini 
et al., 1996; Korge et al., 1997; Ishida-Yamamoto et al., 1998a).  This disorder (syn. 
Loricrin Keratoderma, Camisa’s syndrome) was described by Camisa & Rossana 
(1984). Generalized desquamation at birth and collodion babies may be a feature 
(Matsumoto et al., 2001; Gedicke et al., 2006). It is due to mutations in loricrin 
(Maestrini et al., 1996; Korge et al., 1997; Armstrong et al., 1998; Takahishi et al., 
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1999b; Matsumoto et al., 2001; O’Driscoll et al., 2002; Gedicke et al., 2006). Eight 
families with four different mutations in the loricrin gene have been reported so far. 
In each of these, point insertion mutations result a shift of the reading frame and a 
termination codon delayed by 22 amino acids. In the elongated carboxy-terminal 
domain many of the glycine loops are replaced by arginine residues, thereby 
drastically altering the physical and chemical properties of the loricrin polypeptide 
(Korge et al., 1997; Ishida-Yamamoto et al., 1998a). The most frequent mutation, 
730insG, has been found in families from the UK (Maestrini et al., 1996; Korge et 
al., 1997; O’Driscoll et al., 2002), Japan (Takahashi et al., 1999b ; Matsumoto et al., 
2001) and Germany (Gedicke et al., 2006). 
1.17 Inherited PPK due to altered differentiation: connexins 
Many inherited keratodermas are associated with defects in gap junction 
communication. Mutations in Cx26 (Kelsell et al., 1997), Cx 30 (Xia et al., 1998) 
and Cx31 (Liu et al., 2000; Grifa et al., 1999) have not only been shown to underlie 
non-syndromic sensorineural hearing loss but also hearing loss in association with 
disorders of epidermal keratinisation (Kelsell et al., 2001). 
Vohwinkel syndrome (OMIM 124500), independently reported by 
Vohwinkel (1929) and Wigley (1929), is characterized by honeycomb-like 
keratoderma, starfish-like keratoses on the knuckles and circumferential digital bands 
(“pseudoainhum”). The association of autosomal dominant sensorineural deafness 
has been confirmed as a feature in later reports (Nockemann, 1961; Gibbs et al., 
1966; Ocaňa-Sierra et al., 1975; McGibbon & Watson, 1977; Wereide, 1984). 
Germline mutations in Cx26, initially found in 3 unrelated families, underlie the 
condition (Maestrini et al., 1999). A heterozygous missense mutation, p.D66H, was 
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identified in GJB2, which encodes Cx26, in a large British pedigree containing 10 
affected members which was also found in unrelated Spanish and Italian pedigrees. 
Cx26 is expressed in a wide variety of tissues, including the epithelial supporting 
cells surrounding the sensory hair cells of the cochlea and in the fibrocytes lining the 
cochlear duct (see section 1.8).  
Bart-Pumphrey syndrome (OMIM149200) is an autosomal dominant 
condition characterized by knuckle pads, PPK, mixed sensorineural and conductive 
deafness and leukonychia (Bart & Pumphrey, 1967). Mutations in the GJB2 gene 
have been reported (Richard et al., 1998a; 2004; Alexandrino et al., 2005; Leonard et 
al., 2005). As not all family members reported showed leukonychia (Alexandrino et 
al., 2005; Leonard et al., 2005), it has been questioned whether this is a diagnostic 
feature in this phenotype (Akiyama et al., 2007). As most pathogenic GJB2 
mutations causing both sensorineural hearing loss and skin manifestations cluster in 
the first extracellular loop of the Cx26 peptide (Richard et al., 1998a; 2004; 
Maestrini et al., 1999; Alexandrino et al., 2005; Leonard et al., 2005; Akiyama et al., 
2007), it suggests that this is important for the correct formation and/or function of 
gap junctions (Akiyama et al., 2007). 
 Hidrotic ectodermal dysplasia (syn. Clouston syndrome) (OMIM129500) is 
an autosomal dominant disorder characterized by progressive, diffuse PPK with 
punctiform accentuation and relative sparing of palms, alopecia ranging from focal 
alopecia to universal loss of hair starting after puberty, nail dystrophy and variable 
features including sensorineural deafness, and is particularly prevalent in the French-
Canadian population of Quebec (Clouston, 1929; 1939). Clouston syndrome been 
confused with PC due to the thick, ridged and short nails (van Steensel et al., 2003), 
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although hypotrichosis or alopecia is not usually a feature in the latter, and has only 
rarely been reported (Templeton & Wiegand, 1997). Thus, the presence of alopecia 
in addition to hypertrophic nail dystrophy may be more suggestive of an underlying 
connexin rather than keratin defect. Mutations in GJB6 encoding Cx30 were first 
identified in 12 Clouston syndrome families of varying ethnicity, clustered in two 
mutation hotspots, G11R and A88V (Lamartine et al., 2000). A further mutation, 
p.V37E, in a Scottish case of Clouston syndrome has also been documented (Smith 
et al., 2002). 
 Erythrokeratoderma variabilis (EKV) (OMIM133200) belongs to the 
clinically and genetically heterogeneous group of erythrokeratodermas, and although 
not classified as an inherited PPK, may present with palmoplantar hyperkeratosis. 
Mutations in the GJB3 gene encoding Cx31 have been identified (Richard et al., 
1998b; 2000; Morley et al., 2005) as well as mutations in the GJB4 gene encoding 
Cx30.3 (Macari et al., 2000; Richard et al., 2003). Mild palmoplantar keratoderma 
has also been reported in oculodentodigital dysplasia (ODDD) (OMIM164200) 
caused by a heterozygous mutation in Cx43 (Gong et al., 2006). 
1.18 Other PPKs 
It is already apparent that PPK can be the result of a variety of different processes. 
Other rare keratoderma syndromes indicate that there are many other pathways 
involved.  
 Papillon-Lefèvre syndrome (PLS) (OMIM245000) is a rare autosomal 
recessive disease that is characterized by erythematous PPK and early-onset 
periodontitis resulting in loss of primary and secondary teeth, and frequent pyogenic 
skin infections (Papillon & Lefèvre, 1924; Gorlin et al., 1964; Haneke, 1979). Haim-
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Munk syndrome (HMS) (OMIM245010) is a rare autosomal recessive PPK with 
similar features as PLS, but distinguished by arachnodactyly, acro-osteolysis, 
onychogryphosis and pes planus (Haim & Munk, 1965). 
 The PLS and HMS disease locus was mapped to chromosome 11q14-q21, a 
region where the lysosomal protease cathepsin C gene (CTSC) maps, by three 
independent linkage studies (Fischer et al., 1997; Laass et al., 1997; Hart et al., 
1998). Cathepsin C (dipeptidylpepidase I) is a lysosomal papain-like cysteine 
proteinase capable of removing dipeptides from the amino-terminals of protein 
substrates, and loss-of-function mutations were simultaneously reported in PLS 
(Toomes et al., 1999; Hart et al., 2000). Subsequently, more than 50 mutations in 
CTSC have been reported in families with both PLS (Selvaraju et al., 2003; Hewitt et 
al., 2004; Jouary et al., 2008) and HMS (Hart et al., 2000; Cury et al., 2005). 
Missense and nonsense mutations are the most frequent, but small deletions, 
insertions and splice site mutations have also been reported (Selvaraju et al., 2003; 
Jouary et al., 2008).  
 Mal de Meleda (OMIM248300) is a rare autosomal recessive PPK 
characterized by erythematous PPK, palmoplantar hyperhidrosis, hyperkeratotic 
plaques over joints, perioral erythema, brachydactyly and nail abnormalities, first 
described on the Adriatic island of Meleda, now Mljet, in Croatia (Hovorka & 
Ehlers, 1897; Neumann, 1898; Schnyder et al., 1969). Three different homozygous 
mutations in the gene encoding for SLURP-1 (secreted mammalian Ly-6/uPAR-
related protein 1) were found to underlie Mal de Meleda in 19 Algerian and Croatian 
families (Fischer et al., 2001). Subsequently, further mutations have been reported in 
Tunisian and Turkish families (Charfeddine et al., 2003; Hu et al., 2003). SLURP-1 
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is a secreted member of the Ly-6/uPAR superfamily of proteins that shares 
significant homology with secreted snake and frog cytotoxins. It potentiates the 
action of acetylcholine on the α7 nictonic receptor, which plays an important role in 
the differentiation of stratified squamous epithelia (Kurzen et al., 2004). 
Recombinant SLURP1 has a proapoptotic effect on keratinocytes and upregulates the 
expression of transglutaminase 1, keratin 10, p21, and caspase-3 (Arredondo et al., 
2002). 
Mitochondrial mutations have been reported in association with a variety of 
multisystem disorders, often with sensorineural deafness as a common symptom 
(Wallace, 1993). A mitochondrial mutation A7445G has been reported that co-
segregates with variable expressivity of PPK and progressive deafness in a number 
of pedigrees (Reid et al., 1994; Sevior et al., 1998; Martin et al., 2000). Although 
Reid et al. did not report palmoplantar involvement, its presence in their family was 
confirmed (C Munro, personal communication). The A7445G point mutation in 
mtDNA consists of an adenine to guanine substitution found in homoplasmic form in 
leucocytes from patients with the NEPPK-deafness combination (Sevior et al., 1998; 
Martin et al., 2000) which serves to add serine to elongating protein chains during 
mitochondrial synthesis. The penetrance and expressivity of PPK and deafness varied 
in the pedigrees, suggesting that additional environmental and/or genetic factors are 
involved (Reid et al., 1994).  
 Tyrosine aminotransferase deficiency causes PPK, dendritic corneal ulcers 
and progressive mental impairment in the condition oculocutaneous tyrosinaemia 
(syn. Tyrosinaemia type II, Richner-Hanhart syndrome). It is an autosomal recessive 
condition caused by homozygous defects of the tyrosine aminotransferase gene at 
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16q21.1-q22.3 (Fellman et al., 1969). Deficiency of the enzyme leads to increased 
levels of serum tyrosine (Bonhert et al., 1982). 
1.19 Conclusion 
In pathological thickening of palmoplantar skin, even considering only those forms 
due to inherited gene mutation, it is apparent that a variety of mechanisms must be 
activated. Identifying underlying mutations has provided information about the 
functional importance of proteins involved in the differentiation of palmoplantar 
keratinocytes, but the mechanisms by which the molecular defects cause the clinical 
phenotype remain obscure. Nonetheless, the pathways of pathological hyperkeratosis 
in inherited PPK serve as a model for a wider spectrum of common conditions in 
which palmoplantar hyperkeratosis is a cause of significant morbidity, in the 
expectation that better understanding may lead to better management. While 
restricting this study to the inherited PPKs, in order to investigate the variety of 
possible mechanisms of palmoplantar hyperkeratosis, families representative of 



























































Chapter 2.1 Clinical Characterisation of the Inherited Palmoplantar 
Keratodermas 
2.1.1 Introduction 
The inherited PPKs are an extremely heterogeneous group of skin diseases that can 
be classified on the basis of the pattern and age of onset of hyperkeratosis on the 
palm and sole, on their associated features and syndromes and, more recently, by 
their inherited genetic defect (Lucker et al., 1994; Itin & Lautenschlager, 1995; 
Stevens et al., 1996; Ratnavel & Griffiths, 1997; Judge et al., 2004; Itin & Fistarol, 
2005) (see chapter 1). Due to the rarity of these conditions, they have been difficult 
to characterize and investigate. It is known that clinical patterns may not be 
consistent within families, and indeed allocation to, for example, focal and diffuse 
forms may be difficult. No controlled prospective clinical trials have been published 
other than a comprehensive review and report of new phenotypic data undertaken for 
PC (Leachman et al., 2005). Publications are biased towards extreme or unusual 
manifestations of these conditions, or unusual associations which in isolated cases 
may be coincidental. There has been relatively little exploration of the spectrum of 
clinical or pathological phenotypes that may be observed. This study provided an 
opportunity for systematic documentation and assessment of clinical features and 
response to treatment in this cohort of inherited PPKs. 
 
2.1.2 Methods 
Patients were recruited to the study from a tertiary referral genodermatoses clinic for 
the West of Scotland or from cases known to the department. For the purposes of 
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skin biopsy, patients who were pregnant, under the age of 18 years, receiving 
anticoagulants, with known arterial disease or peripheral neuropathy, or unable to 
give consent were excluded. A detailed explanation of the nature of the study was 
given to the patients in conjunction with a Patient Information Leaflet (Addendum 
A). Informed consent was obtained. Approval was obtained from the Ethical 
Committee of the Southern General Hospital, Glasgow. Documentation of the 
clinical phenotype in palmoplantar and other affected tissues was carried out, 
specifically looking at symptoms, signs and prior response to treatment. The clinical 
pattern of PPK was recorded in each individual studied. As the expression of several 
implicated genes (keratins, loricrin) is tissue and differentiation specific, the history 
and clinical findings were closely assessed in each case, specifically examining 
features such as hair and nail changes, mucosal, periodontal, and laryngeal disease, 
keratitis, sensorineural deafness, and other neuropathies. Family trees were 
documented for all pedigrees. 
2.1.2.1 History 
A standard questionnaire (Addendum B) was devised and used to ensure accurate 
documentation in all patients of the following: date of birth; gender; occupation; sites 
of hyperkeratosis (e.g. balls of feet, toes – plantar, lateral or dorsal aspects, palms, 
heels etc.); type of hyperkeratosis: focal, diffuse, striate, punctate, transgredient 
(keratoderma extending beyond palmoplantar skin); colour of palms and soles; 
texture (smooth, rough, fissured); presence or absence of erythema or blistering on 
palms or soles; associated pain; hair changes (e.g. woolly/unruly); nail changes; 
presence of knuckle pads; presence of mucosal, periodontal or laryngeal disease; 
history of keratitis; sensorineural deafness; other neuropathies; history of vaginal or 
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cervical abnormalities, or phimosis; difficulty with lactation or sweating. A full past 
medical history, drug history, any known drug allergies, and any previous therapies 
for keratoderma were also noted.  
2.1.2.2 Examination 
A full physical examination of the skin was performed, including hair and nails. 
Where deemed appropriate, a physical examination of other systems was also 
performed. Clinical photography was performed, following informed consent. 
 
2.1.3 Results 
2.1.3.1 Patients recruited 
Sixteen patients with inherited PPK (15 with known underlying mutations and one 
whose mutation was ascertained during the course of the study, chapter 2.3) were 
recruited to the study (Table 3) from known local pedigrees. Pedigrees had already 
been documented in those pedigrees with known mutations at the time of recruitment 
and were re-confirmed, but a full pedigree was documented for the striate PPK 
pedigree (chapter 2.3).  
2.1.3.2 Clinical Findings 
Of the 16 patients recruited, 9 were female and 7 male. Their mean age was 48.1 
years (range 34-78). The range of clinical features in the cohort of patients is 
summarised (Table 4). Occupational history revealed that 5/16 PPK patients had 
experienced some difficulty in a particular job, with deterioration of the 
hyperkeratosis due to the nature of the work e.g. metal sheet worker whose palmar 
hyperkeratosis worsened (K1). 2/5 had to change occupation as a result and 2/5 had 
taken early retirement on health grounds. All patients complained that the texture of  
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Type of PPK Mutation Reference No. patients 
Keratin 1 Mild 
Epidermolytic 
G4124A Hatsell et al., 2001 2 
Keratin 9 Epidermolytic 1362ins3 Coleman et al., 1999 1 
  R162Q Covello et al., 1998a 1 
    Total 2 
Keratin 17 PC-2 N92D McLean et al., 1995 6 
 PC-2 N92S Covello et al., 1998b 2 
    Total 8 
Desmoglein 
1* 
Striate p.Arg144stop Chapter 2.3 1 
Loricrin Loricrin InsG231 Korge et al., 1997 2 
Mitochondrial 
DNA 
PPK and deafness A7445G Reid et al., 1994 1 






Table 4. Summary of clinical findings in cohort of inherited PPK patients 












Focal hyperkeratosis palms 1/2  0/2 1/8 1/1 1/2 1/1 
Diffuse hyperkeratosis palms 1/2  2/2 0/8 0/1 1/2 0/1 
Focal hyperkeratosis soles 2/2 0/2 8/8 1/1 1/2 1/1 
Diffuse hyperkeratosis soles 0/2 2/2 0/8 0/1 1/2 0/1 
Hyperkeratosis knees/elbows 0/2 1/2 0/8 1/1 1/2 0/1 
Presence of pseudoainhum 0/2 0/2 0/8 0/1 1/2 0/1 
Toenails 1/2  1/2 8/8 0/1 0/2 0/1 
Fingernails 0/2 1/2 8/8 0/1 0/2 0/1 
History of blistering 0/2 2/2 6/8 1/1 0/2 1/1 
Plantar pain 1/2  1/2 8/8 1/1 2/2 1/1 
Erythema 0/2 2/2 2/8 1/1 2/2 0/1 
Follicular keratoses 0/2 0/2 6/8 0/1 0/2 0/1 
Cysts (any type) 0/2 0/2 8/8 0/1 0/2 0/1 
Natal teeth 0/2 0/2 3/8 0/1 0/2 0/1 
Laryngeal/Periodontal/Mucosal 
abnormalities 
0/2 1/2 6/8* 0/1 1/2** 0/1 
Hyperhidrosis 1/2  1/2 7/8 1/1 2/2 1/1 
Knuckle pads 0/2 1/2 0/8 0/1 2/2 0/1 
Sensorineural deafness 1/2  0/2 0/8 0/1 0/2 1/1 
Unruly/wiry hair 0/2 0/2 1/8 0/1 0/2 0/1 
Abnormal eyebrows 0/2 0/2 5/8 0/1 0/2 0/1 




PC-2= Pachyonychia congenita type 2; *Mutation in Desmoglein 1 identified during course of study, 
see chapter 2.3 




their hyperkeratosis would become rough and fissured if not pared regularly, and 
14/16 patients had smooth hyperkeratosis due to their own regular manual paring 
(Figures 6-9). All patients developed symptoms “in childhood”, with no clear 
differences in onset between different subtypes. Minimal information was available 
regarding the neonatal history of the patients recruited. 
 
Plantar pain and hyperhidrosis were the most common symptoms across all subtypes 
of inherited PPK; intermittent “shedding” of skin was specific to K9 subtype. 
14/16 complained of plantar pain and 15/16 of hyperhidrosis (particularly 
palmoplantar). 10/17 patients complained of intermittent blistering, which was 
uniformly at pressure points/post trauma. 2/2 K9 patients experienced intermittent 
“shedding” of their skin, whereby the hyperkeratotic areas would simply peel off 
spontaneously every 6-12 months, a symptom specific to this subtype. 3/8 K17 
and1/2 Loricrin (both male and female) patients complained of very sparse axillary 
and pubic hair.  
  
Recurrent abscesses, cysts, toe and fingernail dystrophy were common features in 
pachyonychia congenita type 2  
Aside from focal plantar hyperkeratosis, the most common findings among the K17 
patients were onychodystrophy (both finger and toenail) (100%), plantar pain 
(100%), recurrent abscesses (100%), recurrent cysts (100%) and hyperhidrosis – 
specifically plantar (87.5%) (Figure 8). All patients complained of recurrent 
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E   F  
Figure 6.  Plantar keratoderma in inherited PPK due to underlying K1, K9, K17, DSG1, loricrin 
and mitochondrial mutations (a, b, c, d, e and f respectively).  Diffuse hyperkeratosis evident in (b) 
and (e), with evidence of a honeycomb pattern in the latter. Focal hyperkeratosis in (a, c, d and f) 
involving the plantar surface and extending to the medial surface of the great toe, a site of friction. 
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Figure 7. Clinical photographs of loricrin keratoderma, showing evidence of honeycomb pattern 
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Figure 8. Clinical photographs of pachyonychia congenita type 2 demonstrating 
onychodystrophy (a, b, c, d), pili torti (e) and cysts (f). Variation in nail thickness and subungal 
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Figure 9. Striate/focal palmar hyperkeratosis (a) in underlying desmoglein 1 mutation (see 











incision and drainage, or excision. The history was consistent with secondarily 
infected cysts. 
 
The majority of inherited PPK patients were receiving minimal treatment other than 
manual paring. 
Previous treatments including manual paring (16/16); emollients (16/16); topical 
salicylic acid (3/16). 5/16 PPK patients had been prescribed oral retinoids (1/2 K9, 
1/2 Loricrin, 2/8 K17, 1/1 DSG1) of whom 2 were still taking them. The average 
dose was 30mg (range 20-50mg), and duration of treatment ranged from 6 months to 
15 years. Effect of treatment ranged from minimal effect (2/5), specific improvement 
in nail dystrophy (1/5) to moderate improvement in hyperkeratosis (2/5). 1/2 Loricrin 
patient stopped oral retinoids due to skin thinning and peeling; he had also undergone 
surgery for constricting digital bands. 1/8 K17 PPK patients had received cautery and 
1/8 oral antibiotics, incision and drainage, for the treatment of cysts. 
 
Focal Hyperkeratosis is most common on the plantar surface of the metatarsal area, 
the ball and the heel of the foot 
Those patients with focal plantar hyperkeratosis were specifically assessed for 
particular patterns/sites where hyperkeratosis was most common or most severe 
(Table 5). 13/16 PPK patients had focal plantar hyperkeratosis, including one patient 
with loricrin keratoderma but with a milder phenotype resulting in focal, not diffuse, 
hyperkeratosis only. The plantar surface of the metatarsal area was uniformly 
affected, with the balls and heels being affected in the majority. Extension of 
hyperkeratosis to medial or lateral aspects of the toes/feet was not restricted to a  
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particular subtype. Keratoderma was uniformly more severe on plantar compared to 
palmar surfaces. Although accentuated in pressure points of feet, or areas of chronic 
use of the hands, no other clear patterns of distribution of hyperkeratosis became 
apparent. 
 
Table 5. Pattern of focal plantar hyperkeratosis in cohort of inherited PPK patients with 






DSG1 (n=1) Loricrin (n=1) Mitochondrial 
(n=1) 
Plantar metatarsal area 2/2 8/8 1/1 1/1 1/1 
Ball of foot 2/2 5/8 1/1 1/1 1/1 
Heel 2/2 6/8 1/1 1/1 1/1 
Medial aspect great toe 0/2 3/8 0/1 0/1 1/1 
Extension to lateral 
surfaces 
2/2 4/8 0/1 0/1 1/1 
 
 
2.1.3.3 Abnormal adult dentition in PC-2  
During clinical assessment of the pedigrees recruited, it was noted that a large 
multigeneration family (Figures 6 & 8) with PC-2, having a known heterozygous 
missense mutation in the helix initiation motif of K17 (Asn92Asp) (McLean et al., 
1995) exhibited abnormal adult dentition. Of 18 affected members over 2 generations 
available for interview, 7 reported having either full or upper dentures fitted in their 
late teenage years due to “crumbling” and exaggerated friability of their adult teeth.  
There was no history of increased caries. All affected patients had been initially 
treated with multiple crowns to prevent the disintegration of their teeth, without 
benefit. This history is suggestive of either enamel loss or attrition, but it has not 
been possible directly to assess any affected teeth. By contrast, none of their 9 




2.1.3.4 Associated extracutaneous features 
1/1 patient with PPK due to mitochondrial DNA mutation had bilateral sensorineural 
deafness, diagnosed at the age of five. 1/2 K1 patients had a history of sensorineural 
deafness which had developed in later life, as had his affected father and daughter 
but other family members affected by PPK were not affected by hearing loss. 1/8 
K17 patient had had a cerebral haemorrhage in her 20s, resulting in unilateral loss of 
vision and a history of treated hyperthyroidism. 1/8 K17 patient had a co-existent 
diagnosis of multiple sclerosis. 1/2 Loricrin and 1/8 K17 patients complained of 
recurrent gingivitis, and 1/8 K17 patient suffered recurrent mouth ulceration. 
 
2.1.4 Discussion 
2.1.4.1 Clinical features of the inherited PPKs 
Phenotypic variations seen in affected PPK members who have inherited the same 
disease-causing mutation suggest that age, lifestyle and/or modifying genetic factors 
affect the clinical manifestation of PPK (Kelsell & Stevens, 1999). The findings of 
this study confirm the suspicion that the common clinical classification of PPKs may 
be a poor guide to the underlying mutation. Significant differences in the severity of 
disease in individuals within the same pedigree with the same underlying mutation 
were observed. 
 Mild diffuse keratoderma has generally been reported with underlying K1 
mutations (Hatsell et al., 2001; Terron-Kwiatkowski et al., 2002; 2004; 2006) 
however at the time of clinical assessment, both K1 patients in our cohort displayed 
mild focal plantar keratoderma. One patient previously described more generalised 
hyperkeratosis prior to his retirement, when he was more active, indicative of the 
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variation of clinical features over time, and being dependent on lifestyle/modifying 
environmental factors. Atypical EPPK where the keratoderma was not strictly limited 
to the palms and soles but extended slightly on the wrists and flexures has been 
found in association with underlying K1 mutations (Terron-Kwiatkowski et al., 
2004). 
Similarly, striate PPK (Whittock et al., 2002a) and NEPPK associated with 
extension of hyperkeratosis from the sole along the Achilles tendon and occasionally 
the extensor tendon of the great toe have been reported (Kimonis et al., 1994). EPPK 
(Vörner type) associated with underlying K9 mutations (Reis et al., 1992; 1994) has 
been characterised clinically by a diffuse pattern of severe hyperkeratosis limited to 
the palms and soles and histologically by suprabasal epidermolysis (Vörner, 1901). 
These features were seen in both K9 PPK patients assessed in this cohort. 
The most common clinical features of PC-2 in this cohort (plantar 
keratoderma, plantar pain, hyperkeratosis, cysts and onychodystrophy) correlate with 
the findings of an analysis of cases from the International Pachyonychia Congenita 
Research Registry (IPCRR), cases from the National Registry for Ichthyosis and 
Related Disorders (NRIRD) and new prospective data of 57 PC patients (Leachman 
et al., 2005). The IPCRR data are strongly skewed to PC-1 (K6a/K16) cases, 
explaining some of the differences noted with this cohort of 8 K17 PPK patients 
(Table 6). Recurrent abscesses were uniformly a significant feature in this cohort 
most likely due to secondary infection of cysts. PC-2 patients have been found to 
develop all types of cysts, including epidermal inclusion cysts, pilosebaceous cysts, 






Table 6. Summary of phenotypic symptoms in PC-2 recruited in this study compared to 
 PC case studies, IPCRR and NRIRD data (table adapted from Leachman et al., 2005). 
 




NRIRD (n=11) Current study 
(n=8) 
Toenails 426 of 435 (98%) 55 of 57 
(98%) 
9 of 10 (90%)  8 of 8 (100%) 
Fingernails 424 of 434 (97%) 56 of 57 
(98%) 
10 of 11 (91%) 8 of 8 (100%) 
Plantar pain 71 of 74 (96%) 54 of 57 
(95%) 
10 of 11 (91%) 8 of 8 (100%) 
Plantar 
keratoderma 
288 of 312 (92%) 55 of 57 
(96%) 
10 of 11 (91%) 8 of 8 (100%) 
Oral leukokeratosis 216 of 309 (95%) 43 of 57 
(75%) 
NR 0 of 8 (0%) 
Palmar 
keratoderma 
171 of 215 (80%) 35 of 57 
(60%) 
7 of 11 (63%) 1 of 8 (12.5%) 
Follicular keratoses 149 of 189 (79%) 37 of 57 
(65%) 
NR 6 of 8 (75%) 
Cysts (any type) 72 of 100 (72%) 20 of 57 
(35%) 
NR 8 of 8 (100%) 
Larynx 
(hoarseness) 
31 of 44 (70%) 9 of 57 (16%) NR 0 of 8 (0%) 
Hyperhidrosis 111 of 169 (66%) 42 of 53 
(79%) 
4 of 11 (36%) 7 of 8 (87.5%) 
Hair abnormalities 64 of 120 (53%) 15 of 57 
(26%) 
0 of 11 (0%) 6 of 8 (75%) 












IPCRR = International Pachyonychia Congenita Research Registry; NRIRD = The National 
Registry for Ichthyosis and Related Disorders; NR = not reported 
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variable severity were reported by the majority in this cohort. However, both studies 
may be subject to ascertainment bias, because patients with more severe disease are 
probably more motivated to participate in surveys or studies. 
Plantar hyperkeratosis was more severe than palmar hyperkeratosis in all 
subtypes of inherited PPK, reflecting their weight-bearing role and trauma due to 
mobility, although other patterns of distribution of hyperkeratosis did not emerge. It 
is probable that chronic manual work (e.g. post office sorting, metal sheet work) 
exacerbated palmar involvement in K1 and Loricrin subtypes, although this only 
occurred in 2 patients. It was clear from this cohort of 16 PPK patients that their 
choices of employment, and any subsequent changes in work, were influenced by 
their disease. A limitation of this study in comparison of clinical features between 
different subtypes of inherited PPK is the small number of each subtype recruited. In 
the IPCRR questionnaire, 12 of 57 participants reported that they were unable to 
work or attend school because of the severity of their condition, with plantar pain 
being identified as the most disabling feature (54 of 57) (Leachman et al., 2005). 
Significant differences in severity of disease were also seen within the 
loricrin pedigree e.g. in the uncle with severe diffuse palmoplantar hyperkeratosis 
with constricting digital bands (pseudoainhum) compared with his nephew with mild 
focal palmoplantar hyperkeratosis. Honeycomb keratoderma was apparent in both 
cases, but very mild in the latter case with only very subtle clinical features of 
ichthyosis which could easily have been overlooked if the family history was not 
known. These two features have previously been reported in all families with loricrin 
mutations to date (Maestrini et al., 1996; Korge et al., 1997; Armstrong et al., 1998; 
Takahishi et al., 1999b; Matsumoto et al., 2001; O’Driscoll et al., 2002; Gedicke et 
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al., 2006). Other features including pseudoainhum, prominent knuckle pads and 
collodion baby were not uniformly present in the two patients recruited in this study, 
reflecting previous reports, where autoamputations/mutilating keratoderma were only 
observed in three families (Maestrini et al., 1996; Korge et al., 1997; O’Driscoll et 
al., 2002). 
 
2.1.4.2 Abnormal adult dentition in PC-2 
One of the striking features of PC-2 is the frequent first presentation with primary 
dentition erupted at birth (pre-natal or natal) or within the first 30 days of life 
(neonatal). Frontal teeth are typically affected; they are soft, friable, and said to be 
prone to caries, usually being lost within the first few months of life (Clementi et al., 
1986; Feinstein et al., 1988; Munro, 2001). In addition to natal teeth, early multiple 
tooth development at 4-5 months and in one case, early natal tooth loss without 
immediate permanent tooth replacement, have been reported 
 In some cases, second primary teeth, non-permanent teeth occurring after the 
loss of natal teeth, will develop in addition to the natal teeth but have been thought to 
be ultimately replaced by normal permanent teeth during childhood.  Histologically, 
the polypean dental papillae of these natal teeth show mucosal hyperplasia and 
irregular rete ridge proliferation. Cytoplasmic vacuolization and oedema are seen in 
the upper and spinous layers of the mucosa. Irregular osteodentine-like structures 
with cell inclusions and interglobular dentine are seen (Anneroth et al., 1975).  K17 
(Leachman et al., 2005). 
Hutchinson-like tooth deformity in the absence of congenital syphilis, in a 6 year old 




expression has been described in the early stages of epidermal appendage 
development (McGowan & Coulombe, 1998) and in the predominantly hard portion 
of the hair shaft 
Although the premature loss of primary teeth in conjunction with early 
eruption may be of no clinical significance, the clinician should not overlook loss of 
primary or permanent teeth in the absence of trauma (Hartsfield, 1994). Non-
traumatic early loss of adult dentition is usually caused by caries or destructive 
periodontal disease. It is possible that the abnormal dentition in PC-2 may be a result 
of dentine abnormality, which is non-keratin related, instead of a keratin-related 
enamel abnormality. 
(McGowan & Coulombe, 2000), but its expression in tooth 
progenitors is not known. 
Abnormalities in adult teeth have not previously been described in PC-2.  
However, we were only able to obtain a history of unusual increased friability, 
suggesting a dentine abnormality, and not of caries. Dental friability has not 
previously been noted and as only some members were affected, it may be 
multifactorial with K17 mutation contributing indirectly. The effect might 
alternatively be specific to the Asn92Asp mutation. The presence in PC-2 of 
structurally abnormal, premature teeth and possibly adult teeth suggests that K17 
expressing keratinocytes play an important role in odontogenesis and tooth eruption 
and is an area for further study 
 
(McLean et al., 1995). It is possible that this finding is 
unique to this particular family or their circumstances as it has not been supported by 
the PC database (Leachman, personal communication). However, it would still be 
advisable to ensure that PC-2 patients have appropriate dental examination and care. 
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2.1.4.3 Pain, hyperhidrosis and the inherited PPKs 
Pain and hyperhidrosis were the most important symptoms for many patients. 
Hyperhidrosis has been commonly described in association with the inherited PPKs. 
The feet most usually are involved as often they are malodorous and sweaty as well 
as hyperkeratotic and often complicated by a high ambient temperature (Schönfeld, 
1980; Feinstein et al., 1988; Judge et al., 2004; Itin & Fistarol, 2005; Leachman et 
al., 2005). Water retention by abnormally keratotic and porous stratum corneum 
probably contributes to maceration and microbial overgrowth, although it is possible 
that in addition, there is a real increase in sweat excretion (Judge et al., 2004). It is 
thought that plantar pain is also exaggerated by excessive plantar sweating, 
especially at high ambient temperatures, as frank blistering may occur below the 
hyperkeratosis, with friction from footwear and tissue maceration from sweating 
being contributing factors (Swartling & Vahlquist, 2006). 
Hyperhidrosis, even in the absence of other associated conditions such as 
PPK, is an embarrassing condition and poses a management challenge. Specific 
recommendations for the treatment of plantar hyperhidrosis include education 
regarding local hygiene, using an absorbent foot powder twice daily, and avoiding 
occlusive boots or sports shoes; the use of topical aluminium chloride (AlCl); tap 
water iontophoresis and intradermal botulinum toxin with appropriate analgesia 
(Hornberger et al., 2004). Lumbar sympathectomy has been reserved for severe cases 
but condemned due to severe side-effects e.g. sexual dysfunction (May et al., 1969). 
Systemic anticholinergic agents commonly give side-effects of dry mouth, visual 
disturbance, urinary retention and urgency, flushing and constipation (Kim et al., 
2003) limiting their use. 
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Far fewer studies have been directed at the treatment of plantar compared to 
other forms of focal hyperhidrosis as it is thought to be less common or perceived as 
less problematic than axillary or palmar disease (Hornberger et al., 2004). Of 139 
patients in a larger observational study, 84% had a good or excellent response to 
topical 30-40% AlCl in a salicylic acid gel (Benohanian et al., 1998). A study of 
topical 25% AlCl in absolute ethanol resulted in 10/11 patients achieving euhidrosis 
(Jensen & Karlsmark, 1980). Response rates to tap water iontophoresis were in 
excess of 90% in 5 observational studies (Bouman, 1952; Grice et al., 1972; Abell & 
Morgan, 1974; Shrivastava & Singh, 1977; Akins et al., 1987). Treatment of plantar 
hyperhidrosis in inherited PPK has been reported with standard topical therapies 
including aluminium chloride which may reduce blistering (Tidman & Wells, 1988), 
and plantar injections of botulinum toxin using Bier’s block for anaesthesia have also 
been described in PC, giving both dryness and relief of plantar pain for 
approximately 3 months (Swartling & Vahlquist, 2006) (see Appendix A).  
However, data on the prevalence of hyperhidrosis may differ depending on 
how it is defined. Primary focal hyperhidrosis is defined as focal, visible, excessive 
sweating of at least 6 months duration without apparent cause with at least two of the 
following characteristics: bilateral and relatively symmetric, impairs daily activities, 
frequency of at least one episode per week, age of onset less than 25 years, positive 
family history and cessation of focal sweating during sleep (Hornberger et al., 2004). 
Although plantar hyperhidrosis has been reported in inherited PPK, and this was 
confirmed by 15 of 16 patients in this study, no formal, objective assessment of 
plantar sweating in PPK has been reported.  
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Tests quantifying sweat production are not practically or routinely performed 
in clinical practice, and verbal reporting/estimation of symptoms by patients is used 
to assess benefit of treatment. No controlled studies on the sensitivity and specificity 
of history, physical examination, or laboratory testing in accurately diagnosing or 
characterising the severity of primary focal hyperhidrosis are available (Hornberger 
et al., 2004). Most studies on focal hyperhidrosis are clinical trials providing only 
measurement values before and after treatment e.g. botulinum toxin therapy 
(Odderson, 1998). Gravimetric assessment provides an appropriate tool to objectify 
hyperhidrosis and has been used to compare the sweat production of healthy control 
subjects with patients suffering disabling axillary sweating (Naumann et al., 1998; 
Hund et al., 2002). Interestingly, no definite cut-off value was found that clearly 
distinguished patients with hyperhidrosis from normohidrotic individuals. Minor’s 
starch-iodine test has also been described in mapping areas of excessive sweating 
prior to treatment with botulinum toxin (Naumann & Lowe, 2001) and surgery 
(Swinehart, 2000), however this does not provide accurate information on the 
quantity of sweat produced. A more detailed clinical and physical evaluation of 
plantar hyperhidrosis in inherited PPK is warranted . 
2.1.4.4 Quality-of-life issues 
Quality-of-life (QoL) questions were not specifically addressed in this study, but a 
number of points were raised by participants during their involvement with this 
study. These included the impact of plantar pain and hyperkeratosis on their 
employment (sections 2.1.4.1 and 2.1.4.3) and mobility which often impacted on 
family life; cosmetic concerns about skin and nail care; embarrassment regarding 
sweaty, malodorous feet and limitations in footwear selection. 
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 By attempting to measure QoL , the effects of disease upon individuals can 
be ascertained, and subsequently, to judge the benefit of therapeutic intervention. 
Health-related QoL is defined as the subjective perception of the impact of health 
status, including disease and treatment, on physical, psychological and social 
functioning and well-being (Leidy et al., 1999). According to standardized and 
validated QoL surveys, the negative effects of hyperhidrosis alone, without 
associated PPK, are comparable to other conditions such as severe psoriasis, end-
stage renal disease, rheumatoid arthritis and multiple sclerosis (Cina & Clase, 1999; 
Swartling et al., 2001). The IPCRR questionnaire specifically asked about time 
required for grooming and concerns about the cosmetic appearance of their skin and 
nails, with 38 of 57 participants reporting that this negatively impacted on their 
quality of life. Several participants also reported electing not to have children 
because of their fear of having a child with PC (Leachman et al., 2005), although 
first trimester prenatal diagnosis for individuals with known mutations is now a 
possibility (Smith et al., 1999b). Disease-specific health related QoL measures are 
felt to be the most accurate way of measuring the impact of a particular disease 
(Beattie & Lewis-Jones, 2006), and the development and validation of an appropriate 
QoL questionnaire for inherited PPK is an important area for future study. 
2.1.4.5 Treatment of PPK 
This study highlights the inconsistency and inadequacy of treatment of PPK. The 
goals of treatment of patients with inherited PPK are aimed at combating a number 
of features of the disease: hyperkeratosis of the skin, nails or mucous membranes; 
blisters; pain; hyperhidrosis; pseudoainhum (mutilating PPKs); cysts and infection 
(PC). There have previously been no specific treatments targeted at the inherited 
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PPKs but rather the same therapies are used or recommended for many 
hyperkeratotic conditions, including callosities, psoriasis or ichthyosis (Milstone et 
al., 2005). More recently therapeutic siRNAs specifically for PC have been 
developed (Smith et al., 2008) (see Section 4). 
 Mechanical paring remains a mainstay of treatment, either by the individual, 
using pumice stones, emery boards, paring knives etc. or by regular attendance to 
podiatry/chiropody departments. In our cohort, the majority of patients performed 
their own manual paring at home, on approximately a weekly basis. Efforts to 
distribute weight, pressure and friction, using specially constructed shoes, orthotics, 
insoles or simply socks and gloves are mechanical approaches that many patients 
find useful (Milstone et al., 2005). One PC-2 patient in this study needed access to a 
wheelchair at times when plantar pain was severe. Twenty-nine of 57 participants in 
the IPCRR questionnaire also reported an inability to walk without an aid (Leachman 
et al., 2005). Easy access to podiatry, physiotherapy and orthotic services is thus 
essential in the treatment of these conditions.  
 Keratolytics e.g. salicylic acid in white soft paraffin or propylene glycol may 
facilitate removal of outer keratin layers (Milstone et al., 2005), but no patients in 
this cohort found this a useful or practical treatment given the extent of their 
hyperkeratosis (see section 2.1.4.6). Benzoic acid compound ointment is mildly 
keratolytic and may be useful in reducing fungal and bacterial overgrowth and the 
resulting bad odour. Topical retinoids have little effect (Judge et al., 2004). Systemic 
retinoids may be beneficial for patients with marked functional impairment, but 
response is unpredictable. Isotretinoin (Thomas et al., 1984), etretinate (Lucker & 
Steijlen, 1991) and acitretin (Judge et al., 2004) have all been used (see section 
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2.1.4.7). Increasing tenderness, skin thinning and blistering is a limitation however, 
and only 2/16 PPK patients in this study were currently taking retinoids. Systemic 
retinoids may be beneficial for nail care as well as palmoplantar hyperkeratosis, but 
other treatments range from topical pastes of 20-40% urea or 15-20% salicylic acid 
to ablation of the nail matrix (Thomsen et al., 1982). Reduction in periodontal 
swelling and erythema has also been reported following treatment with oral 
isotretinoin in Papillon-Lefèvre syndrome (Sethuraman et al., 2005). Surgical 
intervention may also be necessary for the treatment of pseudoainhum in order to try 
to avoid autoamputation, as in the case of one loricrin PPK patient in the cohort. 
The commonest specific chemical interventions in PPK are the use of topical 
salicylic acid and of oral retinoids. The relevance of their actions to possible disease 
mechanisms is therefore considered further. 
2.1.4.6 The action of salicylic acid  
Salicylic acid is used in concentrations of 0.5% to 60% in almost any vehicle (Fluhr 
et al., 2008), with concentrations of 20-50% being used as superficial chemical 
peeling agents (Zakopoulou & Kontochristopoulos, 2006). It is thought that it may 
exert a direct solubilizing effect on the stratum corneum, with dissolution of 
intercellular cement and reduction of adhesive forces within the stratum corneum 
(Marks et al., 1975; Huber & Christophers, 1977; Loden et al., 1995). Corneocyte 
intercellular bonding, corneocyte desquamation, stratum corneum hydration, 
corneocyte swelling and stratum corneum softening have also all been proposed as 
mechanisms of action (Lebwohl, 1999). Antihyperplastic properties of salicylic acid 
on pathologic hyperproliferation of the epidermis (Fluhr et al., 2008) contrast with a 
promotion of epidermopoiesis in normal guinea pig skin, where epidermal thickness 
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was increased by 40% and deep epidermis by 19% (Weirich et al., 1978). In humans, 
a reduction of stratum corneum cell layers after 3 weeks of application was shown 
(Roberts et al., 1980), as well as alteration of intercellular structure resulting in 
desquamation of corneocytes (Huber & Christophers, 1977). 
Salicylic acid is absorbed after topical application (Lin & Nakatsui, 1998; 
Schwarb et al., 1999; Benfeldt et al., 1999), which is confirmed by the development 
of systemic toxicity after percutaneous absorption after application onto large areas 
of skin (Schwarb et al., 1999). Epidermal barrier damage, achieved by repeated tape 
stripping, irritant dermatitis due to sodium lauryl sulphate and by delipidization, has 
a pronounced effect on the cutaneous penetration of salicylic acid in both humans 
and shed snake skin models (Harada et al., 1992; Benfeldt et al., 1999). This is 
relevant clinically in the treatment of inflamed hyperkeratotic skin such as in PPK, as 
well as in hyperproliferative conditions such as psoriasis. The topical bioavailability 
of salicylic acid in the stratum corneum varies substantially both with different 
original concentrations and among different formulations, dependent on the base 
used (Tsai et al., 1999). 
2.1.4.7 The action of retinoids 
The one intervention able to affect hyperkeratosis significantly is oral retinoid 
therapy. Retinoids define a class of compounds comprising vitamin A (retinol) and 
its natural and synthetic derivatives (Sorg et al., 2006). They are lipophilic molecules 
which diffuse through cellular and other phospholipid membranes, so easily 
penetrate the epidermis. Retinoids are involved in regulation of cell proliferation, cell 
differentiation and morphogenesis. Their biological effects are mediated by their 
interaction with the nuclear retinoic acid receptors (RARs, α, β and γ) and retinoid X 
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receptors (RXRs, α, β and γ). Adult human skin predominantly expresses the 
isoforms RAR-γ and RXR-α (Elder et al., 1991; Fisher et al., 1994), and it is thought 
that the binding affinity of retinoids to various RAR subtypes contributes to their 
relative potency. These ligand-receptor complexes modulate the expression of genes 
involved in cellular differentiation and proliferation (Fisher et al, 1996) by mainly 
participating together as heterodimers, to regulate transcription (Chambon, 1996; 
Chawla et al., 2001). Principally all-trans retinoic acid, the active vitamin A 
derivative, is the endogenous ligand for RARs, whereas its 9-cis isomer (9-cis-
retinoic acid) activates both RARs and RXRs (Levin et al., 1992; Allenby et al., 
1994).  
There are two types of cellular retinoid binding proteins, the cellular retinoic 
acid binding proteins (CRABPs I and II) and the cellular retinol binding proteins 
(CRBPs). These proteins act as intracellular storage sites for retinoids and may 
facilitate retinoid transport from the cytoplasm into the nucleus (Donovan et al., 
1995). In normal human skin, CRABPII protein levels are much higher in the 
epidermis than dermis and CRABPI in the dermis than epidermis (Roos et al., 1998).  
Vitamin A deficiency in humans and animal models results in epithelial 
squamous metaplasia prone to malignant conversion (Hong & Itri, 1994) and natural 
and synthetic retinoids are used as chemopreventive agents for epidermal cancers 
(Altucci & Gronemeyer, 2001). Altered expression of RARs and RXRs during 
carcinogenesis is thought to reduce the ability of epidermal cells to respond to 
retinoic acid and contribute to carcinogenesis (Sun & Lotan, 2002). Retinoids have 
not only been used in the treatment of skin cancer, but also psoriasis, acne, skin 
ageing and pigmentation (Zouboulis, 2001). Drugs that increase retinoic acid 
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concentration in the skin have regulatory effects on epidermal keratinisation, 
proliferation and inflammation (Orfanos et al., 1997).  
All-trans-retinoic acid increases basal keratinocyte proliferation with 
accelerated turnover of epidermal cells and thickening of epidermis (Varani et al., 
2001). Epidermal growth factor receptor activation has been shown to be central in 
this retinoid-induced epidermal hyperplasia (Rittié et al., 2006). In contrast, in 
psoriatic skin, the number of cycling epidermal cells is reduced thereby normalizing 
hyperproliferation. Enhanced epidermal differentiation and reduced cell-mediated 
inflammation were unexpected outcomes observed in 10 psoriatic patients treated 
with oral etretinate (Gottlieb et al., 1996). A reduction in epidermal thickness and 
keratinocyte proliferation were seen, but also, increased keratinocyte differentiation, 
as indicated by increased filaggrin production, numbers of keratohyaline granules, 
greater abundance of keratin filaments and increased secretion of intercellular lipids. 
The stratum corneum was unusually thin, thought to be due to retinoid-induced 
shedding of corneocytes. 
Retinoids improve dermal functions when used in the treatment of skin aging 
in vitro. Fibroblast proliferation and collagen production are increased (Griffiths et 
al., 1993; Varani et al., 2000) and matrix metalloproteinase-mediated extracellular 
matrix degradation is decreased (Fisher et al., 1996). Topical retinoid also partially 
ameliorates epidermal atrophy induced by topical corticosteroid, in both humans 
(McMichael et al., 1996) and mice (Lesnik et al., 1989). However, in vivo, retinoid 
application can induce epidermal hyperplasia resulting in erythema and scaling 
(retinoid dermatitis) limiting its use (Kang et al., 1995). 
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Retinoids have an effect on the expression of cytokeratins, altering the 
differentiation process towards a nonkeratinizing, mucosa-like epithelium (Kopan et 
al., 1987; Rosenthal et al., 1990; 1992; Steijlen et al., 1991; Eichner et al., 1992; 
Griffiths et al., 1996).  Keratins which are not usually present in adult human skin 
e.g. K4, K13 and K19 are induced.  In association with epidermal thickening, stratum 
granulosum thickening, pararkeratosis and a marked increase in the number of cell 
layers expressing epidermal transglutaminase, other distinct changes in 
differentiation are seen. These include an increased number of cell layers expressing 
both involucrin and filaggrin in acute and chronic treatment, and an increased 
number of layers expressing loricrin in chronic treatment alone. Three major 
epidermal differentiation products K1, K10 and K14 were not altered, suggesting that 
retinoids reprogramme some, but not all, aspects of human epidermal differentiation 
in vivo (Rosenthal et al., 1990; 1992).  
Other characteristics of mucosal epithelia acquired following treatment with 
retinoic acid include glycosaminoglycans accumulation, a decrease in the mucin-type 
cell surface carbohydrate structure T antigen, and an alteration in the differentiation 
pattern of cell surface carbohydrates (Griffiths et al., 1996). Retinoids also produce 
changes in CRABP-II and retinoic acid 4-hydroxylase, both of which are significant 
in retinoic acid metabolism (Elder et al., 1993). Acitretin, an aromatic synthetic 
retinoid, has high affinity for CRABPs and low affinity for RARs (Norris et al., 
1994). A shift in tretinoin binding from CRABPs to RARγ heterocomplexes is 
induced, suggesting that acitretin treatment results in a redistribution of endogenous 
tretinoin from cytoplasmic to nuclear compartments, thus indirectly potentiating 
retinoid activity (Tian et al., 1997). 
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Evidence for the clinical efficacy of oral retinoids in inherited PPK is limited, 
with most reported studies being open or anecdotal, with small numbers of patients 
treated. Both acitretin and etretinate have been reported as effective in disorders of 
keratinisation, with optimal dosage varying between patients (Happle et al., 1987; 
Blanchet-Bardon et al., 1991; Katugampola & Finlay, 2006). As an increasing 
number of people with severe disorders of keratinisation are relying on oral retinoids 
as a single systemic treatment,  longer follow-up data is essential in counselling those 
embarking on long-term treatment (Katugampola & Finlay, 2006), with intermittent 
treatment  recommended when possible (Happle et al., 1987). 
The effects of retinoids on keratin expression in disorders of keratinisation 
have been examined in patients with ichthyosis and Darier’s disease (Kanerva et al., 
1984; Steijlen et al., 1991) and BCIE due to K1 and K10 mutations (Virtanen et al., 
2001). 3 of 9 patients with either Darier’s disease, non-erythrodermic lamellar 
ichthyosis or autosomal dominant ichthyosis vulgaris were found to have an 
induction of K4 and 1 of 9, of K13 (Steijlen et al., 1991). In a single case of 
ichthyosis hystrix, a clinical response to etretinate in the first year of treatment was 
associated with a thinning of the thick horny layer only, with persistence of 
phenotypic changes in the keratinocytes histologically and ultrastructurally (Kanerva 
et al., 1984). In the BCIE group, 5 of 6 patients with K10 mutations benefited from 
oral acitretin or topical retinoid therapy (none of whom had palmoplantar 
hyperkeratosis), compared to none of the 6 patients with K1 mutations with 
associated PPK. Quantitative analysis of mRNA expression of K2e, a normal 
constituent of upper epidermis, was diminished especially in non-responders. It was 
postulated that retinoid therapy was more effective in K10 mutations as they may be 
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less vulnerable to a down-regulation of K2e, which may be potentially functioning as 
a substitute for the mutated protein in patients with K1 mutations.  
Although the induction of different keratins may be a mechanism for 
correcting defects in keratin genes affecting palms and soles, there is little data on the 
effects of retinoid treatment in keratoderma. Lesional and non-lesional skin (from the 
knee) was studied before and after treatment with oral isotretinoin in a father and son 
with PC, demonstrating an alteration of glycoprotein distribution in only lesional 
epidermis (Thomas et al., 1984). Further clinical studies studying retinoid use in 
inherited PPK and their effects on differentiation of palmoplantar skin are warranted. 
 
2.1.5 Conclusion: Clinical issues 
The inherited PPKs are a highly heterogeneous group of disorders presenting with 
thickening of palmoplantar epidermis. They demonstrate both clinical and genetic 
heterogeneity, as confirmed by our study of this cohort from the West of Scotland. In 
the study population, we have confirmed a high degree of social and occupational 
disability due to keratoderma. Pain and hyperhidrosis are major symptoms.  
Treatment options remain limited particularly with respect to hyperhidrosis 
and plantar pain. Retinoids remain a mainstay of treatment however benefits are 
variable between patients, and limited by side-effects such as skin thinning and 
subsequent blistering.  
A previously unreported feature of abnormal adult dentition was noted in this 
cohort of PC-2 patients with an underlying K17 mutation. Pending further evidence, 
we recommend that dermatologists caring for children with PC-2 should bear in 
mind a possible effect on permanent dentition and consider appropriate dental 
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examination and care. Moreover, the presence in PC-2 of structurally abnormal, 
premature teeth and possibly adult teeth suggests that K17 expressing keratinocytes 














































Chapter 2.2 The Collection of a Resource 
In pursuit of the primary aim of the work described in this thesis, I sought to 
establish a tissue and cell culture resource for elucidating the pathogenesis of the 
inherited PPKs. In attempting to establish a bank of biopsy material from patients 
and controls, I concentrated on a small but varied group of disorders with known 
genetic aetiology. Whenever possible, several patients with the same known genetic 
mutation were recruited to aim to distinguish between changes due to variation 
between individuals and samples with that specifically due to the disease. 
2.2.2 Methods 
2.2.2.1 Collection of specimens 
Approval was obtained from the Research Ethics Committee of the Southern General 
Hospital, Glasgow. Fifteen patients with an inherited PPK discussed in chapter 2.1 
were recruited for establishment of the resource. One patient with an inherited PPK 
with a mutation which was initially unknown but which was identified during the 
course of the project (chapter 2.3) was also recruited. Affected or control subjects 
were given an appropriate Patient Information Leaflet (Addendum A). 
 Plantar samples were obtained following informed consent, using the 
posterior tibial and saphenous nerve block (Appendix A). Single or duplicate 
elliptical biopsies were taken from both affected skin and, where keratoderma was 
focal, unaffected skin. The skin specimens were processed for light microscopy, 
immunocytochemistry (both paraffin embedded and frozen sections) and electron 
microscopy (morphology and immunostaining) (chapters 3.1 and 3.2). Control 
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samples of palmoplantar skin were taken, with informed consent, from four healthy 
individuals of similar age and sex undergoing minor surgery for other reasons. 
 Seven samples of non-palmoplantar skin (lower back) were obtained from the 
cohort of recruited keratoderma patients for keratinocyte culture, to provide a 
resource for functional studies in conventional and organotypic skin model culture 
systems. Five control biopsies were taken from non-palmoplantar skin, with 
informed consent, from healthy individuals of similar age and sex undergoing minor 
surgery for other reasons.  
2.2.2.2 Primary Keratinocyte Culture  
Subcutaneous tissue was trimmed from skin samples if necessary, transferred to 
dispase solution (25 units/ml) (Cascade Biologics, Invitrogen, CA, USA) and left at 
4-6oC overnight. Using sterile forceps, the epidermis was peeled from the dermis and 
placed in 0.025% trypsin/0.01% EDTA solution (Cascade Biologics) at 37oC for 3-4 
minutes, before removing the dermis. Defined trypsin inhibitor (DTI) (Cascade 
Biologics) was added in a 1:1 volume to the trypsin, followed by 10 mls of Epilife® 
Medium with 60μM Calcium chloride with Growth Supplement (Cascade Biologics) 
(containing 5 mls Penicillin/Streptomycin per 500 mls Epilife). The mixture was then 
centrifuged, the supernatant removed and a further 10mls Epilife added to the pellet, 
centrifuged and the supernatant removed. 5 mls Epilife was finally added and mixed, 
and then placed in a sterile 6cm2 Petri dish which had been previously coated with 
Coating Matrix (Cascade Biologics) 20 minutes before use. The Petri dish was 
incubated at 37oC in a humidified atmosphere of 5% CO2 in air, with Epilife medium 
changed every 2-3 days. Once confluent, the keratinocytes were split at a 1:4 ratio 
into Epilife, and at later passage, into 75cm2 flasks. 
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2.2.2.4 Freezing of cells 
Confluent keratinocytes were trypsinised and resuspended in DTI (1:1 ratio to 
trypsin) and 10mls Epilife. Following gentle washing twice with Epilife, 
keratinocytes were resuspended in 2mls of Synth-a-Freeze® cryopreservation 
medium containing 10% dimethylsulfoxide (DMSO) (Cascade Biologics). 1ml 
aliquots of suspension were placed in each sterile cryovial, with approximately 1 x 
106 cells per vial. The vials were wrapped in cotton wool, then bedded down in a 
sealed insulated box for 5-6 hours in -20oC, followed by 24-48 hours in -70o
2.2.3 Results 
C, before 
being transferred to liquid nitrogen for long-term storage. 
2.2.3.1 Collection of Specimens 
Plantar skin specimens (Figure 10) from all 16 keratoderma patients and four 
controls recruited, and non-plantar skin specimens from selected patients from each 
pedigree and five controls, were collected. A bank of biopsy material is now 
established (Tables 7&8). 
 
Table 7. Plantar specimens collected forming the bank of biopsy material; numbers of samples 



















KRT1 (2) 2 2 - 2 2 
KRT9 (2) 2 2 - 2 2 
KRT 17 (8) 8 8 8 8 8 
DSG1 (1) 1 1 0 1 1 
Loricrin (2) 2 2 - 2 2 
Mitochondria 
(1) 
1 1 1 1 1 






Table 8. Keratinocyte resource established from inherited PPK and control non-plantar skin 
samples. 
 







2.2.3.2 The Keratinocyte Resource 
Non-plantar skin was used to establish a keratinocyte culture resource from 7/16 of 
the recruited inherited PPK patients, and 5 healthy individuals for controls (Table 8). 
2.2.4 Conclusion 
A bank of biopsy material was obtained from inherited PPK patients and controls, 
successfully establishing a tissue and cell culture resource in this rare group of 
genodermatoses. I proceeded to use the tissue resource to try to identify common and 
distinct pathways of hyperkeratosis by morphological, immunocytochemical and 
gene expression studies (Chapter 3). The keratinocyte resource has been made 
available for collaborative study, initially both to the Lane and McLean laboratories, 
Dundee, and via the European Geneskin network (www.geneskin.org)  for functional 



















Figure 10.  Grossly thickened stratum corneum in plantar biopsy from inherited PPK patient 














































































Chapter 2.3 Investigation of a Pedigree with Striate Palmoplantar 
Keratoderma 
2.3.1 Introduction 
During the course of this study, a 3 generation pedigree presenting with striate 
keratoderma was encountered. In order to fulfil the criteria for inclusion it was 
necessary to establish the mutation underlying the disease in this family. This also 
provided the opportunity to explore the means by which such families are 
investigated.  
Striate palmoplantar keratodermas (SPPKs; OMIM 148700) are rare, mainly 
autosomal dominant, genodermatoses characterized by linear hyperkeratosis of the 
volar aspects of the fingers, extending onto the palm (Judge et al., 2004). There is 
strong evidence that SPPK is due to defects in desmosomes, the major epithelial 
intercellular adhesion junctions, which confer strength and rigidity to tissues that 
experience high mechanical stress. Twenty causative mutations in desmosomal 
proteins desmoglein 1 (DSG1) and desmoplakin (DP), and in keratin 1(K1) which 
links to desmosomes, have been reported (Rickman et al., 1999; Armstrong et al., 
1999; Hunt et al., 2001; Lai-Cheong et al., 2007; Hershkovitz et al., 2009; Dua-
Awereh et al., 2009).  
2.3.2 Methods 
2.3.2.1 SPPK pedigree 
The proband (II-1) was a 40-year-old Scot (Figure 11) who presented with painful 
thickening of the skin on his palms and soles, hyperhidrosis, and intermittent 
associated blistering, since childhood. There was no history of abnormal hair, nails or  
95 
 
A  B   
 




Figure 11.  Family with striate palmoplantar keratoderma (SPPK).  
Clinical pictures of the proband II-1: striate keratoderma on (a, b) palms, (c) soles, (d) bilateral 





Figure 12. Pedigree of the family with SPPK. Filled symbols represent affected individuals.  














I - 1 I - 2 I - 3 
II - 1 II - 2 
III - 1 III - 2 
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dentition, or cardiac disease. At the time of presentation, he was on no oral 
medication and managed his hyperkeratosis only with emollients and manual paring.  
Clinical examination showed linear hyperkeratosis of the volar aspects of 
fingers, more extensive focal plantar hyperkeratosis and mild hyperkeratosis of the 
knees. His father, paternal uncle and 8 year old daughter were similarly affected 
(Figures 11 & 12), in keeping with an autosomal dominant inheritance pattern. 
2.3.2.2 DNA extraction 
Following informed consent, genomic DNA was extracted from saliva samples from 
the proband, his affected daughter and his unaffected son (II-1, III-1 and III-2) using 
OrageneTM DNA Self-Collection Kit (DNA Genotek Inc., Canada), following the 
protocol recommended by the manufacturer. The mixed saliva/Oragene sample was 
incubated at 50oC for a minimum of 2 hours, before adding 40 μl Oragene PurifierTM 
per 1 ml sample, vortexing for several seconds, incubating on ice for 10 min and 
centrifuging for 10 min. The supernatant was removed carefully, without disturbing 
the pellet, and an equal volume added of 96-100% ethanol at room temperature and 
mixed by inversion. This was centrifuged at 2,500g (3,600rpm) for 10 min and the 
ethanol removed, not disturbing the DNA pellet. This was inverted onto tissue paper 
for 5 min and then turned upright to air dry for 5 min. 125 μl TE buffer (10 mM Tris-
HCl, pH 8.0, and 1 mM EDTA) per 1 ml sample was used for resuspension and DNA 
dissolved by incubating at 50o
2.3.2.3 Mutation detection  
C for 1 hour.  
Based on previous studies implicating genetic mutations of desmosomal proteins in 
PPK (Armstrong et al., 1999; Whittock et al., 1999; Hunt et al., 2001), we first 
carried out mutational analysis of the DSG1 gene. Polymerase chain reaction (PCR) 
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amplification of each exon of DSG1, including exon/intron boundaries was 
performed, using primers previously described (Hunt et al., 2001) (Table 9) on two 
affected individuals, one unaffected family member and one normal unrelated 
control. PCR products were sequenced on an ABI 3130 or 3730 automated 
sequencing machine, as per standard protocols 
 The PCR reactions were carried out in 50 μl volume containing: 1 μl DNA, 5 
μl each primer at 5 μM (10μl total), 5 μl 10x PCR buffer containing 1.5 mM MgCl
(Milingou et al., 2006). 
2 
(High Fidelity PCR buffer, Roche, Mannheim, Germany) or buffer previously 
described (Whittock et al., 2002a), 5 μl dNTPs (0.25 mM each), and 29 μl H2O, and  
0.2 μl (1U) Taq polymerase (Bioline Limited, London, UK). The PCR reaction was 
carried out under the following conditions: 94oC for 2 min, then 94oC for 15 sec 
(strand separation), 55oC for 30 sec (primer annealing), 72oC for 60 sec (strand 
elongation) for 35 cycles (primers 9 and 11 for 40 cycles) and 72o
2.3.2.4 DNA agarose gel electrophoresis and purification 
C for 5 min.   
Agarose gel electrophoresis was used for the separation, size determination and 
relative quantification of DNA fragments. 1% analytical grade agarose (Melford, 
UK) was dissolved in 1xTBE (890 mM Tris, 890 mM boric acid and 10 mM EDTA) 
by microwaving. After cooling 4 μl of Invitrogen SYBR Safe DNA Gel stain was 
added per 80 ml agarose gel. 5 μl aliquot of each DNA sample was mixed with 2 μl 
DNA loading buffer into the wells along with the appropriate DNA molecular weight 
marker (Hyperladder IV Bioline). The electrophoresis was carried out at 150 volts. 
DNA was visualized under UV light and images were captured with an Ultra Violet 
Products Gel documentation System, Image Store 7500. DNA was then purified 
using the QIAquick PCR purification kit protocol (Qiagen, Crawley, UK) using a  
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Table 9.  Desmoglein 1 primers 
 
Primer  Sequence 5’-3’    PCR size (bp) Annealing temp 
(o
DSG1.1F CAGCTGGAGGAAGGGTGTG  529  55  
C) 
DSG1.1R GGCATTAACATGATCTTGAGTC  
 
DSG1.2F GACTCACAAGCCTATGGTTTC  635  55 
DSG1.3R GTAGCTTCTCGGTGAGACATG 
 
DSG1.4F CAAGGTCATCACATGCAACAAC 401  55 
DSG1.4R CAGTCGTGGGATGCTCGTG 
 
DSG1.5F CACAGTGCTAGCATAATGCTC  379  55 
DSG1.5R GGAGCTGCTTCCGTAGTTG 
 
DSG1.6F CAGTGAAGTCCACATCATAAGG 647  55 
DSG1.6R GGACATATAGCAAGTCATTCC 
 
DSG1.7F GGCTGTCTACGTCAAGTGTG  271  55 
DSG1.7R CATAACATGTGCCTCTGTAAG 
 
DSG1.8F ATCAACATTCCAGTATAAGCC  494  55 
DSG1.8R CTGTATTGACAAACTGTCTCCAG 
 
DSG1.e8F2 GTTTTCACTTCTTGTTTCAG  213  55 
DSG1.e8R2 ACCATACCTTAACAACCTTT 
 
DSG1.9F GGTGAACAATCAGAGCTCAC  829  55 
DSG1.9R GACGAATCACGGCCTGTGG 
 
DSG1.9F2 GATTTTCTTTCACCTGGAACG  636  55 
DSG1.9R GACGAATCACGGCCTGTGG 
 
DSG1.10F CTCCATATTGCTAAGACTGCC  487  55 
DSG1.10R GGACTCATGGTCTTAGCTAC 
 
DSG1.11F CTGTGTTGTCCAACCATTCC  492  55 
DSG1.11R CCCAGTGCCAAACACAGAAG 
 
DSG1.12F GTCTGACCATCATTCAGCTTG  928  55 
DSG1.13R CTAAGTACTCTTTGATGGTTGAG 
 
DSG1.14R CACATATTACAAGGCAAGTTGTTA 398  55 
DSG1.14R GAATCTAGTTAGGAGACTCCTG 
 
DSG1.15F1 CATTCCTCTTTGGAAATGCTCTG 672  55 
DSG1.15R1 CATCTCGCAAGTCAGGCATC 
 





microcentrifuge, and was carried out according to the manufacturer’s instructions, 
prior to sequencing. 
2.3.2.5 mRNA isolation  
Following informed consent, an elliptical biopsy of normal arm skin was obtained 
from the proband under local anaesthetic, which was snap frozen in liquid nitrogen 
and stored at -70oC. This was bisected; one piece was used for mRNA extraction, 
and the other for protein extraction (see 2.3.2.7). mRNA was isolated using a 
QuickPrep micro mRNA purification kit (Amersham Biosciences, UK) as specified 
by the manufacturer’s instructions. Tissue was manually homogenized in extraction 
buffer (buffered aqueous solution containing guanidinium thiocyanate), until a 
uniform suspension was obtained. This was diluted by adding 2 volumes of elution 
buffer (10 mM TrisHCL, pH 7.5, 1 mM EDTA) to the extract and centrifuging for 1 
min to obtain a clear homogenate. The homogenate was added to a pellet of 
oligo(dT)-cellulose which was then resuspended and centrifuged for 10 seconds. This 
was washed in 1 ml of high salt buffer (10 mM TrisHCl, pH 7.5, 1 mM EDTA, 0.5 
M NaCl) five times, followed by two washes using 1 ml of low salt buffer (10 mM 
TrisHCl, pH 7.5, 1 mM EDTA, 0.1 M NaCl). The washed oligo(dT)-cellulose pellet 
was resuspended in 0.3 ml low salt buffer  and transferred to a MicroSpin column. 
This was centrifuged for 5 sec, washed with 0.5 ml low salt buffer 3 times, then 
eluted with 2 x 0.2 ml elution buffer at 65oC. Following ethanol precipitation, RNA 
was dried and resuspended in 5 μl DEPC-treated H2
2.3.2.6 RT-PCR 
O. 
A 20 μl reaction containing 5 μl mRNA, 1 μl Oligo (dT) 0.5 mg/ml (Roche), 1 μl 
RNAsin® (40 U/ μl, Promega, Madison, WI, USA) was heated to 70oC for 10 min 
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and cooled to 42oC. This solution was mixed with 4 μl 5x Avian Myeloblastosis 
Virus (AMV) buffer, 2 μl 10 mM dNTPs and 7 μl H2O, followed by 1 μl of AMV 
reverse transcriptase (Promega, Madison, WI, USA) and mixed. The reaction was 
incubated at 42oC for 1 hour; then heated to 70oC to inactivate the reaction. 
Following cooling to 42oC, 1 μl AMV reverse transcriptase (10U/ μl) was added and 
incubated at 42oC for 1 hour. cDNA was stored at -20o
 2 sets of primers were designed using Oligo 6.8 software, and produced by 
MWG, in order to amplify exon 5. DSG1 cDNA primers are described in Table 10. 
The primers were designed to span at least one intron to check for any genomic 
contamination in the cDNA. The RT-PCR reactions were carried out in 50 μl volume 
containing: 5 μl each primer, 5 μl dNTP (0.25 mM each) , 5 μl 10 x High Fidelity  
C.  
 
Table 10.  Desmoglein 1 primers for RT-PCR 
Primer  Sequence 5’-3’    PCR size (bp) Annealing temp 
(o




DSG1.E5F2 CCGCATCTCTGGAGTAGGA  321  53 
DSG1.E5R2  GAGTTCAAATTGTTCGGTTCA 
 
PCR buffer II (Roche, Mannheim, Germany), 2 μl DMSO, 3 μl MgCl2, 23 μl H20, 2 
μl cDNA and 0.25 μl Expand High Fidelity Enzyme Mix. The RT-PCR reaction was 
carried out under the following conditions: 94oC for 5 min, then 94oC for 30 sec 
(strand separation), 50oC for 1 min (primer annealing), 72oC for 2 min (strand 
elongation) for 38 cycles before 72oC for 5 min. Control cDNA from an unaffected 
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individual, cDNA from HaCaT cells (a keratinocyte cell line) and a negative sample 
were also used.  
2.3.2.7 Protein isolation and Western Blotting 
Normal arm skin from the proband (see 2.3.2.5) was also used for protein isolation to 
be compared with a normal control. The skin biopsy  was homogenised in 150 μl 
urea extraction buffer (8 M urea, 50 mM Tris-HCl pH 7.5, 10 mM reducing agent 
DTT, protease inhibitor cocktail, Roche). Homogenates were centrifuged at 16,000g, 
4o
 Proteins were separated on 4-12% Bis-Tris NuPAGE
C for 10 min to pellet debris. The supernatant was removed and protein 
concentration determined using Coomassie Protein Assay (Pierce, IL, USA). Skin 
extracts were diluted 1/25 with extraction buffer and 1.5 mls Coomassie Reagent 
added to each sample, left for 4 min at room temperature and absorbance measured at 
595nm and converted to mg protein using a graph plotted using known quantities of 
BSA.  
® Novex Gel 
(Invitrogen, CA, USA). ~5 μg of protein was loaded, SeeBlue® Plus2 Pre-Stained 
Standard (Invitrogen) was run alongside. Samples were run on 2 gels which were run 
in MOPS SDS Running buffer at 200V for 50 min. SimplyBlueTM Safe Stain 
(Invitrogen) was used to stain one gel. Separated proteins on the second gel were 
transferred to nitrocellulose membranes NuPage® transfer buffer, for 1 hour at 30V. 
Blots were stained with Ponceau Stain (Sigma USA) a reversible stain, for 5 min to 
verify equivalent transfer of proteins. The membranes were washed with water to 
remove Ponceau Stain and were then blocked with 5% non-fat dried milk (Marvel) in 
PBS with gentle shaking for 1 hour at room temperature. Mouse monoclonal 
antibody to human desmoglein 1 (MCA2271, AbD Serotec, UK), clone 27B2, 
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isotype IgG1 was diluted 1:500 in PBS containing 0.05% Tween and 5% dried milk 
and the blot incubated with shaking for 1 hour at room temperature. After 3 x 5 min 
rinses in PBS-Tween, either rabbit anti mouse alkaline phosphatase conjugated 
D0314 or goat anti mouse horse radish peroxidase conjugated D0447 
(DakoCytomatin, Denmark) secondary antibodies were used. These were diluted 
1:1000 in PBS- 0.05% Tween, and incubated for 1 hour to detect bound monoclonal 
primary antibody. Blots were washed 3 x 5 min in PBS- 0.05% Tween. Proteins were 
detected either with BCIP/NBT (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue 
tetrazolium, Promega) if incubated with alkaline phosphatase conjugated secondary 
antibody or by ECL if incubated with horse radish peroxidase conjugated secondary 
antibody. For NBT/BCIP staining - 10 ml buffer (100 mM Tris, pH 9.5; 100 mM 
NaCl; 5 mM MgCl2) 66 μl of NBT (50 mg/ml) and 33 μl BCIP (50 mg/ml) was 
added. Blot was incubated with substrate until bands appeared (within 2-10 mins). 
For ECL staining - blots were covered with fresh detection substrate; a 1:1 mixture 
of solution I and II, (Solution I - 1 ml luminol stock; 0.44 ml coumaric acid stock, 10 
ml 1M Tris pH 8.5 in 100 ml, Luminol 250 mM stock Fluka in DMSO): Solution II 
64 μl of 30% H202
2.3.2.8 Light and electron microscopy 
; 10 ml 1 M Tris pH 8.5 in 100ml (p-coumaric acid, 90 mM stock 
in DMSO, Sigma) for 2.5 min. Substrate was removed and blot was placed between 
2 pieces of cling film, and X-ray film placed against the blot and exposed for 3 sec to 
30 min before being developed.  
Fresh elliptical plantar biopsies of affected plantar skin were obtained under 
peripheral nerve block (Appendix A), dissected into three pieces (chapter 2.2), two of 
which were prepared for paraffin-embedding and transmission electron microscopy 
104 
 
(chapter 3.1.2.1 and 3.1.2.3). Haematoxylin and Eosin (H&E) staining was 
performed as described (chapter 3.1.2.2).  
2.3.2.9 Immunohistochemistry 
Fresh affected plantar skin was snap frozen in liquid nitrogen and stored at -70oC.. 
Serial frozen sections were cut at 5 μm, attached to Silane-coated glass microscope 
slides and stored at -20o
 Sections were allowed to come to room temperature, then incubated in fresh 
acetone (BDH Laboratory supplies, Poole, England) for 10 mins at room 
temperature. After washing twice in phosphate buffered saline, PBS (Sigma, UK) 
over 5 min, sections were incubated for 10 min in fresh 3% hydrogen peroxide to 
block endogenous peroxidase. After blocking with normal rabbit serum (see chapter 
3.2.2.5), the sections were incubated with primary antibody diluted in PBS at 37
C prior to use.  Mouse monoclonal antibody to human 
desmoglein 1 (MCA2271, AbD Serotec, UK), clone 27B2, isotype IgG1, was used 








Desmoglein 1 gene analysis 
Sequence analysis of the DSG1 gene revealed a novel heterozygous A-to-T 
transversion in exon 5 (c.430A>T), converting an arginine residue to a premature 
termination codon (p.Arg144stop). The mutation was also detected in cDNA 
following extraction of RNA from skin biopsy of the proband. The mutation was 
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present in his affected daughter and absent in his unaffected son (Figure 13).  Five 
other sequence variants detected were known, synonymous polymorphisms.  
Protein isolation 
Protein extractions were successful, as confirmed by running the samples on the gel 
and staining with SimplyBlueTM
Light and Electron Microscopy 
 Safe Stain. Initial results showed a reduction in 
protein in the proband, however, antibody staining needed to be optimised further, 
using different dilutions and more stringent washing steps to interpret results fully.  
Light microscopy of affected plantar epidermis showed acanthosis with mild 
spongiosis and intracellular vacuolation. The granular layer was thickened and 
hyperkeratosis was present. A mild upper dermal perivascular chronic inflammatory  
cell infiltrate was noted and the presence of suprabasal cell-cell disadhesion (Figure 
14). Comparative histological results/measurements are described in chapter 3.1.3.1. 
Light microscopic analysis of semithin sections stained with 1% toluidine blue 
demonstrated orthohyperkeratosis, acanthosis and cell-cell separation in the spinous 
layers resulting in intercellular widening, suggestive of a possible underlying 
desmosomal abnormality (Figure 15). Electron microscopy revealed normal keratin 
intermediate filaments but separation of keratinocytes in the spinous layer resulting in 
loss of cell contact in places. Cell vacuolation was a non-specific feature also 
observed. Desmosomes appeared normal in size and number (Figure 16). 
Immunohistochemistry revealed prominent desmoglein 1 staining in suprabasal and 
spinous layers, with some weak basal staining (Figure 17). This was closely 
comparable to affected plantar skin from 3 PPK patients with underlying mutations in 
loricrin, K9 and mitochondrially inherited mutations, and normal plantar skin. 
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Figure 13. DNA sequencing of the DSG1 gene. Sequencing reveals a heterozygous A-to-T 
transversion in exon 5 of the DSG1 gene (designated c.430A>T), converting an arginine residue 
(AGA) to a premature termination codon (TGA; designated p.Arg144stop) in the proband (a). The 















Figure 14. Morphologic changes occurring in Haematoxylin and Eosin (H&E) stained affected 
plantar skin in proband, demonstrating acanthosis, mild spongiosis and intracellular vacuolation, 
hypergranulosis and hyperkeratosis. A mild upper dermal perivascular chronic inflammatory cell 





Figure 15. Light microscopic changes occurring in 1% aqueous toluidine blue stained semithin 
sections of affected plantar skin in proband.  Abnormalities in spinous layer of the epidermis; the 
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Figure 16. Electron micrographs of affected plantar skin in proband. Normal keratin intermediate 
filaments (a) and cell separation in spinous layers with loss of cell contact in places (b). Desmosomes 
appear normal in size and number. Scalebars=5μm. 
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Figure 17. Desmoglein 1 staining of affected plantar skin in proband. Prominent staining of 









2.3.4.1 Desmosome structure 
Desmosomes are intercellular junctions abundantly expressed in a variety of epithelia 
including epidermis (see chapter 1) and cardiac muscle. They are found in great 
abundance in tissues that experience mechanical stress. They contain two types of 
cadherin (three desmocollins, DSCs, and four desmogleins, DSGs) and other 
cytoplasmic proteins including desmoplakin, envoplakin, periplakin, plectin, bullous 
pemphigoid antigen 1, corneodesmin (CDSN) and microtubule actin cross-linking 
factor (plakin family), and plakoglobin (PG) and certain plakophilins (PKP) 
(armadillo family)(Green & Jones, 1996; Yin & Green, 2004) (Figure 4, chapter 1). 
These molecules are assembled in highly organised cell membrane complexes and 
serve in both cell-cell adhesion and in the peripheral anchorage of keratin 
intermediate filaments, conferring resistance to mechanical stress.  
2.3.4.2 Desmosomal diseases 
Mutations in genes encoding desmosome components underlie a number of 
autosomal recessive or dominant skin disorders characterized by skin fragility, 
hyperkeratosis and in some cases, nail, hair and cardiac abnormalities (Lai-Cheong et 
al., 2007) (Table 11). A relationship between some forms of genetic skin disease and  
abnormalities in desmosomes had been previously suggested in disorders such as 
Darier disease and Hailey-Hailey disease, but linkage studies in these conditions 
have not mapped to known desmosome gene loci (Richard et al., 1995; Wakem et 
al., 1996). The first human mutations in a desmosome were identified in the PKP1 
gene (McGrath et al., 1997). Subsequent autosomal-recessive mutations have been  
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identified in DSP, plakoglobin and DSG4 and autosomal dominant mutations 
reported in PKP2, DSP, DSG1 and 2, and CDSN (Table 11). The genomic 
organization of DSCs and DSGs is similar to that of classic cadherins, suggesting 
evolution from a common ancestor through multiple gene duplication and divergent 
evolutionary events (Nollet et al., 2000). Specifically, the desmosomal cadherins are 
all clustered within a 650-kb region of chromosome 18 at locus 18q12.1 (Arnemann 
et al., 1991). This organisation has promoted speculation that a master regulator 
region controls desmosomal cadherin genes (Dusek et al., 2007). The human DSG1 
comprises 15 exons spanning approximately 45kb (Hunt et al., 2001) and is situated 
within a 250-kb cluster on 18q12.1 containing the four genes arranged in the order 







Table 11. Illustration of the autosomal-dominant and –recessive disease phenotypes associated 









 Plakophilin 1 Skin fragility ectodermal dysplasia 
syndrome 
Arrythmogenic right ventricular 
cardiomyopathy 
Plakophilin 2  
Woolly hair, keratoderma, 
cardiomyopathy 
Arrythmogenic right ventricular 
cardiomyopathy 
Striate palmoplantar keratoderma 
Desmoplakin Woolly hair keratoderma +/- 
cardiomyopathy 
 Plakoglobin Naxos disease 
Striate palmoplantar keratoderma Desmoglein 1  
Arrythmogenic right ventricular 
cardiomyopathy 
Desmoglein 2  
 Desmoglein 4 Localised recessive hypotrichosis 
Recessive monilethrix 






Figure 18. Predicted gene and protein details of human desmoglein 1 (Whittock & Bower, 
2003b).  (a) The desmoglein 1 complex occupies ~250kb, with DSG1 lying between DSG4 and the 
desmocollin gene cluster. (b) DSG1 genomic organization: the human gene consists of 15 exons 
spanning ~45kb genomic DNA. Exons shown by vertical boxes, introns by horizontal lines. (c) The 
encoded protein desmoglein 1 (see figure 19): domains represented as signal (S), preprotein (P), five 
extracellular domains (EC1-4, EA), transmembrane domain (TM), intracellular anchor domain (IA), 
intracellular cadherin-typical segment domain (ICS), linker domain (LD), repeat unit domain (RUD) 












2.3.4.3 Striate PPK 
Of 20 previously identified mutations, fifteen are in the DSG1 gene, four in the DP 
gene and one is in K1 (Rickman et al., 1999; Armstrong et al., 1999; Hunt et al., 
2001; Lai-Cheong et al., 2007; Hershkovitz et al., 2009; Dua-Awereh et al., 2009). 
SPPK1 and SPPK2 refer to disease associated with mutations in genes encoding 
DSG1 and DP, respectively (Armstrong et al., 1999; Rickman et al., 1999; Hunt et 
al., 2001; Whittock & Bower, 2003b; Kljuic et al., 2003b; Milingou et al., 2006;  
Hershkovitz et al., 2009; Dua-Awereh et al., 2009). SPPK3, reported in a large 
British kindred, is associated with a frameshift mutation in the V2 domain of K1 
(Whittock et al., 2002a). Thus SPPK can result from a perturbation in either the 
intermediate filament network (K1), the desmosomal plaque (DP) or the 
transmembrane cadherin (DSG1). One further case involving a DSG1 mutation has 
been reported in which the PPK was focal rather than striate (Milingou et al., 2006) 
(Figure 19).  
2.3.4.4 Syndromic striate PPK 
DP mutations have also been described in association with syndromic SPPK 
presenting with either right or left ventricular cardiomyopathy, woolly hair and 
SPPK (Norgett et al., 2000; 2006). Striate keratoderma, woolly hair and dilated left 
ventricular cardiomyopathy developing in teenage years was first described by 
Carvajal (Carvajal-Huerta, 1998). The first recessive pathogenic mutation found in 
the DP gene was a homozygous frameshift mutation, c.7901delG, identified in 
affected members of three Ecuadorean families with Carvajal syndrome (Norgett et 
al., 2000). All affected family members presented with a striate form of PPK, with 
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some non-volar involvement particularly at sites of pressure or abrasion. The 
associated  
 
Figure 19. Protein domain organisation of Desmoglein 1 showing mutation sites: site of our 
mutation (red arrow) in EC1, the first eight previously reported autosomal dominant mutations in 
DSG1 in striate PPK (blue arrows), and one case of focal keratoderma with additional non-acral 
hyperkeratosis (green arrow). 
















dilated left ventricular cardiomyopathy was characterized by cardiac enlargement 
and disrupted cardiac contraction. Subsequently, a family with a novel dominant 
mutation in DP, an insertion of 10 amino-acid residues, starting in codon 608, 
designated c.1822ins30, has been reported with striate PPK, woolly hair and 
biventricular cardiomyopathy resulting in early death (Norgett et al., 2006). 
Clinically, mutations in DP result in a variable combination of skin, hair and 
cardiac abnormalities. The pattern is not always striate, but sometimes more focal or  
more diffuse. Moreover, the age of onset is variable and the degree of trauma to the 
palms and soles clearly has an influence on the clinical severity and presentation 
(Lai-Cheong et al., 2007).  
2.3.4.5 Diseases associated with plakoglobin, desmoplakin and plakophilin 
mutations 
Autosomal recessive arrhythmogenic right ventricular cardiomyopathy causing heart 
failure and sudden death, congenital woolly hair, and development of progressive, 
nonepidermolytic diffuse PPK, or Naxos disease, was first reported in seven 
pedigrees from the Greek island of Naxos (Protonotarios et al., 1986; 2001). 
Approximately 1 in 1,000 of the population are affected (Antonoiades et al., 2006) 
although additional cases have been documented on the neighbouring island of Milos 
and in Bologna, Italy (Lai-Cheong et al., 2007). Coonar et al. (1998) mapped the 
gene to 17q21 and subsequently a homozygous 2-base pair deletion, c.2157delTG, in 
the PG gene was identified in affected individuals (McKoy et al., 2000). This 
deletion caused a frameshift mutation resulting in premature termination of the 
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protein by 56 amino acid residues. The dermatologic features of PPK and woolly hair 
are present in all individuals who are homozygous for the mutation but there are no 
reports of skin or hair abnormalities in heterozygous carriers. In homozygous 
individuals, over 90% have electrocardiographic abnormalities (mostly T wave 
inversion in V1-V3 leads), associated with arrythmias, syncope, heart failure, and 
sudden death, but heterozygotes show no overall increased cardiac morbidity or 
mortality (Antoniades et al., 2006). 
Other DP mutations have been described in association with cardiac and 
cutaneous syndromes (Alcalai et al., 2003; Uzumcu et al., 2006): the phenotype in 
affected individuals involves abnormalities in the skin (blisters or PPK), hair 
(woolly), and heart (arrythmogenic right ventricular cardiomyopathy). Two unrelated 
cases of “skin fragility/woolly hair syndrome” were found to be compound 
heterozygotes for different combinations of nonsense/missense mutations in 
desmoplakin, p.C809X/p.N287K, and p.Q664X/p.R2366C. These consist of 
keratoderma, woolly hair and nail dystrophy, but without cardiac abnormalities 
(Whittock et al., 2002b). 
Mutations in PKP are responsible for ectodermal dysplasia/skin fragility 
syndrome which results in trauma-induced skin erosions, dystrophic nails, sparse hair 
and painful PPK. Premature termination codons affecting both alleles of the PKP1 
gene were found (McGrath et al., 1997). Clues to the desmosomal pathology came 
from skin biopsy analysis, which showed widening of spaces between keratinocytes 
throughout most of the epidermis (apart from the basal layer) with ultrastructural 
evidence of a reduced number of small, poorly formed desmosomes. In total, nine 
different PKP1 mutations have been published (Lai-Cheong et al., 2007), which 
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collectively, with cell biologic studies on keratinocytes lacking PKP1, demonstrate 
the importance of PKP1 in the formation of desmosomal plaques and in stabilizing 
desmosomal proteins (South et al., 2003). 
2.3.4.6 Autoantibodies and DSG 1  
Pemphigus foliaceous and vulgaris are autoimmune disorders characterized by 
blisters and erosions of the skin with additional involvement of mucous membranes 
in pemphigus vulgaris. In pemphigus foliaceous, blistering occurs high in the 
epidermis, either in the granular layer or just beneath the stratum corneum, whereas 
in pemphigus vulgaris, the blistering occurs just above the basal layer of the 
epidermis (Whittock & Bower, 2003b). Compelling evidence has accumulated that 
IgG autoantibodies against DSG1 and DSG3 are pathogenic and play a primary role 
in inducing blister formation (Amagai, 2003).  
 Staphylococcal scalded skin syndrome (SSSS) is a generalized, confluent, 
superficially exfoliative disease that is caused by at least three serotypes of the 
exfoliative toxin (ET) of Staphylococcus aureus. The splits occur in the superficial 
epidermis, at the level of the granular layer (Amagai, 2003). Molecular modelling, 
crystallographic, and recombinant desmoglein cleavage studies have demonstrated 
that these toxins belong to a family of glutamic acid-specific serine proteases which 
target glutamic acid 383 within EC3 of DSG1 resulting in its cleavage (Whittock & 
Bower, 2003b). Thus circulating autoantibodies towards the extracellular domains of 
DSG1 can compromise essential cell-cell adhesion. 
2.3.4.7 Desmogleins and desmosome size and number 
It is believed that the distinctive distribution of lesions in patients with striate 
keratoderma result from impaired desmosome function where they are most stressed, 
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namely the palms and soles (Whittock et al., 1999; Hunt et al., 2001), although 
differences in desmosome structure and protein expression at these weight-bearing 
sites may be responsible for localisation (Wan et al., 2003). Electron microscopy of 
involved skin has shown reduced numbers of desmosomes in suprabasal layers in 
both DP and DSG1 mutations with decreased desmosome size evident only in 
DSG1-associated SPPK (Wan et al., 2004). Expression of keratins K5, K14 and K10 
were also reduced in DSG1-associated SPPK, demonstrating perturbations in 
epidermal differentiation accompanied by a marked disruption of components of the 
epidermal scaffold including desmosomes and the keratin intermediate filament 
network. However, Wan et al. (2004) found that cell-cell adhesion and perinuclear 
aggregation of keratin intermediate filaments were less marked in DSG1-associated 
disease, postulating a possible compensation by other desmosomal cadherin family 
members. In our pedigree, although cell-cell dysadhesion was clearly evident in 
suprabasal layers on electron microscopy, desmosomes appeared normal in size and 
number. It is still not fully understood how a particular DSG1 mutation will result in 
such a specific phenotype. Although human and mouse models have given some 
insight, understanding the precise role of desmosomes in cell biology has been 
difficult owing to the heterogeneity of their molecular composition. 
2.3.4.8 DSG1 expression 
DSG1 expression is restricted to certain specialized epithelia such as epidermis, 
tongue, tonsil and oesophagus (Whittock & Bower, 2003b). Within the epidermis, 
desmoglein isoforms are expressed in a tightly regulated cell type- and 
differentiation-specific manner. The expression of DSC1/DSG1 and DSC3/DSG3 is 
restricted to certain stratified, squamous epithelia, in contrast to DSC2 and DSG2 
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which are expressed ubiquitously in all tissues that contain desmosomes, and can be 
found in simple epithelia, as well as in the myocardium and basal layer of complex 
epithelia (Dusek et al., 2007). DSG1 and 3 are expressed in a graded and reciprocal 
fashion (Figure 20), with DSG1 being first expressed in the suprabasal layers of the 
epidermis but becomes more concentrated in the upper, most differentiated layers 
(Arnemann et al., 1993). DSG2 is expressed in basal layers, DSG3 in basal and first 
suprabasal layers (Schmidt et al., 1994) and DSG4 concentrated in the granular and 
cornified layers (Bazzi et al., 2006). It has been suggested that the differentiation- 
specific pattern and ratios of desmosomal cadherins may regulate epidermal 
development and differentiation (Getsios et al., 2004; Green & Simpson, 2007). 
Immunohistochemistry of affected plantar skin of our patient demonstrated 
predominant spinous staining, with some weaker staining of the lower layers, which 
paralleled staining in PPK patients with other underlying mutations. Further study is 
required to assess fully the effect of the mutation on DSG1 expression. 
2.3.4.9 Desmoglein regulation influences tissue morphogenesis 
The specific distribution pattern of desmosomal components is not merely a result of 
differentiation but may drive tissue morphogenesis and function (Yin & Green, 
2004). This differential expression pattern of desmosomal cadherins may indicate 
functions beyond adhesion, perhaps regulating cell behaviour (Dusek et al., 2007). 
Transgenic mice in which the ratio of DSG3 to DSG1 in the suprabasal epidermis 
was altered by forced expression of DSG3 using an involucrin promoter, resulted in a 
lamellar histology resembling normal mucous membrane, and perinatal lethality due 
to severe dehydration following excessive transepidermal water loss. Premature loss 







Figure 20.  Desmosomal cadherin expression patterns in epidermis (Dusek et al., 2007).  
Desmogleins (DSG) and desmocollins (DSC) are present in different layers of the epidermis, with 
relative levels shown by arrows (right hand side). Pemphigus vulgaris (PV), pemphigus foliaceous 
(PF)/staphylococcal scalded skin syndrome (SSSS) are associated with blisters at different locations, 


















corneum (Elias et al., 2001). These data demonstrate that differential expression of 
desmoglein isoforms affects stratum corneum structure and function. 
A similar mouse model resulted in epidermal hyperproliferation and abnormal 
differentiation, using a K1 suprabasal promoter to drive abnormal differentiation 
(Merritt et al., 2002). This phenotype had some features in common with human 
ichthyosiform diseases, again supporting the view that desmoglein isoform 
distribution contributes to the regulation of epidermal differentiation.  
Multiple DSG isoforms confer similar levels of adhesion when expressed in 
undifferentiated human keratinocytes. Getsios et al. (2004) found that DSG1 
uniquely promoted stratification and differentiation of cells growing in submerged 
culture of undifferentiated keratinocytes, with the ratio of DSG1:DSC1 being a 
critical determinant of desmosomal adhesion of fibroblasts. In DSG1-deficient 
organotypic epidermal “rafts” using siRNA-mediated knockdown, the intermediate 
layers and markers of spinous differentiation were under-represented (Green & 
Simpson, 2007). Specific removal of DSG1 adhesive ectodomain by chronic 
exposure to exfoliative toxin A did not inhibit stratification, which suggests that 
DSG1 is required for normal epidermal morphogenesis, independent of its adhesive 
role. 
Furthermore, a number of cell adhesion proteins have been identified as 
caspase substrates involved in the programmed cell death pathway apoptosis. DSG1 
has been shown to be a novel caspase and metalloproteinase substrate whose 
cleavage contributes to the dismantling of desmosomes and plays a role in regulation 
of keratinocytes undergoing UV-mediated apoptosis (Dusek et al., 2006). Decreased 
expression of DSG1 in keratinocytes is associated with increased cytoplasmic and 
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nuclear levels of plakoglobin (Simpson et al., 2007), upregulating Bcl2 expression 
and thus inhibiting apoptosis (Hakimelahi et al., 2000). Although epidermal 
cornification does not involve induction of canonical apoptotic pathways (Lippens et 
al., 2005), DSG1 deficiency may result in downregulation of pro-apoptotic 
signalling, possibly contributing to the pathogenesis of SPPK. 
DP has been shown to cause increased keratinocyte proliferation, enhancing 
G1 
Thus, DSG1 participates in both epithelial morphogenesis as well as being 
the target of differentiation-specific enzymes that remodel keratinocytes during the 
final stages of stratification and desquamation (Yin & Green, 2004). It is possible 
that this may play a role in how hyperkeratosis is transduced in DSG1-associated 
SPPK. 
to S phase entry in the cell cycle (Wan et al., 2007) suggesting that deficient 
desmosomal plaque function may trigger cell proliferation. The role of DSG1 in the 
regulation of cellular proliferation has not been explored to date. 
2.3.4.10 DSG1 Mutation Sites 
As in most reported pedigrees, the novel mutation we have found in DSG1 is in the 
extracellular domain of the protein (Figure 19). In the majority of reports, premature 
termination codons are predicted to result in haploinsufficiency secondary to 
degradation of the aberrant DSG1 mRNA by nonsense mediated mRNA decay 
(NMD) (Cui et al., 1995). Mutations in the DSG1 gene may affect the number and 
size of desmosomes (Wan et al., 2004) although this was not detected using electron 
microscopy in our case. However the actual mechanism whereby desmosomal 
disruption due to DSG1 mutations results in this phenotype needs further molecular 
and cellular studies. 
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Similarly, premature termination codons are responsible for the majority of 
DP-associated cases although two exceptions were reported by Norgett et al. (section 
2.3.4.5) (Norgett et al., 2000; 2006). In SPPK associated with K1, an out-of-frame 
deletion results in the formation of a mutant protein lacking a portion of the glycine 
loop motif in the V2 domain but gaining 70 amino acids, causing disease either by a 
dominant negative effect or haploinsufficiency due to NMD.  
 Similar to the classical cadherins, DSG1 comprises a signal peptide to direct 
it to the endoplasmic reticulum, and a preprotein domain that ends in a basic 
cleavage recognition site RRQKR resulting in a mature protein of 1000 amino acids. 
The first three extracellular domains of desmogleins (EC1-3) are required for 
heterophilic binding to the first two extracellular domains of desmocollins. Within 
the desmosome, the cytoplasmic tails of desmogleins bind ‘arm’ repeats of PG 
(Whittock & Bower, 2003b). 
2.3.5 Conclusion 
The novel mutation we report in the DSG1 gene in SPPK adds to the preponderance 
of mutations in this gene and emphasises the key role played by desmoglein 1 in the 
structure and function in the epidermal desmosomes. The phenotype is likely to be 
due to haploinsufficiency at points of maximum stress, but DSG1 mutations may 
have more subtle consequences for protein expression and desmosomal function yet 







































Chapter 3.1 Morphological Analysis of Affected Plantar Skin in 
Inherited Palmoplantar Keratoderma 
3.1.1 Introduction 
Morphologic observation, investigation and nosologic distinction have always been 
important tools in dermatology (Anton-Lamprecht, 1994). Some of the defective 
molecules involved in inherited keratodermas have a primary role in maintaining the 
mechanical integrity of the epidermis and its appendages in the face of persistent 
physical trauma (Judge et al., 2004), and defects may be expected to affect 
morphology. Moreover, analysing the structure of the epidermis may provide clues to 
the pathways involved in the pathogenesis of these diseases.  
The pathogenesis of site-specific disorders, such as the inherited PPKs, and 
the underlying predilection factors are poorly understood (Swensson & Eady, 1996). 
In attempting to identify structural alterations in different forms of inherited PPK, it 
is also essential to understand the morphology of normal human palm and sole skin. 
A systematic study of histological and ultrastructural features in normal plantar skin 
and affected plantar skin from this cohort of inherited PPK was undertaken in an 
attempt to better identify common and distinct pathogenic pathways. 
 
3.1.2 Materials and Methods  
Fresh elliptical plantar biopsies of affected skin were dissected into three pieces 
(chapter 2.2), two of which were prepared for paraffin-embedding and transmission 




3.1.2.1 Tissue processing and sectioning of plantar skin: light microscopy  
The first piece of skin was processed for light microscopy at the Departments of 
Pathology, Southern General Hospital and Western Infirmary, Glasgow. The 
following steps were undertaken for routine specimen preparation, processing, 
embedding and cutting. 
 Specimens were fixed for 24 hours in 10% paraformaldehyde, and processed 
in a Shandon “Citadel 2000” automatic dehydration and wax machine. Embedding of 
the tissue was carried out using a Shandon Histocentre at 60oC. Paraffin sections 
(4μm) were cut with a Leitz 1501 rotary microtome. Sections were floated out on a 
water bath at 56oC and lifted onto 1% silane (Sigma Chemical Co., USA) coated 
glass microscope slides. The slides were allowed to dry on a 60oC hot plate and then 
incubated for 30 minutes at 80o
3.1.2.2 Haemtoxylin and Eosin (H & E) staining 
C. 
The sections were deparaffinised and hydrated through a gradient of xylene (5 min), 
95% ethanol (3min), 99% methanol (2min) and water (1 min). The slides were 
stained as follows:  
• 4 min in Haematoxylin (CellPath) 
• 1 min water 
• 10 dips in acid/alcohol (1% hydrochloric acid in 70% methanol) 
• 1 min in water 
• 1 min in Scott’s tap water substitute (0.04M NaHCO3, 0.16M MgSO4
• 2 min in Putt’s Eosin (CellPath) 
) to 
enhance the development of the haematoxylin colour 
• 10-20 dips in water 
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Slides were dehydrated in a gradient of 99% methanol (3min), 95% ethanol (3 min) 
and xylene (5min), before being finally fixed with Pertex mounting solution 
(CellPath, UK) using a coverslip. All pictures were taken with a Zeiss Axiovert S100  
upright microscope. 
 A number of specific features were assessed: hypergranulosis (number of cell 
layers containing granules counted at 5 random points per section, mean and range 
recorded for 2 different sections); hyperkeratosis (thickness of stratum corneum, mm, 
measured at 5 random points per section, mean and range recorded for 2 different 
sections; ortho/parakeratosis or both, and corneum compact or basket-weave 
pattern); presence of acantholysis (either basal or suprabasal); presence of 
inflammatory infiltrate (dermal or dermal+epidermal; diffuse or focal); capillary 
enlargement in rete ridges; acanthosis (cell count from basal to granular layer at 5 
random points per section, mean and range recorded for 2 different sections); quality 
of granules of granular layer (dust-like or coarse at high magnification); dermal 
papillae to rete ridges (measurement, μm, taken at 5 random points per section where 
possible, mean and range recorded for 2 different sections); sweat glands (any 
abnormalities noted, presence of parakeratosis in corneum around glands); spinous 
cells (even-ness of eosin staining/uneven prominent eosin staining); presence of 
mitotic figures in basal layer (number of mitotic figures counted/number of basal 
cells per section, mean and range recorded for 2 sections). A random selection of 
slides were also scored by a blinded second observer and results compared. 
3.1.2.3 Light and electron microscopy  
The second piece of skin was further bisected and processed for transmission 
electron microscopy (TEM). 
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1. One piece was processed for morphological assessment by suspending in fixative 
which consisted of 2.5% glutaraldehyde in 0.1M phosphate buffer, ph 7.4 at 20o
 Semi-thin sections: Thick resin sections (0.35-1μm) were cut with a glass 
knife (Reichert Ultracut E machine), mounted on glass slides and stained with 1% 
aqueous toluidine blue for examination preparatory to selecting an area for ultrathin 
sectioning. Gold or silver interference colour sections were cut using a diamond 
knife and mounted on Formvar coated copped grids (100-300 mesh).  
C for 
1 hour. This was followed by further fixation in aqueous 1% osmium tetroxide for 60 
minutes. The specimens were dehydrated in alcohol, then processed with propylene 
oxide and embedded in ARALDITE/Embed 812 (Cat.#13940) epoxy resin (Hayat, 
1989).  
 Ultra-thin sections: The thin sections were stained with 2% methanolic 
uranyl acetate for 5 minutes and then with Reynold’s lead citrate for 5 minutes 
before examination. Thin sections were examined in a Zeiss 902 transmission 
electron microscope operating at 80kV. 
2. The second piece was processed for immunostaining by suspending in fixative 
which consisted of 0.25% glutaraldehyde/4% paraformaldehyde in phosphate buffer 
solution at 4o
 Ultrathin sections (60-80nm) were cut with a diamond knife and mounted on 
Formvar coated nickel grids (300 mesh). The sections were stained with 0.5% 
aqueous uranyl acetate (in 50% ethanol) and Reynolds lead citrate before observation 
in a Zeiss 902 transmission electron microscope operating at 80kV.   
C for 1 hour. Specimens were dehydrated in alcohol, and processed for 
embedding in LR White resin for immunocytochemistry (Robertson et al., 1992).  
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 A number of specific features were assessed: abnormalities in keratin 
intermediate filaments e.g. loss of normal alignment, reduced number or keratin 
aggregation; desmosomes (discussed in Chapter 2.3); the presence of prominent 
keratohyaline granules and whether bipartite granules were seen; cytolysis; 
abnormalities in cornified cell envelope formation e.g. severe hyperkeratosis, loosely 
versus densely compacted stratum corneum; cell vacuolation and evidence of cell-
cell separation. 
3.1.2.4 Control specimens 
Ethical approval was obtained from the Western Infirmary and the Southern General 
Hospital, Glasgow, to use the normal edges of acral skin biopsies (either plantar or 
palmar skin) in patients undergoing biopsy for other reasons, where the additional 
skin was being removed for surgical closure. Two biopsies of normal plantar skin 
and one of normal palmar skin from unaffected patients were obtained from the 
Department of Pathology, Western Infirmary for light microscopy, and processed in 
the same way as the PPK specimens. 
 Specimens of normal plantar skin from four unaffected patients (two of which 
were obtained at post-mortem) were kindly provided by Dr Patricia JC Dopping-
Hepenstal, Department of Cell and Molecular Pathology, St John’s Institute of 
Dermatology, where they had been processed for transmission electron microscopy 
to the embedding stage using standard methods (Eady RAJ, 1985). Processing 
differed only in the use of half-strength Karnovsky fixative (2% formaldehyde with 
2.5% glutaraldehyde in Sörensen’s phosphate buffer pH 7.4) as primary fixative 
immediately after biopsy, and in embedding in TAAB 812 (medium hardness) epoxy 




Plantar skin biopsies were obtained from 16 subjects affected  by keratoderma, and 3 
controls. 
3.1.3.1 Light microscopy: H&E staining 
 
Histological changes are not uniform across different subtypes of inherited PPK and 
even vary between individuals within subtypes, other than the presence of prominent 
eosin staining of spinous cells in inherited PPK due to underlying K1 and K17 
mutations. 
Hypergranulosis was most striking in Loricrin, K17 and DSG1 subtypes, with K1, 
K9 and Mitochondrial subtypes being comparable to normal acral controls (Tables 
12a & b; Figure 21). There was evidence of alternating hypogranulosis evident in the 
Mitochondrial subtype (1/1), which was associated with alternating areas of 
parakeratosis and orthokeratosis. Stratum corneum was most markedly thickened in 
K17 and Loricrin subtypes, with K1, DSG1 and Mitochondrial subtypes comparable 
to normal acral controls. Acantholysis was noted in 1/2 K1, 2/2 K9, 2/8 K17, 1/2 
Loricrin and 1/1 Mitochondrial patients and was not consistent within subtypes but 
varied between individuals. A dermal inflammatory infiltrate present in 5/8 K17, 2/2 
Loricrin, 1/2 K9, 1/1 DSG1 and 1/1 Mitochondrial subtypes, was thus not unique to a 
specific subtype or uniform within subtypes. Acanthosis was most prominent in K17, 
DSG1, Loricrin and Mitochondrial subtypes with K1 and K9 subtypes comparable to 
normal acral controls. Deep epidermal ridges were present K17, DSG1, Loricrin and 
Mitochondrial subtypes only, in comparison to normal acral controls. Intense eosin
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Table 12a. Summary of histologic features in affected plantar skin of PPK patients compared to normal acral controls.  
Patient/Underlying Mutation Hyper-granulosis: 
mean (range) 
Stratum Corneum: 







KRT1 (n=2)            Overall Mean 3.2 (1-5) 0.945 (0.5-1.4) 1/2 1/2 2/2 
      Patient 1 2.8 (1-5) 0.9 (0.8-1.1) BW, Ortho - Y (D) Y 
      Patient 2 3.6 (3-4) 0.99 (0.5-1.4) BW, Ortho, 
Prominent stratum 
lucidum 
SB (focal) N Y 
KRT9 (n=2)            Overall Mean  3.2 (2-4) 1.185 (0.32-1.5) 2/2 1/2 2/2 
      Patient 3      3 (2-4) 0.42 (0.32-0.5) BW, 
Ortho 
SB  (extensive) Y (D) Y 
      Patient 4 3.4 (2-4) 1.95 (1.5-2.2), BW, Ortho SB  (focal) N Y 
KRT17 (n=8)          Overall Mean 5.775 (1-10) 2.33 (0.8-3.8) 2/8 5/8 2/8 
      Patient 5 4.4 (3-6) 1.7 (1.1-2.0)  BW, 
Ortho/Para 
- N N 
      Patient 6 7 (4-10) 2.5 (2.3-2.8) BW, Ortho - Y (D) N 
      Patient 7 5.6 (3-8) 0.96 (0.8-1.1), BW, Ortho - N N 
      Patient 8 7.4 (4-10) 2.9 (2.6-3.3), BW, 
Ortho/Para 
SB  (focal) Y  (D + E) Y 
      Patient 9 5.2 (1-9) 3.6 (3.2-3.8), BW, Ortho SB  (focal) Y (D) N 
      Patient 10 6.8 (4-10) 2.7 (2.4-3.0)  C, Ortho - Y (D) N 
      Patient 11 3.8 (2-5) 1.4 (1.1-1.7), C, Ortho - N Y 
      Patient 12 6 (4-9) 2.9 (2.6-3.2), BW, Ortho - Y (D) N 
DSG1 (n=1)            Overall Mean  5.4 (4-7) 0.8 (0.7-1.1) 0/1 1/1 0/1 
      Patient 13 5.4 (4-7) 0.8 (0.7-1.1), BW, Ortho - Y (D) N 
Loricrin (n=2)        Overall Mean  7.1 (3-12) 2.55 (1.7-4.1) 1/2 2/2 2/2 
      Patient 14 8 (6-12) 3.0 (2.4-4.1), BW, Ortho SB  (focal) Y (D + E) Y 
      Patient 15 6.2 (3-7) 2.1 (1.7-2.2), BW, Ortho - Y (D) Y 
Mitochondrial        Overall Mean  3.4 (1-6) 0.67 (0.3-1.4) 1/1 1/1 1/1 
      Patient 16 3.4 (1-6) *alternating 0.67 (0.3-1.4), BW, 
Ortho, Prominent stratum 
lucidum, areas of 
parakeratosis  
SB  (focal) Y Y 
Controls (n=3)        Overall Mean  3.6 (1-5) 0.92 (0.66-1.2) 0/3 0/3 0/3 
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      Subject 17 2.8 (1-5) 1.1 (0.9-1.2), BW, Ortho - N N 
      Subject 18 4 (2-4) 1.0 (0.8-1.2), BW, Ortho - N N 

































BW=Basket-weave pattern stratum corneum; C=Compact stratum corneum; B=Basal; 
SB=Suprabasal; D=Dermal infiltrate; E=Epidermal infiltrate: 
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Dermal papillae to rete 
ridges μm: mean (range) 




(per 1000 basal 
cells) 
KRT1 (n=2)    Mean Total 10.8 (5-16) 2/2 Coarse 186 (100-280)  2/2 Prominent eosin  
      Patient 1 10.4 (6-15) Fine - Coarse 202 (100-280) Normal Prominent <5 
      Patient 2 11.2 (5-16) Fine - Coarse 170 (150-190) None present  Prominent 6 
KRT9 (n=2)    Mean Total 10.4 (6-15) 2/2 Coarse 146 (110-230)  0/2 Prominent eosin  
      Patient 3      7.6 (6-9) Fine - Coarse 140 (130-160) None present Even <5 
      Patient 4 13.2 (11-15) Fine - Coarse 152 (110-230) Normal Even 5 
KRT17 (n=8) 17.1 (7-29) 8/8 Coarse 324 (120-630)  8/8 Prominent eosin  
      Patient 5 12.2 (9-16) Fine - Coarse 148 (120-160) Normal Prominent <5 
      Patient 6 13.8 (7-18) Fine - Coarse 594 (520-630) Normal Prominent <5 
      Patient 7 16.2 (8-24) Fine - Coarse 310 (250-350) Normal Prominent 7 
      Patient 8 16.6 (8-26) Fine - Coarse 405 (250-560) Normal Prominent Difficult to assess 
      Patient 9 25 (15-34) Fine - Coarse 285 (280-290) None present Prominent 2 
      Patient 10 17.6 (12-26) Fine - Coarse 280 (170-430) Normal Prominent 7 
      Patient 11 17.8 (11-29) Fine - Coarse 320 (300-330) None present Prominent <5 
      Patient 12 17.8 (12-25) Fine - Coarse 253 (290-360) Normal Prominent <5 
DSG1 (n=1) 27.6 (10-35) 1/1 Coarse 460 (310-550)    
      Patient 13 27.6 (10-35) Fine - Coarse 460 (310-550) Normal Even <5 
Loricrin (n=2) 17.7 (10-44) 2/2 Coarse 318 (180-420)  0/2 Prominent eosin  
      Patient 14 19.4 (14-44) Fine - Coarse 296 (180-420) Normal Even Difficult to assess 
      Patient 15 16 (10-24) Fine - Coarse 340 (300-380) Normal Even <5 
Mitochondrial 20.6 (14-27) 1/1 Coarse 460 (310-550)  0/1 Prominent eosin  
      Patient 16 20.6 (14-27) Fine - Coarse 460 (310-550) Normal Even <5 
Controls (n=2) 10.5 3/3 Coarse 169 (130-220)  0/3 Prominent eosin  
      Subject 17 14.2 (9-17) Fine - Coarse 184 (150-220) Normal Even 5 
      Subject 18 12.4 (8-16) Fine - Coarse 172 (150-220) Normal Even <5 
      Subject 19 (palmar) 4.8 Fine - Coarse 152 (130-170) Normal Even <5 
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Figure 21. Morphologic changes occurring in Haematoxylin and Eosin (H&E) stained affected 
plantar skin in PPK patients with underlying keratin 1, 17, 9, loricrin and mitochondrial 
mutations (a,b,c,d,e respectively) compared to normal unrelated plantar control (f). (a) 
Hyperkeratosis present but no evidence of acanthosis or dermal inflammatory infiltrate; (b) 
hypergranulosis and diffuse dermal inflammatory infiltrate extending to epidermis; (c) hyperkeratosis 
and epidermolysis mainly in spinous layer; (d) localised dermal inflammatory infiltrate; (e) alternating 
hypergranulosis and absent granular layer associated with parakeratosis around sweat glands, with 




staining of spinous cells was particularly noted in all K17 and K1 patients (Figure 
22) although pyknotic nuclei were not noted. 
Scores were closely comparable with those of a blinded second observer. It 
was impossible accurately to score mitotic figures on 2/16 PPK patients due to the 
presence of a dermal and epidermal infiltrate, which penetrated the basal layer of the 
epidermis. 
3.1.3.2 Light microscopy: semithin sections 
 
Light microscopic analysis of semithin sections confirms prominent granules in PPK 
patients with underlying keratin mutations, suggestive of the presence of keratin 
aggregates, but is not a uniform feature in these subtypes. 
Skin from all PPK specimens showed orthohyperkeratosis, with no clear evidence of 
parakeratosis (Figure 23), and was a consistent feature on semithin analysis 
compared to normal plantar controls. Intercellular separation was detectable in both 
samples from patients with underlying K9 mutations, with one showing evidence of 
epidermolysis correlating to the H&E findings. The DSG1 patient also showed 
evidence of cell-cell separation/intercellular widening. Coarse inclusions in the 
granular layer were noted in 1/2 K1, 1/2 K9 and 6/8 K17 patients, suggestive of the 
presence of keratin aggregates; however coarse inclusions were also present in 1/4 







Figure 22. Haematoxylin and Eosin (H&E) stained affected plantar skin in PC-2 patient with 
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Figure 23. Light Microscopic changes occurring in 1% aqueous toluidine blue stained semithin 
sections of affected plantar skin, in PPK patients with underlying loricrin, mitochondrial,  keratin 
1, 9, and 17 mutations (a,b,c,d and e respectively) compared to normal unrelated plantar control 
(f).  (a and b) Hyperkeratosis and acanthosis present, suggestion of acantholysis in (b); (c and e) 
demonstrate coarse inclusions in granular layer suggestive of keratin aggregates; (d) epidermolysis 
correlating to changes on H&E stained sections; (f) acanthosis of normal plantar skin, with some 




3.1.3.3 Electron microscopy 
Electron microscopy shows abnormal keratin filaments in PPK with underlying 
keratin mutations only but is not a uniform finding within subtypes, with other 
electron microscopic features also variable between individuals. 
Despite the presence of coarse inclusions in the granular layer in 9/16 PPK and 1/4 
plantar control on semithin sections, abnormal keratin filaments, such as keratin 
aggregates or loss of normal filament structure, were only confirmed by electron 
microscopy in 7/16 PPK patients and 0/4 controls (Table 14). Notably, the keratin 
filaments were condensed and compacted in a perinuclear distribution. Cytolysis was 
a feature in only 1/2 K1 and 1/2 K9 patients electron microscopically, despite both 
K9 patients showing acantholysis on H&E sections. Cell-cell separation was noted in 
1/2 K9, and 1/1 DSG1 and Mitochondrial patients. Loosely compacted stratum 
corneum was evident in 3/16 PPK patients and cell vacuolation in 3/8 K17 and 1/1 
DSG1 patients (Figures 24 & 25). 
A lack of clarity of ultrastructural features was observed in plantar samples in 
3/16 PPK patients (underlying mutations keratin 1, 17 and loricrin) and 1/4 plantar 
controls processed at St John’s Institute of Dermatology. It was thought that the most 
likely reason for this was poor infiltration of fixative during processing. As patient 
samples were collected sequentially, adjustments were made in the timing of alcohol 
dehydration steps after each of these cases, but with minimal impact on infiltration 
quality. It was concluded that the difficulties encountered in infiltration occurred 
immediately at the time the biopsy was suspended in fixative (2.5% glutaraldehyde, 
Glasgow and half-strength Karnovsky’s fixative, London) and possibly related to the  
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KRT1 (2) 1/2 0/2 1/2 1/2 2/2 0/2 0/2 
KRT9 (2) 1/2 0/2 0/2 1/2 2/2 (1 LC) 0/2 1/2 
KRT17 (8) 5/8 0/2 2/8 (2 bipartite) 0/8 8/8 (2 LC) 3/8 0/8 
DSG1 (1) 0/1 See ch. 3.4 1/1 0/1 1/1 1/1 1/1 
Loricrin (2) 0/2 0/2 0/2 0/2 2/2 0/2 0/2 
Mitochondria 
(1) 
0/1 0/1 0/1 0/1 1/1 0/1 1/1 
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Figure 24.  Electron micrographs of affected plantar skin in PPK patients with underlying 
keratin 1, 9, 17, loricrin and mitochondrial mutations (a, b, c, d, e respectively), compared to 
normal unrelated plantar control (f). (a) Lucent area suggestive of cytolysis within cytoplasm; (b) 
keratin aggregates (short arrow) and areas of cytolysis (long arrow); (c) presence of bipartite 
keratohyaline granules; (d) normal keratin filaments and no prominent granules; (e) evidence of cell-
cell separation correlating to area of acantholysis on semithin and (f) normal filaments and 
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Figure 25. Electron micrographs of affected plantar skin in PPK patients with underlying K9 


















thickness of the specimen itself. The number of samples in which this was 
encountered was comparable between Glasgow and London processing (ratio 
approximately 1:4) despite using different fixatives, suggestive of a physical problem 
with penetration of the fixative in these cases. Optimal infiltration of acanthotic and 
hyperkeratotic acral skin was achieved when the skin biopsy was physically 
dissected as thinly as possible. 
3.1.4 Discussion 
3.1.4.1 Ridged or glabrous skin of palms and soles 
The ridged epidermis of palmoplantar skin is a unique tissue because of the amount 
of physical stress which it has to endure. To endure this stress, it has evolved 
structural specializations which bring their own hazards. For instance, the epidermis 
normally grows thicker in response to physical stress: palmoplantar skin also 
becomes abnormally thickened and keratotic in many skin disorders caused by 
mutations in genes which weaken the cell cytoskeleton (Swensson et al., 1998) (see 
chapter 1).  
3.1.4.2 Structural clues to genetic disorders of the epidermis 
Hereditary skin diseases, such as the inherited PPKs, have been characterized by a 
variety of histological and ultrastructural features. Indeed, a morphologic approach, 
using light microscopy, transmission electron microscopy in combination with 
immunofluorescence and immunoelectron microscopy, provided vital clues to 
candidate proteins and genes prior to their identification (Eady et al., 1994; Anton-





3.1.4.3 Keratin aggregation in inherited PPK 
Condensation of tonofilament bundles in suprabasal keratinocytes, with aggregation 
and a reduction of intermediate filaments in the perinuclear cytoplasm has been 
noted in inherited PPK due to underlying keratin mutations, including K16 in PC-1 
(McLean et al., 1995; Smith et al., 1999a), K17 in PC-2 (McLean et al., 1995), K1 in 
epidermolytic PPK (Hatsell et al., 2001), and K9 in epidermolytic PPK (Navsaria et 
al., 1995). Aggregates have been noted to be present in whorl-like configurations 
(McLean et al., 1995), sparse amounts of thin and short keratin filament bundles 
being present in the periphery of the cytoplasm (McLean et al., 1995) and tight 
clumps being present at the cell surface often adjacent to desmosomes (Hatsell et al., 
2001). Less dense and shorter keratin intermediate filaments have been reported in 
K1 mutations in striate PPK (Whittock et al., 2002a) and interestingly, perinuclear 
keratin aggregation and compaction has also been noted in striate PPK caused by 
desmoplakin mutations (Armstrong et al., 1999; Whittock et al., 1999). 
 Unusual ultrastructural changes in keratin morphology have been observed in 
suprabasal keratinocytes in two Dutch EPPK families with underlying K1 mutations 
(Terron-Kwiatkowski et al., 2006), two German EPPK families with the same 
underlying mutation (Wevers et al., 1991; Grimberg et al., 2009), diffuse PPK of 
unknown molecular aetiology (Anton-Lamprecht, 1994) and a further German family 
with a novel K1 mutation two residues upstream from the original one reported in the 
1B domain (Grimberg et al., 2009). Rather than forming bundles, the suprabasal 
keratin instead formed tubular structures, seen in both longitudinal and transverse 
sections, coining the term “tonotubular” keratin aggregation. Terron-Kwiatkowski et 
al. (2006) postulated that a single amino-acid substitution in the 1B domain of the K1 
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rod domain was responsible for generating the tonotubular phenotype, due to an 
abnormal hydrophobic dimer-dimer and/or filament interaction 
 Keratin aggregation is not a structural change which is unique to the inherited 
PPKs, but is present in a number of other disorders of keratin proteins, including 
epidermolysis bullosa Dowling-Meara (Anton-Lamprecht, 1996), where it is 
associated with electron-dense aggregates of K5/K14 in the cytoplasm of some basal 
keratinocytes (Anton-Lamprecht & Schnyder, 1982; Ishida-Yamamoto et al., 1991) 
which may or may not predispose those particular cells to rupture. EH or BCIE due 
to K1 and K10 mutations is characterized by suprabasal keratin clumping, originally 
thought to relate to increased amounts of filaggrin but shown to relate to K1 and K10 
(Ishida-Yamamoto et al., 1992; 1994; Anton-Lamprecht, 1994).  Ichthyosis bullosa 
of Siemens demonstrates keratin clumping in granular layers only and ichthyosis 
hystrix Curth-Macklin in suprabasal layers (Anton-Lamprecht, 1994). 
 Intermediate filaments are highly dynamic structures, with the entire keratin 
network being in constant motion despite bundle size and desmosomal anchorage 
(Yoon et al., 2001). In order to examine the effect on keratin dynamics by EBS-type 
mutations, epithelial cells were transfected with mutant K14, revealing keratin 
aggregates to be highly dynamic whereas filaments were extremely static (Werner et 
al., 2004). This data points to the transient nature of keratin aggregates in cells. 
 In our cohort, perinuclear keratin aggregation was present in a majority of 
patients with underlying keratin mutations, but this was not a uniform finding. This 
raised the possibility that this is a secondary phenomenon as opposed to a critical 
step in the development of plantar hyperkeratosis, although it is also possible that the 
absence of keratin aggregation was a sampling phenomenon and may have been 
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present in other areas of hyperkeratotic plantar skin, particularly given the transient 
nature of aggregates. The presence of keratin aggregates in pedigrees with 
desmoplakin and not keratin mutations (Whittock et al., 1999; Armstrong et al., 
1999) also raises the possibility that this structural abnormality is a secondary 
finding. 
3.1.4.4 Granular layer abnormalities, keratohyaline granules and acanthosis in 
inherited PPK 
Acanthotic ridged epidermis with markedly reduced granular layer in places has been 
reported in PC-2 due to K16 and K17 mutations with granular cells showing reduced 
amounts of keratohyalin ultrastructurally (McLean et al., 1995). However, 
hypergranulosis and acanthosis are more commonly reported features (Camisa & 
Rossana, 1984; Sybert et al., 1988; Navsaria et al., 1995; Magro et al., 1997; Kljuic 
et al., 2003b). However, a comparison of acanthosis in inherited PPK to control 
plantar tissue has not been made in the majority of these reports. Although in some 
inherited PPK subtypes in our cohort, acanthosis was notably more severe than in 
acral controls, in others there was very little difference, emphasising the need to 
assess the structural features of keratoderma in relation to normal glabrous skin. 
Darkly stained perinuclear inclusions in upper spinous layers or darkly 
staining granular or filamentous material have been noted by light microscopy in PC-
2 due to K16 and K17 mutations (McLean et al., 1995), SPPK due to desmoplakin 
mutations (Armstrong et al., 1999), EPPK due to K1 mutation (Terron-Kwiatkowski 
et al., 2006), and large and variable granules noted on electron microscopy of 
inherited PPK of unknown aetiology (Magro et al., 1997). In comparison, 
keratohyaline granules have also been described as not overtly abundant in EPPK 
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due to K9 mutation (Navsaria et al., 1995). Hypergranulosis and prominent 
keratohyaline granules are a feature in some cases of loricrin keratoderma (Maestrini 
et al., 1996; Korge et al., 1997; Ishida-Yamamoto et al., 1998a) and granules in these 
cases are loricrin-positive aggregates (Ishida-Yamamoto et al., 1998a). 
Ultrastructurally, vacuolization in suprabasal keratinocytes is a non-specific 
finding documented in a number of subtypes of inherited PPK , as are intracellular 
and intercellular oedema of the stratum spinosum (Smith et al., 1999a), which was 
consistent with the findings in our cohort. Intercellular oedema or loosening of 
intercellular connections has been commonly reported in SPPK due to desmoplakin 
mutations (Armstrong et al., 1999; Whittock et al., 1999; Norgett et al., 2000) and 
desmoglein 1 mutations (Wan et al., 2004).   
The findings in our cohort are consistent with the variations between 
individuals and subtypes in the literature. Although acanthosis is commonly reported, 
the degree of acanthosis compared to normal controls is variable. Both 
hypogranulosis and hypergranulosis with prominent granules are both features of 
inherited PPK and not specific to particular subtypes. This is suggestive that these 
epidermal changes are secondary as opposed to primary pathogenic phenomena. 
3.1.4.5 Cytolysis/epidermolysis in inherited PPK 
Epidermolysis is a feature of inherited PPK limited to subtypes caused by K1 and K9 
mutations (Navsaria et al., 1995; Hatsell et al., 2001; Terron-Kwiatkowski et al., 
2006). However, epidermolysis has not always been identified by all methods of 
structural examination e.g. light and electron microscopy, and may indeed be a subtle 
finding (Hatsell et al., 2001). Although evidence of epidermolysis was seen in all 4 
of the K1 and K9 patients in our cohort either on light or electron microscopy, this 
145 
 
was not a feature that was uniformly apparent for each patient in all sections or by all 
methods. This highlights the limitations of structural analysis: epidermal changes 
may not be uniform across all areas of affected plantar skin and accurate 
documentation of structural features is limited by the size of tissue obtained, the site 
biopsied and also they may change over time. Ideally, serial biopsies should be 
performed although this is clinically impractical. 
3.1.4.6 Cornified envelope in inherited PPK  
Although always thickened in the inherited PPKs, the stratum corneum has often 
been reported as appearing intact morphologically (Sybert et al., 1988; Navsaria et 
al., 1994; Magro et al., 1997; Armstrong et al., 1999; Hatsell et al., 2001; Kljuic et 
al., 2003b). Orthohyperkeratosis (McLean et al., 1995; Smith et al., 1999) and 
prominent stratum lucidum have been noted in PC-2 due to K16 and K17 mutations 
(McLean et al., 1995). In EPPK due to K9 mutation, some extension of keratin 
aggregates into lower parts of the stratum corneum were noted (Navsaria et al., 1995) 
although the enlarged stratum corneum was otherwise normal. Parakeratosis has been 
noted in some cases of loricrin keratoderma (Ishida-Yamamoto et al., 1998a). 
Ultrastructurally, little comment has previously been made on the degree of 
compaction of the stratum corneum; 3/16 PPK patients in our cohort had evidence of 
loosely compacted stratum corneum although the significance of this remains 
unclear.  
3.1.4.7 Inflammatory infiltrate in inherited PPK 
There is a paucity of evidence of inflammation in affected plantar skin in inherited 
PPK. Two cases of unknown molecular aetiology show evidence of inflammatory 
cells surrounding capillary loops extending into the dermal papillae (Sybert et al., 
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1988) and mild perivascular dermal inflammatory infiltrate (Kabashima et al., 2008). 
The presence of inflammation probably will vary with time and the severity of 
clinical features at the time of biopsy, however this was not an uncommon feature in 
our cohort and often associated with some capillary prominence in the dermal 
papillae. As this is not a uniform feature however, it is not likely to be a primary 
mechanism in the development of hyperkeratosis. 
3.1.4.8 Dyskeratosis 
The term “dyskeratosis” denotes imperfect keratinisation of individual epithelial cells 
whose histological features on H&E stains include nuclear pyknosis and condensed, 
intensely eosinophilic cytoplasm (Bergman et al., 2008). Epidermal dyskeratosis 
characterizes other hereditary skin diseases associated with keratin clumping 
ultrastructurally, such as Darier disease and ichthyosis hystrix of Curth-Macklin 
(Mann & Haye, 1970; Gottlieb & Lutzner, 1973; Kanerva et al., 1984). It has more 
recently been described in EH/ BCIE (McKee, 1996; Bergman et al., 2008), EPPK 
due to K9 mutations (Bergman et al., 2008) and in one inherited PPK case of 
unknown molecular aetiology (Magro et al., 1997). Although dyskeratosis was not a 
feature in our cohort, with no evidence of nuclear pyknosis, there was striking 
evidence of prominent, homogenous, eosinophilic cytoplasm throughout the spinous 
layers of the K1 and K17 subtypes. Although this may reflect intracellular aggregates 
of tonofilaments, ultrastructurally this was not confirmed in all cases.  
3.1.5 Conclusion 
Plantar hyperkeratosis is not readily distinguishable between inherited PPK of 
different underlying genetic causes by morphological study. In studying multiple 
specimens and multiple subtypes, it is clear that there is considerable histological 
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variation both within and between subtypes. Although certain specific features may 
be more common in particular subtypes e.g. keratin aggregates in inherited PPK due 
to underlying keratin mutations, these features are not uniformly found and are not 
pathognomonic. This raises the possibility that many of the structural features of 
inherited PPK reported in previous studies are secondary phenomena rather than 
critical steps in the pathogenesis of hyperkeratosis. Previous study has also been 
hampered by the lack of comparison with appropriate control material, and the 










Chapter 3.2 Immunocytochemical Analysis of Affected Plantar Skin 
in Inherited Palmoplantar Keratoderma 
3.2.1 Introduction 
Proliferation and terminal differentiation are tightly controlled in human epidermis 
(chapter 1) and a constant balance between these processes is critical in maintaining 
normal epidermal structure and function. Alterations in this balance are likely to 
contribute to a variety of skin diseases, such as the inherited PPK.  
Changes in the expression pattern and distribution of markers of 
differentiation and turnover were anticipated in PPK, whatever the aetiology.  
Following the initial histological and ultrastructural analysis, an 
immunocytochemical study was performed examining a selection of markers of 
differentiation including a selection of keratins representative of different stages of 
differentiation (keratins 1,9,14 and 17) and markers of late differentiation (filaggrin, 
loricrin and involucrin). Markers of proliferation (Ki67) and apoptosis (activated 
caspase-8) were also studied. 
3.2.2 Materials and Methods 
3.2.2.1 Patients and tissue specimens 
Immunocytochemical analysis of affected plantar skin in all 16 patients recruited was 
undertaken. Fresh elliptical plantar biopsies of affected skin were dissected into three 
pieces (chapter 2.2), one of which was prepared for paraffin-embedding. 
3.2.2.2 Tissue processing and sectioning 
Affected plantar skin was processed for light microscopy at the Departments of 
Pathology, Southern General Hospital and Western Infirmary, Glasgow. Routine 
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specimen preparation, processing, embedding and cutting was performed as in 
chapter 3.1.2.1. 
3.2.2.3 Control Specimens 
Control specimens used were obtained as for H&E staining, chapter 3.1.2.4. Two 
biopsies of normal plantar skin and one of normal palmar skin from unaffected 
patients were obtained from the Department of Pathology, Western Infirmary for 
light microscopy, and processed in the same way as the PPK specimens. 
3.2.2.4 Antibodies 
Sections were stained with the following markers of differentiation, epidermal 
proteins and markers of proliferation/apoptosis (Table 15). 
3.2.2.5 Immunocytochemistry on paraffin-embedded tissue 
Paraffin-embedded tissue sections (4μm) were incubated for 30 min at 80oC and 
rehydrated (as described for H&E staining). Rehydrated sections were then gently 
put into a pressure cooker containing 1 litre pre-heated 10mM citrate buffer 
(LabVision,  pH=6.0). The sections were then microwaved on full power for 10 min 
and then left to cool for 20 min. After washing twice in phosphate buffered saline, 
PBS (Sigma, UK) over 5 min, sections were incubated for 10 min in fresh 3% 
hydrogen peroxide. After washing in PBS over 5 min, sections were incubated with 
normal rabbit serum, 1:5 dilution in PBS (DakoCytomation, UK) for primary mouse 
antibodies or normal goat serum, 1:5 dilution in PBS (DakoCytomation, UK) for 
primary rabbit antibodies. The blocking solution was removed and then the sections 
were incubated with appropriate primary antibodies diluted in PBS (Table 15) at 
37oC for 1 hour. After 3x5min washes in PBS, the sections were incubated for 20 
min with biotinylated rabbit anti-mouse antibody (DakoCytomation, UK) diluted  
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Isotype Catalogue or 
clone no. 
Dilution Source 
CK1 Mouse M 
AH 
IgG1 NCL-CK1 1:50 Novo Castra, UK 




Ab19124 1:25 Abcam, UK 
CK14 Mouse M 
AH 
IgG3 NCL-LL002 1:50 Novo Castra, UK 
CK17 Mouse M 
AH 
IgG2b NCL-CK17 1:50 Novo Castra, UK 






1:50 Novo Castra, UK 
Involucrin Mouse M 
AH 
IgG1 NCL-INV 1:200 Novo Castra, UK 
Loricrin Rabbit P 
AH/AM 
IgG Ab24722 1:500 Abcam, UK 




MIB-1, M7240 1:25 DakoCytomation, 
UK 
Caspase-8 Mouse M 
AH 





1:100 in PBS for primary mouse antibodies, or biotinylated goat anti-rabbit antibody 
(DakoCytomation, UK) diluted 1:100 in PBS for primary rabbit antibodies. The 
sections were again washed 3x5 min in PBS. Avidin horse-radish peroxidase 
conjugate (DakoCytomation, UK) diluted 1:100 in PBS was added and incubated for 
20 min. Samples were washed 3x5min in PBS and colour developed using Liquid 
DAB+ Substrate Chromagen System (DakoCytomation, UK). Negative controls 
were established omitting the primary antibody. Sections were counterstained with 
haematoxylin, dehydrated and fixed (as described in 3.1.2.2). Sections were observed 
and photographed using a Zeiss Axiovert S100 microscope. All sections were stained 
in duplicate or triplicate per antibody, except for CK9 and CK17 where sections were 
stained a minimum of 6 times per antibody using a variety of different conditions 
(see below). A selection of sections per antibody used were analysed by a blinded 




second observer for comparison of analysis. 2/8 K17 PPK samples were not used in 
the final analysis due to the poor quality of epidermal sections obtained. 
Involucrin 
High temperature antigen unmasking technique using citrate buffer/microwave was 
not required, and this step was omitted. 
Cytokeratins 9 and 17 
A variety of conditions were altered for these two antibodies in an attempt to 
optimise staining, including incubation periods with the primary antibody of 2 hours 
at room temperature and overnight at 4oC. Optimal staining was obtained at 
incubation for 1 hour at 37o
 Enzyme digestion was also performed for CK 9 staining, using either trypsin 
or pronase, in an attempt to optimise conditions. The sections were incubated in 
0.1% Trypsin Type II-S (Sigma Chemical Co) and 0.1% calcium chloride in distilled 
water for 30 min at 37oC, washed in running tap water to stop enzyme digestion, 
then washed in Tris-buffered saline for 5 min prior to immunocytochemical staining. 
Sections were also incubated in 0.1% Pronase Type XIII (Sigma Chemical Co) in 
PBS for 15-20 min at room temperature, washed in running tap water to stop enzyme 
digestion, then washed 2x5 min in PBS prior to immunocytochemical staining. 
Optimal staining for CK9 was achieved using the high temperature antigen retrieval 
step using citrate buffer and incubating with primary antibody for 1 hour at 37
C. Microwave times were also altered (reduced and 
increased) for the citrate buffer high temperature antigen retrieval step, but optimal 
conditions were achieved at 10 min full power. 
oC. 
Repeat antibodies were purchased from Abcam and Novocastra for CK9 and CK17 




3.2.3.1 Markers of differentiation 
Cytokeratin 1 staining was predominantly suprabasal in both inherited PPK and 
control specimens, and essentially cytoplasmic in pattern. Weak patchy basal nuclear 
staining was also noted in 1/2 Loricrin, 1/6 K17 and 1/1 Mitochondrial PPK subtypes 
(Figure 26; Table 16) 
Cytokeratin 9 staining showed patchy spinous layer cytoplasmic staining in inherited 
PPK and control specimens. Despite multiple attempts at staining using different 
conditions (see methods), the intensity of staining remained weak throughout (Figure 
27; Table 17). Alternating vertical bands of K9 positive cells was seen in 1/2 Loricrin 
subtype. 
Cytokeratin 14 staining showed continuous predominantly cytoplasmic staining of 
basal and spinous layers in both inherited PPK and control specimens (Figure 28; 
Table 18). 
Normal non-acral skin demonstrated strong positive cytokeratin 17 staining for 
sebaceous glands and hair follicles with no epidermal staining. Staining of inherited 
PPK showed weak patchy suprabasal or spinous layer staining only and the 
mitochondrial PPK subtype showed no staining despite repeated attempts using 
slightly altered conditions (see methods) (Table 19). Plantar control revealed similar 
staining patterns to inherited PPK plantar samples, compared to palmar control 











Pattern of Staining Intensity 
(-/+/++/+++) 
KRT1 (2) SB (2/2) *(1/2) C; patchy N (1/2) +++ 
KRT9 (2) SB (2/2) C +++ 




DSG1 (1) SB (1/1) C ++ 
Loricrin (2) SB (2/2); B patchy 
(1/2) 
C; B=N  C +++ 
B + 
Mitochondria (1) SB + B patchy (1/1) C; B=N C +++ 
B + 










Pattern of Staining Intensity 
(-/+/++/+++) 
KRT1 (2) Sp (2/2) C + 
KRT9 (2) Sp+SB (2/2) C + 
KRT17 (6) Sp (6/6) C + 
DSG1 (1) Sp (1/1) C + 
Loricrin (2) Sp (2/2) C + 
Mitochondria (1) Sp (1/1) C + 
Controls (3) Sp (3/3) C + 
 
 





Pattern of Staining Intensity 
(-/+/++/+++) 
KRT1 (2) B+Sp (2/2) *(1/2) C+M +++ 
KRT9 (2) B+Sp (2/2) C+M +++ 
KRT17 (6) B+Sp (6/6) C+M ++ 
DSG1 (1) B+Sp (1/1) C+M +++ 
Loricrin (2) B+Sp (2/2) C+M ++ 
Mitochondria (1) B+Sp (1/1) C+M ++ 







SB=Suprabasal; B=Basal; C=Cytoplasmic; N=Nuclear;  
* Suggestion of cytoplasmic clumps of staining 
Sp=Spinous; SB=Suprabasal; C=Cytoplasmic; 
B=Basal; Sp=Spinous; C=Cytoplasmic; M=Membranous 
*Suggestion of cytoplasmic clumps of staining 
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Pattern of Staining Intensity 
(-/+/++/+++) 
KRT1 (2) SB patchy (2/2) C + 
KRT9 (2) Sp patchy (2/2) C + 
KRT17 (6) Sp patchy (6/6) C + 
DSG1 (1) Sp patchy (1/1) C ++ 
Loricrin (2) SB patchy C + 
Mitochondria (1) Nil - - 





Table 20. Filaggrin pattern of staining 
PPK Subtype 
(Number, n) 




KRT1 (2) Gr; Cont (2/2) C (2/2) ++ 
KRT9 (2) Gr; Cont (2/2) C (2/2) ++ 
KRT17 (6) Gr; Cont (2/2) C (5/6); F (1/6) ++ 
DSG1 (1) Gr; Cont (1/1) C (1/1) ++ 
Loricrin (2) Gr; Cont (1/2); P (1/2) C (2/2) ++ 
Mitochondria (1) Gr; P (1/1) C (1/1) ++ 









Pattern of Staining Intensity 
(-/+/++/+++) 
KRT1 (2) Sp; B/Gr weaker (2/2) M+C Sp +++ 
B/Gr + 
KRT9 (2) Sp; B/Gr patchy (2/2) M+C Sp +++ 
B/Gr + 
KRT17 (6) Sp; B/Gr patchy (6/6) M+C Sp+++ 
B/Gr + 
DSG1 (1) Sp; B patchy (1/1) M+C Sp +++ 
B + 
Loricrin (2) Sp; B/Gr patchy (2/2) M+C Sp +++; B ++; 
Gr + 
Mitochondria (1) Sp; B/Gr weaker (1/1) M Sp +++, B/Gr ++ 







SB=Suprabasal; Sp=Spinous; C=Cytoplasmic 
Gr=Granular; Cont=Continuous staining; P=Patchy; C=Coarse; F=Fine; 
Sp=Spinous; B=Basal; Gr=Granular; M=Membranous; C=Cytoplasmic; 
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Pattern of Staining Intensity  
(-/+/++/+++) 
KRT1 (2) USp+Gr (2/2) C (2/2) ++ 
KRT9 (2) USp+Gr (2/2)  *  C (2/2) ++ 
KRT17 (6) USp+Gr (6/6) C (6/6); +N (2/6) +/++ 
DSG1 (1) USp+Gr (1/1) C (1/1) + 
Loricrin (2) USp+Gr (2/2)  C (2/2); N (2/2) ** +/++ 
Mitochondria (1) USp+Gr (1/1) C (1/1) ++ 






Table 23. Ki67 staining 
PPK Subtype 
(Number, n) 
Mean positive nuclei/100 basal cells (range) 
KRT1 (2) 10.79 (8.72-12.86) 
KRT9 (2) 17.53 (12.63-28.14) 
KRT17 (6) 12.46 (8.0-25.8) 
DSG1 (1) 15.5 (8.7-21.25) 
Loricrin (2) 13.43 (9.0-19.3) 
Mitochondria (1) 9.82 (7.9-11.75) 








USp=Upper Spinous; Gr=Granular; C=Cytoplasmic; N=Nuclear; SC=Stratum corneum 
• *Strongly positive staining in areas of acantholysis 
• **Positive nuclear staining around sweat duct 
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E  F  
 
 
Figure 26. Cytokeratin 1 staining in affected plantar skin of inherited PPK patients with 
underlying keratin 1, 9, 17, loricrin and mitochondrial mutations (a, b, c, d, e) respectively 
compared to normal plantar control (f). Predominantly suprabasal cytoplasmic staining throughout 
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Figure 27. Cytokeratin 9 staining in affected plantar skin of inherited PPK patients with 
underlying keratin 1, 9, 17, loricrin mutations (a, b, c, d) respectively compared to normal 
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Figure 28. Cytokeratin 14 staining in affected plantar skin of inherited PPK patients with 
underlying keratin 1, 9, 17, loricrin and mitochondrial mutations (a, b, c, d, e) respectively 
compared to normal plantar control (f). Predominantly cytoplasmic staining of basal and spinous 
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Figure 29. Cytokeratin 17 staining in control non-acral skin (a) and affected plantar skin of 
inherited PPK patients with underlying keratin 1, 9, 17 and loricrin and mutations (b, c, d, e) 
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Figure 30. Filaggrin staining in affected plantar skin of inherited PPK patients with underlying 
keratin 1, 9, 17, loricrin and mitochondrial mutations (a, b, c, d, e) respectively compared to 
normal plantar control (f). Staining restricted to granular layer with positive coarse staining of 





A   B  
C   D  
E     F  
 
Figure 31. Involucrin staining in affected plantar skin of inherited PPK patients with underlying 
keratin 1, 9, 17, loricrin and mitochondrial mutations (a, b, c, d, e) respectively compared to 
normal palmar control (f). Membranous and cytoplasmic staining of spinous layers predominantly, 
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Figure 32. Loricrin staining in affected plantar skin of inherited PPK patients with underlying 
keratin 1, 9, 17, loricrin and mitochondrial mutations (a, b, c, d, e) respectively compared to 
normal plantar control (f).  Cytoplasmic staining of upper spinous and granular layers throughout, 
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Figure 33. Ki67 staining in affected plantar skin of inherited PPK patients with underlying 
keratin 1, 9, 17, loricrin and mitochondrial mutations (a, b, c, d, e) respectively compared to 
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Figure 34. Activated caspase 8 staining in breast carcinoma (a) compared to affected plantar 















3.2.3.2 Cornified envelope proteins 
Filaggrin staining in inherited PPK and control samples were largely comparable, 
with staining restricted to the granular layer, being mainly continuous, and 
keratohyaline granules generally staining positively and appearing coarse (Figure 30; 
Table 20). 1/2 patients with Loricrin and 1/1 Mitochondrial PPK subtypes showed 
patchy filaggrin staining, which correlated to alternating areas of hyper- and 
hypogranulosis on H&E staining. 
Involucrin staining was predominantly and uniformly in the upper spinous layer in 
all inherited PPK patients, with variations of staining of basal and granular layers. 
The pattern of staining was both membranous and cytoplasmic, other than in the 
mitochondrial subtype, where it was membranous only. Control samples showed no 
basal staining but otherwise were closely comparable (Figure 31; Table 21). 
Loricrin staining was limited to the upper spinous and granular layers in all inherited 
PPK patients and was mainly cytoplasmic, other than the Loricrin PPK subtype, 
where there was also nuclear staining around sweat ducts. In addition, one control 
sample demonstrated a diffuse staining of the stratum corneum. There were only 
subtle differences of intensity of staining between individuals. Loricrin staining was 
also strongly positive in all areas of acantholysis in K9 patients (Figure 32; Table 
22). 
3.2.3.3 Markers of proliferation/apoptosis 
Ki67 
Ki67 staining was restricted to the basal and epibasal cell layers of the epidermis. 
Ki67 demonstrated a range of scores from 9.82 per 100 basal cells in the 
mitochondrial PPK subtype to 17.53 per 100 basal cells in K9 subtypes, which 
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compared to palmoplantar controls’ score of 16.6 (Figure 33; Table 23). There was 
some variation between individuals and also between different sections for the same 
individual. There was a modest correlation between Ki67 counts on the duplicate 
sections using linear correlation and regression analysis (r2=0.302, p value < 0.05). 
Blinded second observer scores of Ki67 counts were performed, with close 
correlation in scoring between observers using linear correlation and regression 
analysis (r2
Activated Caspase 8 
=0.921, p value=0.09). 
Positive controls (breast carcinoma and testis) showed strong positive nuclear 
staining (Figure 34). All inherited PPK and 2/3 control specimens showed an absence 
of positive staining. 1/3 plantar control specimen showed low numbers of positive 
darkly stained nuclei. 
 
3.2.4 Discussion 
3.2.4.1 Keratins as markers of differentiation 
It is well recognised that changes occur in the expression of keratin intermediate 
filaments during epidermal differentiation (Galvin et al., 1989). Keratins are useful 
markers for the differentiation of epithelial cells and facilitate evaluation of the 
origin of epithelial tumours, as keratin expression varies depending on the type of 
cells, hyperproliferative state, the stage of differentiation and the disease state (Moll 
et al., 1982). Similarly, each of the many different epithelial cells and tissues in the 
human body express particular combinations of keratins (Lane, 1993) (see Table 1, 
chapter 1).  
The type-II keratins K5 and K14 are the primary keratin pair of keratinocytes 
of stratified epithelia (Moll et al., 1982). They are strongly expressed in the 
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undifferentiated basal cell layer and down-regulated in the differentiating suprabasal 
cell layers (Fuchs & Green, 1980). The process of terminal differentiation and 
keratinization is associated firstly with a transition of keratinocytes from the 
proliferative basal layer to the postmitotic suprabasal spinous layers (see chapter 1 & 
3.2.4.7), with a switch in expression to the suprabasal epidermal keratins, type II 
keratins K1 and K10 (Moll et al., 1982; Stoler et al., 1988). However, other keratins 
are selectively expressed. For example, the type I keratin K17 has a unique cell type 
distribution, and is selectively expressed in basal and myoepithelial cells 
(Troyanovsky et al., 1989; 1992) (see 3.2.4.3). The type I keratin K9 also shows 
highly specific expression in terminally differentiating keratinocytes of palmoplantar 
epidermis (Moll et al., 1987; Langbein et al., 1993) (see 3.2.4.2). Underlying keratin 
defects in our cohort of patients included mutations in K1, K9 and K17 genes. The 
keratins studied in the present cohort were specifically chosen due to these 
underlying mutations (K1, K9 and K17) and as a selection of markers of 
differentiation and hyperproliferation. A more exhaustive study of keratins was 
limited by tissue available for study, and the need to study a range of non-keratin 
markers. 
 K1 is expressed in suprabasal cells of stratified, cornified epithelia and is a 
marker of terminal differentiation in stratified epithelium (Gown & Vogel, 1982; 
Leigh et al., 1993). Unlike mouse epidermis, where a significant number of basal 
cells express K10, only small numbers of basal cells in human epidermis express K1 
and K10, and these are co-expressed in epidermal and mucosal sites (Leigh et al., 
1993). Basal cells have been shown to react to K1 in ichthyosis hystrix Curth-
Macklin (Niemi et al., 1990), suggestive that the basic fault of the keratinisation 
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process may be in ultrastructurally normal basal cells. In my study, significant 
differences in K1 staining patterns were not seen between inherited PPK subtypes, 
even in 2 patients with underlying K1 causative mutations, demonstrating normal K1 
expression in plantar skin. However, 1/2 of these patients demonstrated abnormal 
keratin filaments on electron microscopy (chapter 3.1). A suprabasal pattern of K1 
staining was observed throughout subtypes, although in addition, 1/6 K17, 1/2 
Loricrin and 1/1 Mitochondrial PPK subtypes showed patchy nuclear basal staining, 
although this did not correlate with any corresponding ultrastructural abnormality. 
K14, a basal keratin and marker of undifferentiation (Purkis et al., 1990), is 
expressed in basal keratinocytes of epidermis and stratified epithelia. Significant 
differences in its expression were not found between inherited PPK and control acral 
tissues in this study. Changes in keratin expression associated with hyperproliferation 
in hair-bearing epidermis include the induction of K6, K16, and K17 (Weiss et al., 
1984; Stoler et al., 1988; Wilson et al., 1994), although this is not a consistent 
finding (Kopan & Fuchs, 1989). Upregulation of K16 has been observed in BCIE 
(Ishida-Yamamoto et al., 1992).  In PC due to K6 mutations, diffuse epidermal 
staining including the basal layer was observed for K6, K16, K17 and K14, in 
association with prominent ortho and parakeratosis surmounting an acanthotic 
epidermis, suggestive of rapid keratinocyte proliferation and differentiation, although 
specific markers of proliferation were not studied (Leachman et al., 2005). This is in 
keeping with other reports in PC (Su et al., 1990; Wollina et al., 1991). Although 
K17 was not found to be qualitatively increased or altered in distribution in our 
cohort compared to acral controls (section 3.2.4.3), a more detailed study including 




3.2.4.2 Specialised keratin expression pattern in normal human ridged skin 
The epidermis of normal human ridged skin normally grows thicker in response to 
physical stress. It also expresses a more complex pattern of keratins than thin skin, 
which is again probably due to the greater stress that ridged skin has to withstand 
(Swensson et al., 1998). Keratinocytes in ridged skin have an unusually large number 
of keratin filaments in their cytoplasm compared with thin skin (Swensson & Eady, 
1996) (chapter 1). K9  is expressed in terminally differentiated palmoplantar 
epidermis (Knapp et al., 1986; Moll et al., 1987; Langbein et al., 1993), and weak 
expression was noted in both inherited PPK and acral control samples in this study, 
irrespective of the presence of an underlying K9 mutation in two patients, one of 
whom demonstrated keratin aggregates ultrastructurally (see chapter 3.1).  
K9 is abundantly yet heterogeneously expressed in palmoplantar epidermis 
(Moll et al., 1987; Langbein et al., 1993), where it is only expressed in suprabasal 
cell layers, often arranged in vertical columns but sometimes also forming extending 
continuous sheets. Weak K9 staining was observed in all samples in this study with 
discontinuous labelling and alternating vertical bands in 1/2 Loricrin subtypes. 
K1/K10 have in contrast been found to be uniformly distributed in suprabasal 
keratinocytes in palmoplantar skin (Moll et al., 1987), but these were not analysed in 
this study. 
In contrast, K9 was expressed strongly above the primary epidermal ridges 
and in the centre of the papillary ridge in one study of normal human palmoplantar 
skin (Swensson et al.,1998). This was not clearly seen in this study in either PPK or 
control samples although both demonstrated weak epidermal staining throughout. 
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Swensson et al. (1998) observed that K6 and K16 were expressed in some basal cells 
and most suprabasal keratinocytes in palmoplantar samples of six healthy controls, 
compatible with a constitutively high proliferative activity of normal ridged 
epidermis. Nests of K17-positive cells were present at the bottom of deep primary 
epidermal ridges, supporting the notion of functional heterogeneity of basal cells, 
although this was not a feature found in PPK or control acral tissue in this study, 
where expression was suprabasal. K16 expression has previously been noted in 
palmoplantar skin in a complementary pattern in intervening secondary ridge zones 
(Swensson et al., 1998), although this was not studied in this cohort. More detailed 
keratin staining, including K16, in a larger number of control palmoplantar samples 
is warranted to assess whether this is not a consistent feature of acral tissue or if 
staining varies between sites of palmoplantar skin, as the medial sole was 
consistently used in this study (see Appendix A). 
3.2.4.3 K17 expression 
K17, a hyperproliferative keratin, is present in suprabasal layers (Troyankovsky, 
1989; Leigh et al., 1995; Kurokawa et al., 2002) and is expressed in the nail bed 
(McGowan & Coulombe, 2000), palmoplantar epidermis (restricted) (Swensson et 
al., 1994), epidermal appendages, sebaceous glands, hair shaft, other epithelia and 
during wound healing (Smith et al., 2005). In particular, it is found basally in 
myoepithelial cells, basal glandular cells and in the deep outer root sheath (Lane et 
al., 1991) and suprabasally in hyperproliferative psoriasis (Leigh et al., 1995).  
The hair follicle has a complex pattern of keratin expression, with more than 
half the known keratin genes expressed, often with overlapping patterns (Langbein et 
al., 2003; Tong & Coulombe, 2004). Despite this, K17 null mice fail to develop a 
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full pelage hair coat neonatally, which is correlated with hair shaft fragility 
(McGowan et al., 2002) and alterations in apoptosis (Tong & Coulombe, 2006). 
These findings demonstrate both the structural support conferred by K17 and its role 
in regulating hair cycling. Thus K17 expression in hair shaft and epidermal 
appendages may be relevant with respect to the follicular symptoms of PC-2. 
However, K17 expression in both PC-2 and other PPK subtypes in this study did not 
demonstrate significant differences in staining to acral controls, despite the presence 
of keratin aggregates in 5/8 PC-2 patients ultrastructurally (see chapter 3.1). 
3.2.4.4 Keratins and wound healing 
Transient alterations in keratin composition have been studied in wounding of non 
hair bearing epidermis in vitro and in cultured keratinocytes. KRT6/16/17 gene 
transcription is induced and KRT1/10 reduced possibly resulting in a more pliable 
cytoskeleton favouring keratinocyte migration, essential to wound closure (Paladini 
et al., 1996; DePianto & Coulombe, 2004). K6a knockout mice have shown delayed 
re-epithelialization upon partial thickness skin wounding although healing of full 
thickness wounds was normal (Wocjik et al., 2000). Similarly, K17 knockout mice 
demonstrated delayed wound closure (Mazzalupo et al., 2003). It is thought that in 
the context of epidermal wound healing, K16 acts by promoting reorganization of the 
cytoplasmic array of keratin filaments, which precedes the onset of keratinocyte 
migration into the wound site (Paladini et al., 1996) (see chapter 1). Although the 
response to wounding in palmoplantar epidermis has not been studied, similar 
patterns of altered gene expression were not identified in PPK in this cohort. In 
particular, there was no evidence for increased expression of K17, previously 
reported to be induced in regenerating and migrating epidermal keratinocytes in 
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studies of wound healing in hair-bearing skin (Paladini et al., 1996; DePianto & 
Coulombe, 2004). 
3.2.4.5 Keratinocyte proliferation and epidermal thickening 
Ki67 is a protein thought to be associated with chromosomes in mitotic cells 
(Verheijen et al., 1989) and is expressed during G1, G2 and M phase of the cell cycle 
(Sasaki et al., 1987; Wersto et al., 1988). In this study, although there was some 
variation in Ki67 staining between PPK individuals and between subtypes, the scores 
were relatively close to those of palmoplantar controls, suggesting that increased 
epidermal turnover was not a significant factor in the development of hyperkeratosis 
at these sites.  
Epidermal thickening is a clinical feature common to the many keratin 
disorders, but there have been limited investigations into changes in keratinocyte 
proliferation in these disorders. Early studies in icthyosiform dermatoses showed a 3-
fold increase in the number of cells labelled with tritiated thymidine (Frost et al., 
1966) and an increase in the number of mitoses in BCIE. Proliferation has been 
investigated in a number of skin disorders using immunostaining for proliferating 
nuclear antigen PCNA and biochemical staining for nucleolar organiser-region 
associated argophylic proteins AGNORs. This demonstrated increased staining in 
psoriasis, congenital non bullous ichthyosiform erythroderma, BCIE and chronic 
dermatitis, and a decrease in ichthyosis vulgaris, X linked ichthyosis and pityriasis 
rubra pilaris (Kanitakis et al., 1993). The relationship between hyperproliferation and 
epidermal thickening in a mouse model for BCIE has suggested that 




Keratinocyte proliferation and acanthosis has been reported in other 
conditions associated with epidermal thickening, such as psoriasis (Iizuka et al., 
1996; 1997). Histopathologically, hyperproliferation, an aberrant keratinisation 
process and the infiltration of immunocytes in the dermis and epidermis are 
characteristic (Krueger, 2002; Bovenschen et al., 2005). The most marked epidermal 
hyperproliferation (Ki67+ nuclei) has been shown in psoriasis, compared to atopic 
dermatitis and lichen planus (Kawahira, 1999; Bovenschen et al., 2005), although 
disease severity (extent and phase of the disease) were thought to be critical in the 
absolute scores investigated, with severe atopic dermatitis showing more substantial 
Ki67 expression in one comparative study (Bovenschen et al., 2005).  
It has been observed that proliferating cells can vary between body sites quite 
considerably in mouse models (Porter et al., 1998) and that this should be considered 
in any study of proliferation in vivo. Comparative expression of Ki67 in normal skin, 
lesional psoriatic skin and normal plantar epidermis showed positivity ranging from 
2.27, 10.8 to 9.76 positive nuclei/100μm epidermis respectively (Lucke et al., 1999), 
thus there was approximately a four-fold increase in proliferation index between 
normal plantar and non-plantar epidermis. In our study, normal acral control tissue 
showed a mean stratum corneum thickness of 0.92mm in comparison to mean PPK 
stratum corneum of 0.945, 1.185, 2.33, 0.8, 2.55 and 0.67mm for K1, K9, K17, 
DSG1, loricrin and mitochondrial subtypes respectively. Thus, absolute thickness of 
stratum corneum histologically did not reflect the clinical feature of hyperkeratosis in 
PPK compared to normal acral skin. Similarly, the mean Ki67 count for normal acral 
tissue was 16.6 positive nuclei/100 basal cells compared to 10.79, 17.53, 12.46, 15.5, 
13.43 and 9.82 positive nuclei/100 basal cells in K1, K9, K17, DSG1, loricrin and 
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mitochondrial subtypes respectively. Normal palmoplantar skin demonstrated a 
higher proliferative index than clinically hyperkeratotic skin. It is possible that only a 
relatively small change in proliferative index might result in changes in 
differentiation, as demonstrated by premature expression of involucrin in all subtypes 
of PPK in this study (see 3.2.4.9), resulting in palmoplantar skin becoming 
hyperkeratotic, and this change may be hidden in the variance of our data. A more 
detailed study including other proliferative markers e.g. PCNA and BrdU would be 
necessary to reinforce the conclusion that there is no major change in proliferative 
index in PPK. Although late differentiation events have not been studied in this 
cohort, it is possible that an alteration in mechanisms of shedding may be important 
in the development of hyperkeratosis in inherited PPK. 
3.2.4.6 Apoptosis and inherited PPK 
Although staining with caspase-8 was not observed in this study, a more detailed 
study of apoptotic markers including caspase-3 would be warranted to further assess 
the role or apoptosis in the pathogenesis of inherited PPK. Caspases, a family of 
cysteinyl aspartate proteases, are considered the effector enzymes for apoptosis, 
activated in a cascade-like fashion, with many caspases being expressed in the 
epidermis (Villa et al., 1997). Multiple caspases are synthesized in human 
keratinocytes and are involved in terminal differentiation (Takahashi et al., 1998; 
Weil et al., 1999; Raj et al., 2006).  
Caspase-8 was discovered in the course of exploration of the mechanisms by 
which members of the TNF/NGF receptor family induce death of cells (Boldin et al., 
1996). It was chosen for this study as a representative of the upstream initiator 
caspases, which also include caspases-2, -4, -5, -9, -10, -11, -12 and -13, in contrast 
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to effector caspases -3, -6, -7 and -14 (Oliver & Vallette, 2005). Initiator caspases 
activate downstream effector caspases when induced by the trimerized Fas antigen 
which transduces a signal to Fas-associating protein with death domain (FADD) 
(Boldin et al., 1995; Chinnaiyan et al., 1995). Caspase-8 is first activated followed 
by caspase 3 (Chinnaiyan et al., 1996; Boldin et al., 1996), which subsequently 
stimulates caspase 3-activated DNAse (CAD) by proteolytic elimination of the 
inhibitor of CAD (ICAD) (Enari et al., 1998; Sakahira et al., 1998). UVB irradiation 
induces apoptosis of keratinocytes with increased caspase-8, -9 and -3 activities 
(Takahishi et al., 1999a; Takahishi et al., 2001b). Caspase-14 is a unique, non-
apoptotic caspase (Denecker et al., 2008), only expressed in skin (Van de Craen et 
al., 1998) by differentiating but not proliferating keratinocytes (Lippens et al., 2000; 
Rendl et al., 2002). 
Relationships between caspases and keratinocyte terminal differentiation are 
not fully understood, and caspase expression in the epidermis has shown incomplete 
or contradictory results (Raymond et al., 2007). Caspase-1, -2, -3, -4 and -7 mRNAs 
have been detected in human keratinocytes by RT-PCR, but not caspase-5 and – 6 
(Takahishi et al., 1998). Caspase-2, -3, -6, -8, -9 and -14 mRNAs have been detected 
in mouse epidermis but not caspase-1, -7, -11 and -12 (Kuechle et al., 2001). 
Caspase-3 has been shown to be expressed in the active form at the granular layer, at 
the transition to the stratum corneum, and pro-caspase-3 may be activated during late 
keratinocytes differentiation (Dale et al., 1997; Weil et al., 1999). In contrast, 
processed forms of caspase-3, -6 and -7 have not been detected in human epidermis 
(Lippens et al., 2000). A further study of human epidermis detected mRNAs 
encoding caspase-1, -2, -3, -4, -6, -7, -8, -9, -10 and -14 by RT-PCR but 
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immunohistological expression of caspase-2 and -8 was not seen, suggesting that 
caspase-8 expression is controlled at the post-transcriptional level (Raymond et al., 
2007). A more detailed study of caspases, particularly activated caspase-3, in 
inherited PPK is therefore necessary. 
Most skin diseases or cutaneous lesions characterized by epidermal 
hyperplasia or hyperkeratosis, such as psoriasis, skin cancer and lichen simplex 
chronicus are thought likely to involve decreased keratinocyte apoptosis (Raj et al., 
2006). Survivin, an apoptotic inhibitor, is expressed in the upper third of the 
epidermis in psoriasis and lichen simplex chronicus, whereas basal cell and 
squamous cell carcinoma demonstrate staining in all epidermal layers (Bowen et al., 
2004). In psoriasis, spontaneous keratinocyte apoptosis is decreased (Laporte et al., 
2000). Keratinocytes in psoriatic plaques demonstrate resistance to apoptosis and a 
lack of p53 activation (Wrone-Smith et al., 1999; Qin et al., 2002). A number of 
factors probably contribute to this resistance: resistance to TNF signalling; 
upregulation of other cytokines, such as IL-15 (Ruckert et al., 2000) and increased 
levels of Bcl-x (Fukuya et al., 2002). Aberrant expression of apoptosis-related 
molecules Fas, Bcl-xL, Bax and ICAD (inhibitor of caspase 3-related DNase) was 
noted, suggestive of a suppressed apoptotic process (Takahishi et al., 2002).  
3.2.4.7 Terminal differentiation and apoptosis are distinct processes 
In order to maintain epidermal structural homeostasis, proliferation, differentiation 
and cell death of keratinocytes needs to be modulated. Epidermal terminal 
differentiation has been thought of as a specialized form of apoptosis (Haake & 
Polakowska, 1993), but there are some distinct differences between these processes 
(Gandarillas et al., 1999; Takahishi et al., 2000).  
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 Terminal differentiation and apoptosis are both metabolically active 
processes provoking dramatic cellular changes leading ultimately to cell death, which 
are tightly controlled by extracellular matrix interaction via integrins (Gandarillas, 
2000). Differentiating keratinocytes in the granular layer exhibit degraded DNA, 
fragmented by endonucleases, (Gandarillas et al., 1999), and display terminal 
deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling (TUNEL)-
positive cells (Polakowska et al., 1994; Haake & Polakowska, 1993; Maruoka et al., 
1997). Activation of transglutaminases, essential for the production of the CE and 
suppression of the nucleus, is also a feature common to both apoptosis and terminal 
differentiation (Gandarillas, 2000). Apoptosis regulators, Bcl-2, Bcl-x, Bax and Bak, 
are differentially expressed in keratinocytes (Mitra et al., 1997; Rodriguez-
Villanueva et al., 1998). Bcl-2 has been found associated with proliferative 
keratinocytes in both normal skin and basal cell carcinomas (Morales-Ducret et al., 
1995) and Bax expression reduced the latter (Tomkova et al., 1998). Transciption 
factor c-Myc induces apoptosis in a variety of cell types when growth factor 
deprived, and promotes differentiation of epidermal stem cells (Gandarillas & Watt, 
1997, Gandarillas et al., 2000). p53, a paradigmatic pro-apoptotic factor, 
(Gandarillas, 2000), delays cell cycle progression (Harris & Levine, 2005). It may 
activate transcription of pro-apoptotic factors affecting mitochondrial pathways (Bax, 
Noxa, Puma, Apaf-1) and death receptor pathways (Fas, death receptors 4 and 5), 
and repress antiapoptotic molecules (Bcl-2, Bcl-x, Survivin) (Yu & Zhang, 2005). 
Keratinocytes respond to internal, extracellular and environmental death 
signals through coordinating sensors which integrate apoptotic responses via a 
number of pathways. UVB, binding of Fas ligand (Fas-L), tumour necrosis factor, or 
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other cytokines to death receptors stimulates the extrinsic pathway, resulting in 
activation of caspase-8 (Takahishi et al., 1999a; Takahishi et al., 2001a; 2001b). Fas-
ligand induces apoptosis through Fas (CD95), a 45-kDa cell surface protein (Itoh et 
al., 1991; Oehm et al., 1992; Watanabe-Fukunaga et al., 1992), is marginally 
expressed in normal basal keratinocytes (Sayama et al., 1994) but induced by TH1 
type cytokine interferon γ (Takahishi et al., 1995).  
UVB, cytotoxic drugs and DNA damage trigger the intrinsic pathway 
resulting in mitochondrial release of cytochrome c, which combines with the cofactor 
Apaf-1 in the formation of activated caspase-9 (Schwartz et al., 1995; Takahishi et 
al., 1995). Activation of the upstream caspases 8 or 9 leads to activation of 
downstream caspases 3 or 7, which causes intracellular substrate cleavage, cellular 
condensation and nuclear fragmentation (Raj et al., 2006). 
 However, there are clear differences between terminal differentiation and 
apoptosis. In the former, corneocytes are neither phagocytized, nor do they exhibit 
membrane blebbing, a morphologic criteria of apoptosis, and the process is relatively 
slow.  In contrast, apoptosis is rapidly executed, resulting in elimination of individual 
cells within hours, often neighbouring cell phagocytosis (Mitra et al., 1997; 
Gandarillas, 2000). Gandarillas et al. (1999) examined terminal differentiation 
(differentiation marker involucrin expression, formation of CE and anucleation), and 
apoptosis (nuclear condensation, apoptotic DNA fragmentation by TUNEL staining, 
electrophoresis and ELISA, and cell rounding) in primary human keratinocytes and 
found that differentiation and apoptosis were independent of each other. 
Despite the failure to detect changes in this study, mutations in genes causing 
keratoderma might also affect apoptosis. For example, keratins moderate apoptosis 
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by both death receptor and intrinsic pathways, with K8 and K18 interacting with 
TNF receptor 1 (Caulin et al., 2000). Loss of maternal TNFα increased the survival 
of keratin-deficient embryos (Jaquemar et al., 2003) possibly via a cell-autonomous 
mechanism involving K18 binding to TRADD, TNFR-1-associated death domain 
protein (Inada et al., 2001). K17 similarly modulates hair follicle cycling, possibly 
by its interaction with TRADD (Tong & Coulombe, 2006). Desmosomal defects also 
have the ability to alter apoptosis (see chapter 2.3). 
3.2.4.8 Filaggrin and terminal differentiation 
In the later stages of differentiation, during the formation of the CE, epidermal 
keratinocytes express unique proteins including filaggrin, loricrin and involucrin 
(Fuchs & Byrne, 1994). Filaggrin is a crucial component of the CE in the outer layer 
of epidermis. It is an abundant protein that functions to aggregate keratin 
intermediate filaments into tightly aligned bundles or macrofibrils in the stratum 
corneum of the epidermis and other stratified keratinizing epithelia (Dale et al., 
1978). It is synthesized in suprabasal granular cells, as a large, highly phosphorylated 
precursor, profilaggrin, that consists of multiple filaggrin repeats flanked by N- and 
C-terminal domains (Presland et al., 1992; 1997; Pearton et al., 2002). Profilaggrin is 
converted to filaggrin by site-specific proteolysis and dephosphorylation, during the 
transition from the granular layer to stratum corneum (Resing et al., 1989), and its 
expression as this precursor suggests that filaggrin expression may be regulated to 
prevent cytotoxic effects (Presland et al., 2001; Kuechle et al., 2000).  
The gene that encodes profilaggrin, FLG, comprises three exons, the 
initiation codon for translation being located in exon 2, and the bulk of the 
profilaggrin protein is encoded by exon 3. FLG resides on human chromosome 1q21 
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within the epidermal differentiation complex, a region that harbours genes for several 
other proteins that are expressed during terminal differentiation of keratinocytes 
(South et al., 1999). Null mutations in the FLG gene cause the common keratinizing 
disorder ichthyosis vulgaris (Smith et al., 2006) as well as a being a major 
susceptibility gene for atopic dermatitis (Palmer et al., 2006). 
Filaggrin staining in this study revealed relatively consistent and uniform 
staining of the granular layer in all PPK subtypes, other than in 2 individuals with 
alternating areas of reduced filaggrin staining. This correlated with alternating areas 
of hyper and hypogranulosis on H&E sections associated with alternating ortho- and 
parakeratotic stratum corneum. This did not relate to clinical severity of 
hyperkeratosis. 
Reduced expression of filaggrin has been noted using immunohistochemical 
labelling of skin in autosomal dominant ichthyosis vulgaris and atopic dermatitis 
(Fleckman & Brumbaugh, 2002; Manabe et al., 1991). Keratohyalin granules, which 
consist mainly of profilaggrin, were absent in all ichthyosis vulgaris individuals by 
light microscopy and electron microscopy, as well as a consistently absent granular 
layer. Clinical severity usually correlated with the lack of granular layer and 
keratohyalin granules. Profilaggrin expression of cultured keratinocytes in these 
individuals was virtually absent. These disorders are characterized by a markedly 
thickened stratum corneum (orthohyperkeratotic), which further lends support to a 
role for filaggrin in terminal differentiation (Kuechle et al., 2000). Filaggrin is 
expressed at a point in epidermal differentiation where keratinocytes lose their nuclei 
and other organelles and cease synthetic activity (Resing et al., 1989). It has been 
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suggested that filaggrin aids in the terminal differentiation process by facilitating 
apoptotic machinery, due to its keratin binding ability (Kuechle et al., 2000).  
3.2.4.9 Premature involucrin expression in inherited PPK 
Involucrin was the first protein to be identified as a likely constituent of the insoluble 
CE of stratified squamous epithelia and is considered a major protein of terminally 
differentiating keratinocytes (Steinert & Marekov, 1997). It is covalently attached as 
an “early” component of the CE, with a small part of involucrin remaining soluble 
(Ishida-Yamamoto & Iizuka, 1995). Transglutaminase 1 is involved in the formation 
of a lipid-bound envelope by esterification of long chain ω-hydroxyceramides onto 
involucrin (Nemes et al., 1999). It is a 68kDa protein that is expressed in the spinous 
and granular layers of the epidermis, several layers above the stratum basale, 
extending up to the stratum corneum, and can be detected in the cell periphery (Rice 
& Green, 1979). 
In this study, I observed abnormal involucrin distribution in all PPK subtypes, 
being prematurely expressed in the lower spinous and even basal layers in some 
cases, which was distinct from plantar controls. This was a uniform 
immunohistochemical feature of all PPK subtypes in keeping with an altered process 
of epidermal differentiation, raising the possibility of a common mechanism 
underlying hyperkeratosis. This is in keeping with involucrin staining in all 
epidermal layers in 4 cases of Mal de Meleda (Kassar et al., 2008). Involucrin 
immunolocalisation has been already studied and found to be altered in various 
keratinisation disorders such as psoriasis (Ishida-Yamamoto and Iizuka, 1995), 
atopic dermatitis (Jensen et al., 2004), lamellar icthyosis (Hohl et al., 1993; Pena-
Penabad et al., 1999), and Darier’s disease (Kanitakis et al., 1987; Kassar et al., 
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2008), but not BCIE (Ishida-Yamamoto et al., 1995). Psoriasis shows aberrant 
expression of differentiation-related molecules, with increased expression of 
involucrin and cystatin A, a cysteine protease inhibitor, and decreased expression of 
loricrin (Takahishi et al., 1996). In Darier’s disease, differences in staining between 
non-acantholytic and acantholytic epidermis have been reported (Kassar et al., 2008), 
with peripheral and diffuse cytoplasmic staining in non-acantholytic areas compared 
to diffuse cytoplasmic labelling in acantholytic areas. However, in my study, 
involucrin staining was not particularly prominent in areas of acantholysis, in K1 or 
K9 patients, in comparison to loricrin staining (see 3.2.4.10).  
In a study of Hailey-Hailey disease and Mal de Meleda PPK due to mutation 
in the ARS gene encoding a secreted Ly6/μPAR related protein-1 (SLURP-1) 
(Fischer et al., 2001), both were found to have premature expression of involucrin. A 
study on involucrin expression in HHD keratinocytes has shown a decreased 
involucrin protein level caused by lower involucrin mRNA levels due to increased 
rates of involucrin mRNA degradation (Aberg et al., 2007). Involucrin mRNA 
transcription is controlled by cytosolic Ca2+, with increased Ca2+ stimulating RNA 
synthesis via activation of an AP-1 promoter site (Ng et al., 2000). Mutations in 
SLURP-1 are responsible for Mal de Meleda, which modulates intracellular calcium 
content in keratinocytes (Chimienti et al., 2003), and mutations in the ATP2C1 gene 
encoding a Ca2+ pump for Hailey-Hailey disease (Hu et al., 2000). Mutations in 
ATP2A2 gene have been shown to be responsible for Darier’s disease encoding the 
type 2 isoform of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2), a calcium 
pump. However, Hailey-Hailey keratinocytes expressed lower involucrin protein 
levels at both low and high extracellular Ca2+. Premature involucrin expression was 
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found in our study in PPKs of varying underlying mutations raising the possibility of 
other mechanisms affecting epidermal differentiation. Further studies on involucrin 
expression in PPK keratinocytes and its relationship to signalling may help to 
elucidate the significance of the altered involucrin cytoplasmic staining in our cohort.  
3.2.4.10  Loricrin expression in inherited PPK 
Loricrin is a small basic protein synthesized in the upper granular layer and becomes 
a major constituent of the CE (Ishida-Yamamoto et al., 1998a). It is highly insoluble 
perhaps due to its high glycine-content and intra-molecular disulfide bonds. The 
human loricrin protein is 26kDa, consisting of 315 amino acid residues and is 
expressed in the granular layer of orthokeratotic squamous epithelia (Hohl et al., 
1991). It is expressed at the final stage during the process of epithelial differentiation, 
occurring later than involucrin and profilaggrin expression, and is a specific marker 
for keratinisation (Mehrel et al., 1990). The intensity of loricrin expression varies 
between body sites: it is abundant in foreskin and perianal skin, but less so in leg skin 
(Hohl, 1993). In adult human epidermis, loricrin is diffusely distributed within the 
superficial granular cells with some accumulation at desmosomes. L-granules, 
eosinophilic granules distinct from the basophilic filaggrin-containing keratohyalin 
granules (F-granules), are scarcely found in adult human skin (Ishida-Yamamoto et 
al., 1993).  
In this present study, loricrin distribution was essentially limited to upper 
spinous and granular layers in all PPK subtypes, with additional nuclear staining 
around sweat ducts noted in Loricrin PPK. Loricrin staining was particularly 
prominent in areas of acantholysis in K1 and K9 patients, where the disruption of 
cell-to-cell adhesion was associated with both intense cytoplasmic staining and focal 
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areas of stratum corneum breakdown. This raises the possibility that loricrin is 
upregulated at sites of epithelial injury. Loricrin immunolocalisation has been studied 
and found to be decreased in situations of hypo- or agranulotic parakeratotic 
keratinisation including psoriasis, dermatitis, pityriasis lichenoides, porokeratosis 
and precancerous and malignant lesions (Hohl et al., 1993; Juhlin et al., 1992).  In 
contrast, normal loricrin staining has been demonstrated in nonbullous congenital 
ichthyosiform erythroderma, in association with thick, compact cornified layers with 
parakeratosis (Kawashima et al., 2005). In this study, uniform loricrin staining was 
observed in 2 PPK patients with alternating areas of ortho- and parakeratosis. 
High levels of loricrin are found in hypergranulotic and orthokeratotic lesions 
in lichen planus, benign papillomas and pseudocarcinomatous hyperplasia (Hohl et 
al., 1993). Interruption of loricrin expression in porokeratosis was associated with 
early apoptosis of epidermal keratinocytes thought to result in the dysregulation of 
keratinisation (Shen et al., 2002). In this study, both loricrin and apoptotic marker 
expression appeared normal (3.2.4.6) although more detailed study of a range of 
apoptotic markers is warranted. Ichthyosis vulgaris skin shows normal loricrin 
staining in the granular layer, compared to lamellar ichthyosis with deficient 
expression of transglutaminase 1, both loricrin and involucrin are expressed but not 
incorporated into the CE (Hohl et al., 1993). In this study, normal loricrin staining 
was observed in Loricrin, K17 and DSG1 patients with evidence of hypergranulosis.  
Strong immunohistochemical staining for loricrin, involucrin and SPPR1 
were found in BCIE, with some premature labelling associated with the plasma 
membrane of granular cells, possibly relating to abnormal keratin filament 
aggregation and cellular vacuolization (Ishida-Yamamoto et al., 1995).  Loricrin 
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expression in EKV without Cx31 or 30.3 gene mutations was increased, thought to 
reflect the presence of hypergranulosis (Arita et al., 2003), but in another case 
without Cx31 mutation loricrin expression was greatly diminished suggesting a 
disruption of keratinisation at a very late stage (Ishida-Yamamoto et al., 2000a). In 
this study, the normal expression of loricrin across all PPK subtypes compared to the 
uniformly premature expression of involucrin (3.2.4.9) is suggestive of a disruption 
at an earlier stage of differentiation. 
3.2.4.11 Disease mechanisms in loricrin keratoderma 
Loricrin is thought to lead to cutaneous disease by a number of disease mechanisms. 
The first is through abnormalities in CE development; the second is through 
dysfunctional apoptosis of differentiating keratinocytes (Ishida-Yamamoto et al., 
1998c; 1999; 2000b). The loricrin protein is elongated as a result of the 1-bp 
insertion, leading to a frameshift and delayed termination in LOR (Maestrini et al., 
1996). In the epidermis of patients carrying a loricrin mutation, the profilaggrin 
amino-terminal domains aggregate with loricrin in the nuclei (Ishida-Yamamoto et 
al., 1998c). The mutant loricrin is translocated into the nucleus instead of the CE, 
with the mutant C-terminus probably functioning as a nuclear targeting sequence.  It 
is thought that a delay in apoptosis occurs as a result of interactions with nucleic 
acids in the nucleus leading to cross-linking of nuclear transgluaminases (Ishida-
Yamamoto et al., 1998c; 1999; 2000b). This delay in apoptosis is suggested as one of 
the main causes of the phenotype (Gedicke et al., 2006). 
Immunoelectron-microscopic studies of loricrin keratoderma have revealed 
sparse staining for loricin in thin CE with abnormal intranuclear granules in granular 
and cornified layer cells, positive for both C- and N-terminal loricrin, compared to 
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Vohwinkel’s keratoderma which demonstrated normal loricrin distribution (Korge et 
al., 1997). Mutant loricrin in loricrin keratoderma has been noted not to crosslink 
into the CE, but translocates into the nucleus of differentiated epidermal 
keratinocytes (Ishida-Yamamoto et al., 2000b). Electron microscopy of 2 Loricrin 
patients in this study did not reveal any clear nuclear abnormalities but further 
immunoelectron-microscopic studies specifically staining for loricrin are warranted 
(see chapter 3.1). 
To better understand the link between the loricrin genotype and skin 
pathology in loricrin keratoderma, several murine models have been developed with 
either loss or gain of loricrin function, which produce only modest skin phenotypes 
(Yoneda and Steinert, 1993; Koch et al., 2000; Suga et al., 2000; Jarnik et al., 2002). 
These have supported the hypothesis that synthesis of mutant loricrin is responsible 
for the phenotype rather than the lack of wild-type loricrin. A mouse model 
overexpressing human loricrin resulted in a normal phenotype, with all loricrin 
incorporated into the CE (Yoneda & Steinert, 1993). A mild, transient phenotype was 
present in loricrin knock-out mice, which disappeared 4-5 days after birth (Koch et 
al., 2000; Jarnik et al., 2002), with only a transgenic mouse model showing a more 
lasting phenotype (Suga et al., 2000). Mice which were homozygous for the mutant 
transgene had more severe features in the absence of wild-type loricrin, when 
transgenic mice were bred with knockout mice. This suggests that mutant loricrin is 
functional but does not need the wild type to produce the typical phenotype (Suga et 
al., 2000). Gedicke et al. (2006) reported a family with loricrin keratoderma due to 
the previously reported 730insG mutation in whom pseudoainhum were not a 
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feature. Pyrosequencing of transcript of LOR revealed an equal expression of mutant 
and wild-type alleles underlining the gain-of-function theory for loricrin mutations.  
 In contrast, the consequences of mutations in loricrin on epidermal function 
and morphology have been studied in skin from patients previously genotyped for 
mutations in the loricrin gene (Schmuth et al., 2004; Maestrini et al., 1999). This 
revealed abnormal corneocyte fragility and basal permeability barrier function, but 
accelerated repair kinetics, possibly explicable by amplified lamellar body secretion. 
Partial normalisation of the CE in the outer stratum corneum correlated with 
persistence of abundant calcium in the extracellular spaces, positioned to activate 
transglutaminase-1 (Schmuth et al., 2004). These results suggest that the barrier 
abnormality in loricrin keratoderma is linked to a defective cornified envelope 
scaffold, resulting in increased extracellular permeability. In this study, 2/2 loricrin 
patients demonstrated markedly thickened stratum corneum compared to other 
subtypes (see chapter 3.1), and further studies of stratum corneum function are 
needed. 
3.2.5 Conclusion 
Immunocytochemical study of affected plantar skin in inherited PPK due to a variety 
of underlying molecular aetiologies, does not demonstrate significant differences in 
expression of a selection of markers of differentiation, cornified envelope proteins or 
markers of proliferation and apoptosis. Premature keratinocyte differentiation was 
suggested by altered cytoplasmic staining of involucrin in all subtypes, suggestive of 
a common mechanism of hyperkeratosis, and prominent loricrin staining was noted 
in acantholytic areas in EPPK due to K9 mutation. Further ultrastructural and 
functional studies would be beneficial. Overt changes in epidermal turnover were not 
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apparent, with no major change in proliferative index. More detailed analysis of 
proliferative and apoptotic markers, as well as examination of late differentiation 
events and shedding, would be needed further to exclude the relevance of these 

































Chapter 3.3 Towards a Pilot Microarray Experiment 
Biological research has been revolutionised by the complete genome sequences of 
hundreds of organisms, giving rise to the new science of genomics. Microarray 
analysis takes advantage of the vast amount of sequence information and allows 
investigators to examine alterations in the gene expression of thousands of genes 
simultaneously in a single experiment (Wong & Chang, 2005). Several published 
studies have reported attempts to carry out gene expression profiling by microarrays 
or real time RT-PCR using RNA extracted from small skin biopsies or laser capture 
microdissected skin sections (Storz et al., 2003; Nomura et al., 2003; Baumgarth et 
al., 2004). While promising, the technology for producing reproducible data from 
small amounts of tissue is still at a developmental stage and requires validation in 
each laboratory.  
The initial aim was to test different methods of RNA extraction to optimise 
yield and quality of RNA extracted from whole biopsies, separated epidermis and 
microdissected tissue using control biopsy material. Having optimised RNA 
preparation and cDNA synthesis for microarray analysis, a comparison of gene 
expression profiles was planned using involved and uninvolved palmoplantar skin in 










Fresh elliptical plantar biopsies of affected skin from all 16 inherited PPK patients 
recruited were dissected into three pieces (chapter 2.2), one of which was snap frozen 
in liquid nitrogen and stored at -70oC. Where the keratoderma was focal (all PC-2 
family members, n=8), a 4mm punch biopsy of unaffected skin was also obtained. 
Normal control samples of non-plantar skin were also snap frozen in liquid nitrogen 
and stored at -70o
3.3.2.2 Laser microdissection attempts 
C, in the same way as the PPK specimens. 
Comparison between the Arcturus and Leica lasers for laser microdissected samples 
of control tissue epidermis was carried out.  
Leica Laser Microdissection System 
Frozen sections (5 μm) were cut and mounted on glass slides covered with PEN foil 
(2.5 μm thick; Leica Microsystems, Wetzlar, Germany). Samples were washed with 
5 μl RNAsin® (40 U/ μl, Promega, Madison, WI, USA) prior to fixing with 70% 
ethanol at -20o
Circular discs of epidermis were traced on the monitor with the computer 
mouse, and dissected from the frozen sections with the LMD system using a 337-nm 
nitrogen ultraviolet (UV) laser (Leica Laser Microdissection System, Leica 
Microsystems) and dropped immediately into a microcentrifuge tube cap filled with 
200 μl RNeasy lysis buffer (Buffer RLT) (Qiagen, Valencia, CA, USA) containing 
guanidine isothiocyanate, per disc. Variations in laser aperture, intensity and speed 
were made in an attempt to optimise speed and ease of microdissection of the 
C for 10 seconds. They were gently washed twice with 
diethylpyrocarbonate (DEPC)-treated water, and thoroughly air-dried. 
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epidermis. A total of 1 - 4 discs of epidermis were dropped into microcentrifuge tube 
caps, and RNA isolation step (see section 3.3.2.4) performed in order to identify the 
volume of microdissected epidermis required for sufficient RNA isolation to perform 
a microarray analysis. 
Arcturus Laser Microdissection System 
Frozen sections (5 μm) were cut and mounted on untreated glass slides and prepared 
thereafter as per Leica Laser Microdissection specimens. Epidermal cells were traced 
and microdissection attempted using ArcturusXT
3.3.2.3 Manual microdissection of epidermis 
® Laser Capture Microdissection 
and UV Laser Cutting System (MDS Analytical Technologies, CA, USA). 
Comparison between laser microdissected samples of control tissue epidermis and 
manual microdissection of epidermis was carried out. Frozen sections were cut and 
prepared as for Leica Laser Microdissection (see section 3.3.2.2). Full thickness 
epidermis was manually dissected using a dissecting microscope, sterile blades and 
needles under RNAse-free conditions and dropped into a microcentrifuge tube cap 
filled with 350 μl Buffer RLT. 
3.3.2.4 RNA isolation 
Total RNA was extracted from both Leica laser microdissected and manually 
dissected samples of epidermis, and whole biopsies using an RNeasy® mini kit 
(Qiagen) following the protocol recommended by the manufacturer, in the presence 
of DNase I (Qiagen). Whole biopsies were cut into slices less than 0.5cm thick and 
immersed in 600 μl of Buffer RLT. All samples were disrupted and homogenized in 
Buffer RLT, up to 600 μl per sample. Samples were also homogenised by three 
alternative methods: (1) rotor-stator sonicator, using Buffer RLT for 20-40 seconds, 
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until the sample was uniformly homogenous; (2) with the use of a Pyrex tissue 
grinder and addition of Buffer RLT, and homogenizing by passing lysate through an 
18-20 gauge needle fitted to an RNase-free syringe several times; (3) immersion in 1 
ml Trizol (Invitrogen, CA, USA) (ratio 10:1 Trizol: tissue) and then vortexing. The 
tissue lysate was centrifuged for 3 minutes at maximum speed in a microcentrifuge. 
The supernatant was transferred to a new microcentrifuge tube by pipetting, and 1 
volume of 70% ethanol added to the cleared lysate, mixed and transferred 
immediately to an RNeasy mini column placed in a 2 ml collection tube and 
centrifuged for 15 seconds at > 10,000rpm. The flow-through was discarded. 700 μl 
Buffer RW1 (Qiagen) was added to the RNeasy column, and centrifuged for 15 
seconds at >10,000 rpm to wash the column. The flow-through and collection tube 
was discarded. The RNeasy column was transferred into a new 2 ml collection tube, 
and 500 μl Buffer RPE pipetted onto the column. This was centrifuged for 2 minutes 
at >10,000rpm to dry the RNeasy silica-gel membrane. The column was transferred 
to a new 1.5ml collection tube, 30-50 μl RNase-free water pipetted directly onto the 
membrane, and centrifuged at >10,000rpm for 1 minute to elute. RNA concentration 
was tested on an Agilent Bioanalyser. 
 
3.3.3 Results 
Initial attempts at laser capture/microdissection of frozen epidermal cells using the 
Arcturus Laser Microdissection system were unsuccessful and all subsequent laser 
microdissection was performed using the Leica Laser Microdissection System. More 
aggressive vacuum dessication of frozen sections might improve the success of the 
Arcturus Laser microdissection. 
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Attempts at RNA isolation, whether using the Leica laser microdissected epidermis 
(up to 4 discs), manually dissected epidermis or full thickness biopsies, failed to 
yield sufficient RNA for microarray analysis.  Extractions from laser microdissected 
discs revealed no RNA peak for 1 disc of epidermis only, 2 discs degraded RNA 
only, and 4 discs produced very low concentrations of RNA at 11.4ng/μl. To date, 
attempts to extract RNA from full thickness epidermis have also produced only very 
low concentrations (5ng/μl; 8.6ng/μl). 
 
3.3.4 Discussion 
3.3.4.1 Microarray technology 
Global gene expression patterns have the potential to better define biologic 
phenomena and human disease states at the molecular level. Microarray analysis has 
been applied to several dermatologic diseases, including melanoma (Bittner et al., 
2000; Busam et al., 2005), mycosis fungoides (Tracey et al., 2003), cutaneous B cell 
lymphoma (Storz et al., 2003), psoriasis (Bowcock et al., 2001; Oestreicher et al., 
2001; Zhou et al., 2001), atopic dermatitis (Nomura et al., 2003), alopecia areata 
(Carroll et al., 2002), scleroderma (Zhou et al., 2003, 2007; Whitfield et al., 2003) 
and ultra-violet irradiated skin (Becker et al., 2001; Enk et al., 2006).  
 One major application of DNA microarray technology has been the sequence-
specific detection and quantification of mRNA expression. Oligonucleotide DNA 
microarrays were able to identify a few mRNA molecules per cell, within a wide 
linear range. In parallel, cDNA microarrays have been developed using cDNA 
molecules (of about 600-2000 bases in length) to interrogate mRNA samples. Owing 
to the high specificity of DNA sequence detection, the exchange of even one single 
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base may be detected using short oligonucleotides, and thus oligonucleotide DNA 
microarrays have been used for DNA sequencing. Similarly, DNA microarrays may 
detect single nucleotide polymorphisms (SNPs), which may contribute to tumour 
development/progression and predispose to a variety of different diseases (Kunz et 
al., 2004).  
 Although in vitro cell culture experiments might be well controlled, growth 
factors present in cell culture media may impact on gene expression, making 
interpretation of results difficult. Similarly, whole biopsy material analysis does not 
allow for attributing gene expression to certain cell types (Kunz et al., 2004). Laser-
dissection microscopy can facilitate the in situ study of biological processes in solid 
tissues and organs by precisely isolating cells and tissue substructures for further 
analysis. Individual gene expression studies for multi-gene microarray technologies 
from cells isolated by laser-dissection microscopy have been reported (Fink et al., 
2002; Luzzi et al., 2003; Inoue et al., 2003; Baumgarth et al., 2004). Although 
microarray analysis provides the most comprehensive approach to date for gene 
expression studies, the volumes of starting RNA required have at times resulted in 
the need for extensive pre-amplification with complex quality control issues because 
of possible bias introduced by non-linear amplification (Baumgarth et al., 2004). 
Manual microdissection of skin samples prior to RNA isolation has been reported as 
an alternative method of isolating specific material in porokeratosis (Hivnor et al., 
2004). 
3.3.4.2 Towards a microarray experiment in PC-2 
To date, we have established the tissue resource for running a potential microarray 
experiment in PC-2. Due to the thickness of plantar skin, repeated attempts at RNA 
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extraction are required using alternative RNA extraction methods, including the 
RNeasy fibrous tissue kit (Qiagen) containing proteinase K. Laser microdissection 
using the Leica/Arcturus systems is no longer being pursued but rather continuing 
with full thickness biopsies for RNA extraction. Experimentation with the P.A.L.M. 
Laser Microdissection and Pressure Catapulting technology (Carl Zeiss 
MicroImaging, GmbH, Munich, Germany) is being investigated. Other possible 
methods to increase the yield of RNA from plantar samples include trying to increase 
solubilisation by not only pipetting RNA pellet in DEPC-treated water but heating to 
55o
 Where total RNA yield was insufficient to meet the required input for direct 
labelling cDNA microarrays, RNA amplification has also been described (Storz et 
al., 2003). Total RNA samples were cleaned using the QIAamp RNA Mini Protocol 
(Qiagen) to create a high-quality template for subsequent RNA amplification.  
C for 10-15 minutes. Also ensuring that the pellet is incubated with Trizol for 5 
minutes at room temperature may assist homogenisation. 
 Gene expression profiling may be controlled in one manner by comparing 
lesional tissue directly with proximal uninvolved epidermis from the same patient, as 
previously reported (Hivnor et al., 2004). We aim to control a future microarray 
project in PC-2 in the same way, although obtaining further control plantar samples 
from unaffected patients would be a second method of experimental control.  
3.3.5 Conclusion and future prospects 
Despite the use of different approaches, RNA was not successfully extracted from 
biopsy material during the time available. Nonetheless, gene expression profiling 
remains a highly promising approach to addressing the original question posed by 
this study. Further attempts to isolate RNA from these tissue sections for gene 
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expression profiling by microarray is underway, in collaboration with the McLean 
laboratory, Ninewells Hospital, Dundee, as is RNA preparation from normal 
epidermis for optimal yield and quality of RNA. Once completed, we aim to run a 
full microarray experiment on the large K17 mutation pedigree of PPK patients using 
the Affymetrix  U133A chip at the Sir Henry Wellcome Functional Genomics Unit, 





Section 4:  Final Discussion And Conclusion 
4.1. Candidate mechanisms of hyperkeratosis in inherited PPK 
The inherited PPKs demonstrate both clinical and genetic heterogeneity, and 
improved understanding of their underlying molecular defects have helped provide 
information about the functional significance of proteins involved in the terminal 
differentiation of palmoplantar keratinocytes. However, the pathways by which the 
different genetic defects identified cause the common clinical phenotype remain 
obscure. In some cases, the reasons for the preferential involvement of palms and 
soles due to defects in widely expressed genes are still to be elucidated.  
It is possible that a common pathologic defect exists in inherited PPK in the 
final stages of keratinocyte maturation into squames. In this study, I have sought to 
provide a resource for addressing this problem and to begin to investigate 
mechanisms which may be activated in the affected tissues in a variety of genetic 
defects.  A broad range of underlying gene defects of inherited PPK were studied, 
including mutations in K1, K9, K17, DSG1, Loricrin and mitochondrial DNA 
 Three broad groups of mechanisms suggest themselves as candidates for the 
pathological hyperkeratosis seen in inherited PPKs. Firstly, increased thickening of 
the skin may simply be a physiological response to trauma, which is activated by, for 
example, a structural weakness in intermediate filaments. Normal palmar and plantar 
epidermis ordinarily undergoes hypertrophy at sites of friction or with use, and 
therefore it is part of its normal function to respond in this way. The adaptation of 
epidermal thickening as a response to mechanical stress in these specialised tissues 
may thus explain its localisation. Consistent with this possibility, the evidence 
presented in this thesis is generally of minimal change in the parameters studied. The 
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stratum corneum was greatly thickened, but not commonly parakeratotic; there was 
no alteration in a marker of proliferation, and the keratin expression profile was not 
obviously hyperproliferative. It is therefore possible that molecular studies will not 
show major qualitative changes in gene expression. This suggestion is also consistent 
with the fact that while oral retinoids suppress the hyperkeratosis, they often result in 
epidermis which is too thin and sensitive (Milstone et al., 2005), and patients may 
not tolerate their use. Against this hypothesis, the very gross hyperkeratosis seen in 
some forms of keratoderma seems beyond what might be considered physiological. 
The second possibility is that disruption of the epidermis, whether due to 
epidermolytic blistering or desmosomal defects, results in activation of the processes 
of wound healing. Although wound healing has not been studied in palmoplantar 
skin, it is reasonable to predict that there would be similar changes to those seen in 
skin in other sites. There has been considerable study of the effects of defects in 
keratins, desmosomes and gap junctions, all of which may be responsible for PPK, 
on wound healing, as discussed below.  
In the case of keratin defects, epidermal thickening is common to many 
keratin disorders but changes in the epidermis due to keratinocyte dysfunction are 
not clearly understood due to limited knowledge of epidermal tissue homeostasis 
(Porter et al., 1998). The impact of various keratin subtypes on differentiated 
functions of epithelial cells is not fully understood (Magin et al., 2007), although 
there is evidence that changes in keratin expression may affect cell size, cell 
proliferation and the response to stress (Pallari & Eriksson, 2006; Gu & Coulombe, 
2007). Keratin expression changes rapidly during differentiation and tissue injury, 
with differentiated keratinocytes repressing K1 and K10 during wound healing yet 
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keratinocytes proximal to the wound edge induce K6, K16 and K17. However, in this 
study there was limited evidence that these changes were present in affected 
palmoplantar skin. 
   Desmosomal proteins have been shown to have an important role in cell 
proliferation, motility and differentiation (Yin & Green, 2004; Green & Simpson, 
2007). Alteration of desmosome structure correlates with wound healing, and 
desmosomal adhesion may be rapidly modulated in response to wounding (Wallis et 
al., 2000). Mouse models lacking DSC1 resulted in epidermal hyperplasia due to 
increased cell proliferation (Chidgey et al., 2001). Altered expression of DSC3a, 3b 
and DSG3 results in an increase in suprabasal keratinocyte proliferation (Merritt et 
al., 2002; Hardman et al., 2005). Normal embryonal stem cell proliferation appears 
dependent on DSG2 (Eshkind et al., 2002). Keratinocyte cell proliferation is 
increased when DP is downregulated, suggesting a regulatory role in cell cycle 
progression (Wan et al., 2007). Altered expression of DSG2 leads to epidermal 
hyperplasia and the development of pre-cancerous papillomas, as well as an increase 
in the activity of multiple cell growth and survival pathways (Brennan et al., 2007).  
DP and DSG1 haploinsufficiency in striate PPK exhibited increased 
keratinocyte proliferation and altered differentiation, suggesting that normal 
desmosome function was not maintained (Wan et al., 2004). It is thought that the 
effects of structural component changes may relate to their role in stabilizing 
desmosome and classic adherens junction assembly while establishing and 
maintaining keratinocyte architecture. It is possible that subsequently intracellular 
signalling processes are affected (Wan et al., 2007). This is further supported by the 
phosphorylation of DSG3 and its dissociation from plakoglobin, and the transient 
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increase in intracellular calcium concentrations and protein kinase C activity seen in 
human keratinocytes cultured with anti-DSG3 containing sera from pemphigus 
vulgaris patients (Aoyama et al., 1999). In the present study, in one case of striate 
PPK associated with underlying DSG1 mutation there was premature expression of 
involucrin, suggestive of altered differentiation. This change was a uniform feature 
of all PPK subtypes studied, including underlying K1, K9, K17, Loricrin and 
Mitochondrial mutations. In contrast, loricrin expression was normal, raising the 
possibility that late differentiation is not affected but that the change in 
differentiation occurs at an earlier stage. Normal keratin expression, the lack of 
uniformity of keratin aggregates ultrastructually despite the presence of underlying 
keratin mutations, and plantar hyperkeratosis being indistinguishable 
morphologically between subtypes suggests that many of the reported structural 
features of PPK are secondary phenomena as opposed to crictial steps in the 
development of hyperkeratosis.  
Mutations in the gap junction connexin proteins Cx26 and Cx30 are also 
associated with keratoderma (chapter 1). It is not clear how subtle changes in 
intercellular signal transmission within the epidermis result in epidermal thickening 
(Meşe et al., 2006), but under pathological conditions, the normal distribution of 
connexins may be altered. Abnormal gap junction communication may modify the 
natural response pattern of keratinocytes both to stress/injury and during terminal 
differentiation (Rouan et al., 2001). The role of specific Cxs in cell migration and 
proliferation responses remain unresolved but there is good evidence of their 
involvement as a response to wounding. (Kandyba et al., 2008).  
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Interestingly, there is a high carrier frequency of Cx26 (GJB2) gene 
mutations in many ethnic groups (Gasparini et al., 2000; Lucotte & Dieterlen, 2005). 
It has recently been suggested that such defects may provide a heterozygote 
advantage (D’Adamo et al., 2008). Carriers of R134W allele show a thicker 
epidermis than wild-type ones (Meyer et al., 2002) and cells expressing this allele 
form a significantly thicker epidermis in an organotypic co-culture skin model, show 
increased migration, and are less susceptible to cellular invasion by enteric pathogen 
Shigella flexneri (Man et al., 2007). Transfection of deafness-associated mutant 
constructs has resulted in a reduction in cell death compared to wild-type ones 
(Common et al., 2004). It has been hypothesized that a thicker epidermis, due to an 
extended terminal differentiation program and increased cell survival, may lead to an 
improved barrier against infection (D’Adamo et al., 2008). It is postulated that 
alterations in gap junction structure might disturb cell-to-cell interaction, leading to 
epidermal thickening and hyperkeratosis, resulting in a stronger mechanical barrier. 
Unfortunately, it was not possible to obtain samples from families affected by 
PPK due to connexin defects in time for inclusion in this study, but previous studies 
offer some evidence of the effects of such mutations.  In an animal model of a 
connexin skin disorder mimicking Vohwinkel syndrome created by expression of 
Cx-D66H in transgenic mice (Bakirtzis et al., 2003) found epidermal thickening or 
hyperkeratosis similar to the clinical features of humans. They also found premature 
keratinocyte cell death, in contrast to the theory of increased cell survival proposed 
by D’Adamo et al. (2008). Accumulation of Cx26-D66H protein in keratinocyte 
cytoplasm was noted, suggestive of defective trafficking of the protein to the plasma 
membrane (Bakirtzis et al., 2003). In in vitro studies using Cx26 mutations G59A 
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and D66H in Vohwinkel syndrome, Lucifer yellow dye transfer experiments 
demonstrated that mutants did not form functional channels, with mutations exerting 
a dominant-negative action on Cx26, but having selective trans-dominant effects on 
Cx43 and Cx32 (Thomas et al., 2004). Each mutation affected distinct connexins 
differentially which may explain variations in epidermal phenotypes (Meşe et al., 
2006).  
The third group of possible mechanisms for palmoplantar hyperkeratosis is 
the activation of inflammatory mechanisms. These are likely to be relevant in 
hyperkeratotic forms of palmoplantar eczema and psoriasis. The livid marginal 
erythema characteristic of, for example, epidermolytic PPK (Vörner, 1901; Kuster et 
al., 1995), may suggest paracrine inflammatory mediators. In some forms of 
keratoderma, for example mal de Meleda, inflammatory change is a major clinical 
feature (Niles & Clump, 1949; Salamon et al., 1988). In other conditions, such as 
Papillon-Lefèvre syndrome due to homozygous loss of function mutations in the 
granulocyte enzyme Cathepsin C (Toomes et al., 1999), it is easier to postulate 
altered inflammatory responses, and indeed pyogenic periodontitis is a feature of this 
disorder. In severe forms of epidermolysis bullosa simplex such as Dowling Meara 
syndrome, rupture of basal layer keratinocytes may be responsible for the 
inflammation of bullous lesions (McGrath et al., 1992). However, while many 
patients, particularly with focal keratoderma, suffer from pain, inflammation and 
secondary infection, this is often localised and many keratodermas, including those 
with microscopic vacuolation, do not appear inflamed. Although in the present study, 
markers of inflammation and immune activation were not investigated in detail, there 
was no consistent histological evidence to suggest these were present. Consistent 
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with this, topical steroid and systemic immunosuppressive agents have not found a 
role in the management of keratodermas. Nonetheless, keratinocytes have a broad 
capacity to initiate inflammatory and immune responses and further study would be 
needed to exclude the possibility that the genetic defects in keratinocytes directly or 
indirectly induce autocrine or paracrine mediators of altered differentiation. 
MicroRNAs studies, which it is still hoped to undertake, may allow 
distinction between these possibilities. 
4.2 Future prospects: therapeutic siRNA  
It is clear that whatever the mechanism of this group of disorders, their management 
is unsatisfactory. This study has sought to explore pathological mechanisms active in 
PPK, but for inherited disorders, and particularly if the pathogenesis is in fact an 
appropriate activation of a physiological response, an ideal treatment would remove 
the underlying cause rather than seeking to disrupt the pathways which it activates. 
This implies gene-directed therapies. Many disorders of keratinisation, including 
nearly all the human keratin disorders, are associated with dominant mutations, 
typically causing either haploinsufficiency or toxic gain-of-function mutations. 
Genetic therapies for the latter diseases must either suppress the production of the 
mutant proteins or correct the genetic defect in the chromosome (Lewin et al., 2005). 
RNA interference (RNAi) is a highly evolutionally conserved process that is used by 
cells to selectively regulate and silence gene expression, and is widely used as an 
experimental tool (Rugg, 2008). It is increasingly apparent that RNAi also has great 
potential as a therapeutic strategy for treating many human disorders, including 
genetic diseases, viral infections and cancer (Ryther et al., 2005). Skin disorders 
represent a good model for RNAi therapy development because localized cutaneous 
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application of small interfering siRNA (siRNA) may be easier to achieve than 
systemic administration or use of integrating viral vector systems, both for proof-of-
concept experiments in cell culture or animal models and ultimately, treatment of 
human subjects (Lewin et al., 2005). siRNAs act via the RNA-induced silencing 
complex (RISC) to specifically degrade target RNAs, with inhibition of gene 
expression mediated by hybridized RNAs, typically containing a 19bp 
complementary region with two nucleotide 3’ overhangs (19+2 design) that are 
sufficiently small so as to avoid immune surveillance (Leachman et al., 2008). 
 PC is caused by mutations in one of four keratin genes (chapter 1), with most 
patients carrying K6a mutations. Knockout mouse studies of the two major K6 
genes, K6a and K6b, have shown these genes exhibit functional redundancy ie. 
knocking out one of these keratins is tolerated owing to compensatory expression of 
the others (Wojcik et al., 2000, 2001; Wong et al., 2000; Wong & Coulombe, 2003). 
It has been shown that the human genome exhibits far more structural variation 
between individuals in the population than previously recognized (Kehrer-Sawatzki, 
2007) and Smith et al.(2008) hypothesize that ablation of K6a in humans does not 
produce a PC-like phenotype and have developed potent RNAi against K6a as a 
paradigm for treating a localised skin disorder. They have shown that targeting the 
3’-UTR of the K6a gene allows both potent and specific inhibition of K6a expression 
both in cultured cells and early in vivo studies. Coupled with a suitable epidermal 
delivery system, these reagents could provide a potential route to therapy for PC. 
Smith et al.(2008) have delivered siRNA by injection to keratinocytes in the mouse 
foot pad, however, whether this will prove to be a viable method for treatment of PC 
patients will depend on a number of factors, including how many injections are 
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needed and how often they will been to be repeated to maintain gene silencing 
(Rugg, 2008). 
4.3 Summary and Conclusion 
The aim of the work reported in this thesis was to develop a tissue and cell culture 
resource, with the ultimate goal of increasing understanding of molecular 
mechanisms active in the pathogenesis of palmoplantar keratoderma. A large 
resource of palmoplantar biopsy material, and of keratinocyte cultures derived from 
skin biopsies from affected individuals, has successfully been established. Other 
avenues explored in the course of the work have included documentation of clinical 
aspects of the palmoplantar keratodermas and associated ectodermal features; the 
inadequacy of current management; the use of regional nerve block to reduce the 
discomfort of biopsying plantar epidermis; and genetic investigation of a pedigree 
with an unknown mutation.  
The potential of the resource was demonstrated by application in initial 
laboratory studies. Previous studies have reported findings in small numbers of 
samples, without controls. With few exceptions, the present comparative studies of 
morphology at light and electron microscopic level, or using immunocytochemistry 
with a range of markers of differentiation, proliferation and apoptosis, failed to 
identify reliable and consistent differences between keratodermas of markedly 
different molecular aetiologies. Only aberrant involucrin expression was a uniform 
feature of the different keratodermas raising the possibility of a common abnormality 
of differentiation. Indeed the variation from normal palmoplantar epidermis was 
often minimal. It may be that study of a wider range of pathologies, such as those 
due to gap junction defects, would have provided evidence of other mechanisms in 
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play. Equally, the lack of evidence of differences may indicate that there is indeed a 
common final pathway for hyperkeratosis in palmoplantar keratoderma, but that it is 
simply a variation in degree of the normal function of palmoplantar skin, i.e. 
hypertrophy in response to mechanical stress.  
It is hoped that future studies, for example of gene expression, may clarify 
this issue. A pilot study of the potential of cDNA microarray analysis to achieve this 
was thwarted by failure to extract RNA, but it is hoped to overcome these technical 
difficulties. Moreover, the tissue and tissue culture resource established will also 
serve to identify and explore manipulation of genetic or other molecular targets for 
better future care in this challenging group of conditions. 
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Appendix A.  Peripheral Nerve Block for Plantar Skin Biopsy 
1. Introduction 
1.1 Peripheral nerve blockade 
Plantar skin is more often involved than palmar skin in the inherited PPKs, and may 
require biopsy in the assessment of these conditions. Biopsy of plantar skin is 
particularly challenging, due to the pain associated with direct/local infiltration of 
macerated, hyperkeratotic and often blistered skin. There is therefore a need for 
effective methods of anaesthesia.  
Recently, there has been a growing interest in regional anaesthesia, 
particularly in peripheral nerve blockade, in a wide range of surgical areas, from 
orthopaedic and breast surgery to hernia repairs (Singelyn & Capdevila, 2001; 
Mulroy, 2002). Peripheral nerve blockade is being used not only to provide surgical 
anaesthesia but also postoperative analgesia and the treatment of pain related to non-
surgical causes, particularly with the introduction of long-acting local anaesthetics. 
Lower extremity peripheral nerve blocks (PNBs) have never been as widely taught or 
used as other forms of regional anaesthesia. Transient neurologic symptoms 
associated with spinal anaesthesia, increased risk of epidural haematoma with the 
introduction of antithromboembolic prophylaxis regimens, and evidence of improved 
rehabilitation outcome with lower extremity PNBs has led to an increased interest in 
lower extremity PNBs (Enneking et al., 2005). 
1.2 Nerve supply to the foot 
Sensory efferents of the foot are located in five nerve branches: the posterior tibial 
nerve, the deep peroneal nerve, the superficial peroneal nerve, the sural nerve (all 
four from the sciatic nerve) and the saphenous nerve (from the femoral nerve). The 
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posterior tibial nerve is the terminal branch of the sciatic and tibial nerves. It 
descends vertically in the posterior aspect of the leg, deep to the soleus muscle, and 
enters the tarsal tunnel just behind the posterior tibial vessels (Figure 1a). The 
posterior tibial nerve trifurcates into the medial and lateral plantar nerves and the 
calcaneal nerve, which provide cutaneous innervation to most of the plantar surface 
of the foot (Keifer & McQuillan, 1996) (Figure 1b & c).  
1.3 Ankle block and anaesthesia to the sole of the foot 
Ankle block, involving all 5 nerve branches to the foot, is a well described and 
successful means of providing surgical anaesthesia and postoperative analgesia for 
midfoot and forefoot surgery (Levecque et al., 1999; Doty et al., 2006), as well as 
being an established treatment for plantar fasciitis and chronic heel pain (Pavier & 
Liggins, 2001; Govindarajan et al., 2003). Although there are no important variants 
in the innervation of the distal musculature, there is considerable variation in the 
branching and distribution of the sensory nerves of the foot (Enneking et al., 2005). 
For foot surgery, blockade of all 5 nerves has been advocated (Delgado-Martinez et 
al., 2001). Analgesia is achieved for the sole of the foot by blocking the posterior 
tibial nerve and the sural nerve (Keifer & McQuillan, 1996). The majority of the sole 
of the foot is supplied by the former other than the lateral aspect of the sole and a 
small area proximal to the great toe being supplied by the deep peroneal nerve 
(Figure 1c & 1d). Thus for anaesthesizing the medial aspect of the sole, we 
postulated that posterior tibial nerve block alone may be sufficient. 
1.4 Aim 
Our aim was to assess the efficacy of posterior tibial nerve blockade as an alternative 
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Figure 1a). The path of the posterior tibial nerve in the lower leg (Podiatric Medicine and 
Surgery, 2001).  It descends vertically in the posterior aspect of the leg, deep to the soleus muscle, 
and enters the tarsal tunnel just behind the posterior tibial vessels (identified by arrow, nerves shown 
in yellow). 1b) The terminal trifurcation of the posterior tibial nerve in the foot.  1c) Sensory 
innervation of the sole of the foot. Branches of the posterior tibial (PT) and sural nerve supply the 
majority of the sole. 1d) Sensory supply to foot. There is considerable variation in the branching and 
distribution of the sensory nerves of the foot; cutaneous branches extending from the saphenous nerve 
may supply part of the medial aspect of the sole. Images reproduced by kind permission of a) Primal 







Following informed consent, all sixteen inherited PPK patients recruited to the study 
underwent elliptical plantar skin biopsy from the medial aspect of the heel (Figure 2) 
using posterior tibial nerve block in a standard, distal manner (Doty et al, 2006). 
Additional local anaesthetic was delivered by direct infiltration (23G x 1¼ in/0.60 
x30mm needle, BD MicrolanceTM
 
) using 1% plain xylocaine if there was any 
concern about the efficacy of the block. The first five patients biopsied received 
posterior tibial nerve block alone, and the following eleven patients a combined 
posterior tibial and saphenous nerve block. As the posterior tibial nerve is a 
combined motor and sensory nerve, patients were pre-warned about the forthcoming 
numbness in order to avoid neurological trauma. No premedication was given. All 
nerve blocks were delivered by a podiatric surgeon with experience of the technique 
in the treatment of chronic plantar fasciitis. 
 





2.1 Injection technique: Posterior tibial nerve block 
The distal block site was 2cm proximal to the tip of the medial malleolus midway 
between the medial border of the Achilles tendon and the medial malleolus, posterior 
to the posterior tibial artery pulsation when palpated. With the patient supine and 
lower leg laterally rotated by 450, the needle (27G x 13/8 in/0.40x35mm needle, 
Safety Plus XLTM Septodent) was inserted at 900 
2.2 Injection technique: Saphenous Nerve Block 
to the surface of the skin and 
advanced until resistance was felt (Figure 3a). Prior to the delivery of anaesthetic, the 
needle was withdrawn 1-2mm and aspirated, as an essential safeguard when injecting 
in this site due to the proximity of the posterior tibial artery and vein. Nerve block 
was performed using up to a maximum dose of 4.4mls of 3% mepivocaine. The area 
around the posterior tibial nerve was then massaged.  
The saphenous nerve was anaesthetised at the level of the medial malleolus. The 
needle (27G x 13/8 in/0.40x35mm needle, Safety Plus XLTM
2.3 Assessment of Anaesthesia 
 Septodent) was inserted 
at the medial malleolus and a “ring” of local anaesthetic raised from the point of 
needle entry to the Achilles tendon, and anteriorly to the tibial ridge (Figure 3b). 
Nerve block was performed using up to a maximum dose of 4.4mls of 3% 
mepivocaine. 
After performance of the nerve block, subjects were evaluated by the surgeon and an 
independent observer for adequate anaesthesia at the planned surgical site before 
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Figure 3a) Injection technique for delivery of posterior tibial nerve block. The distal block site 
was 2cm proximal to the tip of the medial malleolus midway between the medial border of the 
Achilles tendon and the medial malleolus, posterior to the posterior tibial artery pulsation when 
palpated. b) Injection technique for saphenous nerve block.  The needle was inserted at the medial 
malleolus and a “ring” of local anaesthetic raised from the point of needle entry to the Achilles 







normal sensation; 1 = blunt sensation; 2 = no perception). The surgical procedure 
was not started until the patient had a pinprick score of 2. Additional local 
anaesthetic was used by direct infiltration of the skin if necessary, until a pinprick 
score of 2 was achieved. 
2.4 Outcomes 
The main primary outcome was pain control using visual analogue scales and verbal 
pain scores. All patients were given thorough instructions preoperatively in these 
methods. Ten-centimetre visual analogue scales were marked only “no pain” at one 
end of the scale and “worst possible pain” at the other. Pain associated with posterior 
tibial nerve block as well as the actual biopsy were scored. If additional local 
infiltration was required, they were also asked to score their level of plantar pain 
associated with this injection. Verbal pain scores (Reinhart et al., 2000) were 
completed for the posterior tibial nerve block procedure. A set of descriptions 
randomly placed on a page, were presented to the patient, who selected the best 
description from the following: no pain, just noticeable, weak, mild, moderate, 
strong, severe or excruciating.  
Patients were also asked to compare the pain level of this procedure with any 
previous palmoplantar biopsies. Patients were instructed to record their pain scores, 
both visual analogue and verbal pain, in the first 48 hours after the biopsy, to record 
any additional analgesics required during this period, and any initial problems, and 
return this information by post. All patients were telephoned within the first week 






3.1 Efficacy of Anaesthesia 
3/5 (60%) of patients receiving posterior tibial nerve block alone failed to achieve 
complete loss of pinprick sensation at the biopsy site, despite using the maximum 
dose of mepivocaine, and allowing up to 35 minutes for the block to become 
efficacious. This may have been due to cutaneous branches from the saphenous nerve 
extending to the biopsy site (Figure 1d). Accordingly, the next 11 inherited PPK 
patients were anaesthesized using a combined posterior tibial and saphenous nerve 
block. 
Table 1 lists the mean time in minutes from the performance of the block to 
loss of sensation to pinprick at the surgical site (also see Figure 4), the number of 
patients requiring additional local anaesthetic to achieve loss of sensation to pinprick, 
the mean duration of surgery, the number of patients reporting pain in the first 48 
hours post biopsy. 2 patients receiving the posterior tibial nerve block alone and 1 
receiving a combined block failed to reach loss of sensation to pinprick after 30 
minutes so additional local anaesthetic was given by direct infiltration. 
 
Table 1. Summary of median time to loss of pinprick sensation for posterior tibial compared to 
combined posterior tibial and saphenous nerve blocks.  Requirement of additional local anaesthetic 
and pain experienced post-biopsy are also shown. Range of times to loss of pinprick sensation shown 
in Figure 4. 
 
 Posterior Tibial Nerve Block 
Alone (n=5) 
Combined Posterior Tibial 
and Saphenous Nerve Blocks 
(n=11) 
Median time to loss of 
pinprick sensation (mins)  
10 (range 6-35) 10 (range 3-30) 
Additional local anaesthetic 
needed 
3 (60%) 5 (40%) 
Volume of additional local 
anaesthetic (mls) 
5 2 
Pain in first 48 hours post 
biopsy 

































PTNB                                          Combined Block
 
 
Figure 4. Range of times to loss of pinprick sensation for posterior tibial nerve block alone and 
combined posterior tibial and saphenous nerve blocks. 
 
 
3.2 Outcomes: Pain Scores 
The mean pain scores for the posterior tibial and saphenous nerve blocks, any 
additional local anaesthetic used, any discomfort during the actual biopsy, and first 
48 hours post procedure are shown in Figure 5.  Verbal pain scores for the posterior 
tibial nerve block procedure, any additional local anaesthetic given and the first 48 
hours post biopsy are shown in Figure 6.  
All 5 patients who had previously had palmoplantar biopsies with direct 
infiltration of local anaesthetic alone found posterior tibial nerve block significantly 
less painful. 8 patients found it necessary to take paracetamol to co-codamol in the 
first 48 hours post procedure.  
3.3 Complications 
No complications occurred as a result of delivery of either nerve block (infection, 
haematoma, vascular puncture of greater saphenous vein, or nerve injury). 
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Figure 5. Summary of median pain scores (visual analogue scale) for posterior tibial and 
saphenous nerve blocks, delivery of additional local anaesthetic, and the 48 hours post biopsy.  

















Figure 6. Verbal pain scores for posterior tibial nerve block procedure (PTNB) (n=16), 
additional saphenous nerve block (SNB) (n=11), additional infiltration of local anaesthetic (Addl 





4.1 Non-invasive anaesthesia 
Biopsying hyperkeratotic or inflamed plantar skin poses an anaesthetic challenge. 
Different regional anaesthesia methods, both invasive and non-invasive, are available 
for palmar skin, mainly used for the administration of Botulinum toxin for 
hyperhidrosis. Non-invasive methods generally involve treatment with a topical 
application of local anaesthetic (eg. EMLA cream) (Naumann et al., 1998). Local 
anaesthetics diluted in tap water have been used in an iontophoretic procedure for 
palmar skin (Selander, 1995). However, even though these techniques are easy to 
apply, topical use of anaesthetics provides little relief, and does not eliminate the 
pain of needle pricks, the main disadvantage of this non-invasive anaesthesia 
technique (Blaheta et al., 2002).  
4.2 Intravenous regional anaesthesia 
In order to achieve sufficient anaesthesia, invasive regional techniques such as 
peripheral nerve blocks have also been used. Although serious morbidity related to 
anaesthetic blocks is extremely infrequent, damage to peripheral nerves has been 
reported (Selander, 1995). Intravenous regional anaesthesia (Bier’s block) has mainly 
been reported for palmar (Blaheta et al., 2002; Hornberger et al., 2004) and plantar 
skin (Blaheta et al., 2003; Swartling & Vahlquist, 2006). Bier’s block was found to 
be well tolerated by patients primarily because of the rapid recovery of motor 
function and sensation after tourniquet release. Bier’s block has been used in 3 
patients with PC-1 prior to the delivery of plantar injections of botulinum toxin 
without any complications (Swartling & Vahlquist, 2006). However it is not a 
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procedure without risks, namely, toxic reactions attributed to tourniquet leak of local 
anaesthetic into the systemic circulation (Rosenberg et al., 1983; Heath, 1983). 
4.3 Peripheral Nerve Block 
The results of this open study suggest that posterior tibial nerve block alone or in 
conjunction with a saphenous nerve block greatly reduces the pain of direct 
infiltration of local anaesthetic in this site. The additional time required prior to 
surgery for the administration of the nerve block was in keeping with previous 
reports (Pavier & Liggins, 2001), although there was a wide range (3 to 30 minutes). 
8/16 patients required no further analgesia other than the nerve block for the 
completion of the biopsy, although 5/16 required additional local anaesthetic for 
biopsy of the dermis with inadequate anaesthesia at deeper levels and 3 patients not 
achieving loss of sensation to pinprick without it. The mean pain scores for injection 
of local anaesthetic were low (Table 2) with the nerve block already in place. As this 
is an uncontrolled study, it is not possible to be certain of the degree of benefit of the 
nerve block but the previous experience of a few patients and clinical experience 
suggests that the pain associated with direct infiltration is much greater.  
 Variable efficacy of both single and, to a lesser extent, combined blocks may 
be overcome by delivery of a total ankle block, given the considerable variation in 
the branching and distribution of sensory nerves to the foot, however, small volumes 
of direct local anaesthetic were well tolerated once the dual combined block was in 
place. Although the combined dual block resulted in a slightly lower percentage of 
patients requiring direct infiltration, and a smaller volume of anaesthetic was used in 
these cases, it is difficult to firmly conclude that the combined block was definitely 
more effective than single block alone, given the small numbers. Other possible 
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methods of improvement of efficacy include an operator who has experience of 
nerve blockade for surgery as opposed to pain relief, and the use of nerve stimulators 
(Hadzic et al., 2003). 
 
5. Conclusion 
Providing more prolonged anaesthesia when biopsying painful weight-bearing sites 
may be advantageous in patients with diseased plantar skin, such as in the inherited 
PPKs. Posterior tibial nerve blockade using a longer acting anaesthetic (bupivocaine 
0.5%) has been successfully used in the treatment of chronic plantar fasciitis to 
reduce pain (Pavier & Liggins, 2001; Govindarajan et al., 2003) and in treating 
postoperative pain after hallux valgus surgery (Levecque et al., 1999). It is possible 
that its role in the inherited PPKs may extend beyond that of a surgical tool, and 
provide a therapeutic option for those patients with limited mobility due to plantar 
pain. It also provides an alternative method of anaesthesia for those patients requiring 
treatment for hyperhidrosis with botulinum toxin injections or therapeutic siRNAs 
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Patient Information Sheet  
Addendum A 
Information for Patients: Please read carefully 
You are being asked to take part in a study of the function of the outermost layer of 
the skin, the epidermis. We are trying to understand why in some people the 
epidermis of the hands and feet becomes abnormally thickened and hard. 
Study of the Mechanisms of Keratoderma:  
 
We are studying people who have inherited disorders which cause extreme and often 
painful thickening of the hands and feet. This condition is called keratoderma. Many 
people also suffer from hard skin on their feet for other reasons, like corns and 
callosities, and we hope to understand these better too. 
 
To find out what is going on in these disorders, we also need to study normal skin 
samples.  
 
We are asking you to help by allowing us to take either small samples (biopsies) of 
the affected or unaffected skin of your feet, or biopsies of normal-appearing skin 
from other body sites. Local anaesthetic will be used to numb the skin. 
 
We will be freezing or preserving the skin samples to study the cell machinery using 
special techniques. In some cases, we would like to grow the skin cells for short 
periods in our laboratory. The use of living cells is necessary for us to study the way 




Your participation in the study is entirely voluntary, if you decide not to have this 
biopsy, it will not alter your future treatment. 
 
All information gathered from the study will be confidential. 
 
We will ask you to read carefully and sign a consent form for the procedure, to show 
that it has been explained to you, and that you understand what is being asked of you. 
The study, this information sheet, and the consent form have been approved by the 
Research Ethics Committee of the South Glasgow Hospitals University NHS Trust. 
 
If you would like further information to help you decide whether or not to take part 
in the study, we will be pleased to answer any questions. 
 
      Prof Colin Munro; Dr Mozheh Zamiri 
       Department of Dermatology 
       Southern General Hospital 
       Glasgow  G51 4TF 





Patient Questionnaire: Palmoplantar Keratoderma Medical History and 
Clinical Findings Form 
 
Name:      First Name: 
Hospital Number: 





Sites of hyperkeratosis (plantar/palmar/other): 
History and Clinical Features:  






History of cysts: 
History of excessive sweating: 
Hoarseness/History of Mucosal, Peridontal or Laryngeal disease: 
Deafness: 
History of Malignancy (e.g. SCCs/other) 






Difficulties with Lactation: 
History of Phimosis: 
Clinical course to date: 
Other past medical history: 
If history available: Pregnancy/Preterm birth/Birth weight/Collodion 
membrane/Desquamation/Natal teeth/Atrophic skin/Absence of 
dermatoglyphics/Blisters/Difficulties in first few weeks of life 
Drug history: Local/Systemic 
Family history:  
 Affected relatives: 
 Any consanguineous family: 
 Ethnic origin of parents: 
 Family tree: 
 Family history of deafness/dental abnormalities/other findings 
 
Palmoplantar keratoderma:   
Examination: 
Pattern: Diffuse/Focal/Honeycomb/Striate/Punctate/Transgredient/ 
Sites: Heel/Ball/Anterior arch/Toes/Palms 
Other sites of hyperkeratosis: Knees/Elbows/Wrists/Forearms/Natal cleft/Achilles 









Nail anomalies: Fingernails/Toenails/Subungal hyperkeratosis/Nail 
pigmentation/other 
Cysts: Epidermal inclusion/Steatocystomas/Vellus hair cysts 
Hair abnormalities: 
Oral leukokeratoses: 
Dental abnormalities: (Gingivitis/Periodontitis/Loss of permanent teeth) 
Follicular keratoses: 





skin involvement of extracutaneous lymphoma. Nevertheless,
prognosis and overall treatment are different. A specific ques-
tion is asked with isolated medullary infiltration. Primary
cutaneous medullary MZL does not exist, therefore medullary
involvement is secondary to another lymphoma. Frequency
of medullary involvement may be underestimated in some
studies, consequent to patient selection in order to fulfil the
definition of PCMZL. Moreover, methods of analysis of med-
ullary biopsy are not often specified. Medullary infiltration is
found in 0–53%.3–9 Our study is the largest one to evaluate
the frequency of isolated medullary infitration in cutaneous
MZL.
The consequence of this infiltration for cutaneous MZL is
rarely studied. Zucca et al.,9 as in our series, did not find an
adverse influence of bone marrow involvement on survival.
In conclusion, we present a retrospective study of 44
patients with cutaneous MZL. Isolated medullary involve-
ment was found in 10 patients (23% of the total). The lack
of data in the literature concerning cutaneous MZL with
isolated medullary involvement does not permit prognosis.
The significance and therapeutic implications of this asymp-
tomatic bone marrow involvement are to be defined in the
future.
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Pachyonychia congenita type 2: abnormal
dentition extending into adulthood
DOI: 10.1111/j.1365-2133.2008.08662.x
SIR, Pachyonychia congenita (PC) is a group of hereditary dis-
orders characterized by hypertrophic nail dystrophy and asso-
ciated ectodermal features.1 Two main clinical syndromes have
been distinguished.2 In PC type 1 (PC-1; Jadassohn–Lewan-
dowsky syndrome, OMIM 167200) pachyonychia is associated
with focal palmoplantar keratoderma (PPK), follicular
keratoses and oral leucokeratosis. In PC type 2 (PC-2; Murray–
Jackson–Lawler syndrome, OMIM 167210) associations
include multiple pilosebaceous cysts. Focal PPK in PC-2 may
be milder than in PC-1, and follicular keratoses, bushy eye-
brows, angular cheilosis, hoarseness and (in children) unruly
hair can also occur. Mutations in keratins have been found to
be the molecular basis for both these disorders, affecting one
of the paired keratins of specialized epidermis, K6a ⁄K16
(PC-1) and K6b ⁄K17 (PC-2).3,4
One of the striking features of PC-2 is the frequent first pre-
sentation with primary dentition erupted at birth (prenatal or
natal) or within the first 30 days of life (neonatal). Frontal
teeth are typically affected; they are soft, friable, and said to
be prone to caries, usually being lost within the first few
months of life.5–7 In addition to natal teeth, early multiple
tooth development at 4–5 months and, in one case, early natal
tooth loss without immediate permanent tooth replacement,
have been reported.4
In some cases, second primary teeth, nonpermanent teeth
occurring after the loss of natal teeth, will develop in addition
to the natal teeth but have been thought to be ultimately
replaced by normal permanent teeth during childhood. Histo-
logically, the polypean dental papillae of these natal teeth
show mucosal hyperplasia and irregular rete ridge prolifera-
tion. Cytoplasmic vacuolization and oedema are seen in the
 2008 The Authors
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upper and spinous layers of the mucosa. Irregular osteoden-
tine-like structures with cell inclusions and interglobular den-
tine are seen.8 K17 expression has been described in the early
stages of epidermal appendage development9 and in the pre-
dominantly hard portion of the hair shaft,10 but its expression
in tooth progenitors is not known.
We now report for the first time possible effects on adult
as well as infantile dentition of PC-2. We studied a multi-
generation family with PC-2 due to a heterozygous missense
mutation in the helix initiation motif of K17 (Asn92Asp)
presenting with classical features of dystrophic nails, focal
plantar keratoderma, multiple epidermal cysts, abnormal
eyebrow and body hair (pili torti) and natal teeth.3 Of 18
affected members over two generations whom we were able
to interview, seven reported having either full or upper
dentures fitted in their late teenage years due to ‘crumbling’
and exaggerated friability of their adult teeth. There was no
history of increased caries. All affected patients had initially
been treated with multiple crowns to prevent the disintegra-
tion of their teeth, without benefit. This history is sugges-
tive of either enamel loss or attrition, but it has not been
possible directly to assess any affected teeth. By contrast,
none of their nine unaffected siblings had dentures or any
similar dental problems.
Although the premature loss of primary teeth in conjunc-
tion with early eruption may be of no clinical significance,
the loss of primary or permanent teeth in the absence of
trauma should not be overlooked by the clinician.11 Nontrau-
matic early loss of adult dentition is usually caused by caries
or destructive periodontal disease. It is possible that the abnor-
mal dentition in PC-2 may be a result of dentine abnormality,
which is nonkeratin related, instead of a keratin-related
enamel abnormality.
Abnormalities in adult teeth have not previously been
described in PC-2. However, we were able to obtain a history
only of unusual increased friability, suggesting a dentine
abnormality, and not of caries. Dental friability has not previ-
ously been noted and as only some members were affected, it
may be multifactorial with K17 mutation contributing indir-
ectly. The effect might alternatively be specific to the
Asn92Asp mutation.
Pending further evidence, we recommend that dermatolo-
gists caring for children with PC-2 should bear in mind a pos-
sible effect on permanent dentition and consider appropriate
dental examination and care. Moreover, the presence in PC-2
of structurally abnormal, premature teeth and possibly adult
teeth suggests that K17-expressing keratinocytes play an
important role in odontogenesis and tooth eruption: this is an
area for further study.3
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SIR, Sulphonamides are commonly used antibiotic drugs. The
sulphonamide family includes drugs used to treat the most
common opportunistic infections in patients with AIDS. Their
use is complicated by the unusually high rate of cutaneous
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